

# PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  A61K 31/165, 31/19, 31/215, 31/22, 31/27, 31/40, 31/415, 31/425, 31/44, 31/535, C07C 237/20, 317/24, 317/32, 323/65, 327/26, C07D 213/32, 213/70, 233/84, 277/36, 295/13, 295/26		A1	(11) International Publication Number: <b>WO 98/03164</b>  (43) International Publication Date: 29 January 1998 (29.01.98)
(21) International Application Number: PCT/US97/12874		(74) Agents: GAMSON, Edward, P. et al.; Welsh & Katz, Ltd., 22nd floor, 120 South Riverside Plaza, Chicago, IL 60606 (US).	
(22) International Filing Date: 22 July 1997 (22.07.97)			
(30) Priority Data: 60/022,043 22 July 1996 (22.07.96) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): MONSANTO COMPANY [US/US]; 800 North Lindbergh Boulevard - 04E, St. Louis, MO 63167 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(72) Inventors; and (75) Inventors/Applicants (for US only): FRESKOS, John, N. [US/US]; 7572 York, Clayton, MO 63105 (US). ABBAS, Zaheer, S. [US/US]; 14232 Tullytown Court, Chesterfield, MO 63017 (US). DeCRESCENZO, Gary, A. [US/US]; 932 Colonial Hills Lane, St. Charles, MO 63304 (US). GET- MAN, Daniel, P. [US/US]; 66 Sunny Hill Court, Chester- field, MO 63017 (US). HEINTZ, Robert, M. [US/US]; 603 Nancy Place, Ballwin, MO 63021 (US). MISCHKE, Brent, V. [US/US]; 25 White River Lane, Defiance, MO 63341 (US). McDONALD, Joseph, J. [US/US]; 1036 Johanna Drive, Ballwin, MO 63021 (US).			

(54) Title: THIOL SULFONE METALLOPROTEASE INHIBITORS

### (57) Abstract

This invention is directed to proteinase (protease) inhibitors, and more particularly to thiol sulfone inhibitors for matrix metalloproteinase 13(MMP-13), compositions of proteinase inhibitors, intermediates for the syntheses of proteinase inhibitors, processes for the preparation of proteinase inhibitors and processes for treating pathological conditions associated with pathological matrix metalloproteinase activity related to MMP-13.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

THIOL SULFONE  
METALLOPROTEASE INHIBITORS

Description

5

Technical Field

This invention is directed to proteinase (protease) inhibitors, and more particularly to thiol sulfone inhibitors for matrix metalloproteinases, 10 compositions of proteinase inhibitors, intermediates for the syntheses of proteinase inhibitors, processes for the preparation of proteinase inhibitors and processes for treating pathological conditions associated with pathological matrix metalloproteinase 15 activity.

Background of the Invention

Connective tissue, extracellular matrix constituents and basement membranes are required 20 components of all mammals. These components are the biological materials that provide rigidity, differentiation, attachments and, in some cases, elasticity to biological systems including human beings and other mammals. Connective tissues 25 components include, for example, collagen, elastin, proteoglycans, fibronectin and laminin. These biochemicals makeup, or are components of structures, such as skin, bone, teeth, tendon, cartilage, basement membrane, blood vessels, cornea and vitreous 30 humor.

Under normal conditions, connective tissue turnover and/or repair processes are controlled and in equilibrium. The loss of this balance for whatever reason leads to a number of disease states. 35 Inhibition of the enzymes responsible loss of equilibrium provides a control mechanism for this

-2-

tissue decomposition and, therefore, a treatment for these diseases.

Degradation of connective tissue or connective tissue components is carried out by the 5 action of proteinase enzymes released from resident tissue cells and/or invading inflammatory or tumor cells. A major class of enzymes involved in this function are the zinc metalloproteinases (metalloproteases).

10 The metalloprotease enzymes are divided into classes with some members having several different names in common use. Examples are: collagenase I (MMP-1, fibroblast collagenase; EC 3.4.24.3); collagenase II (MMP-8, neutrophil 15 collagenase; EC 3.4.24.34), collagenase III (MMP-13), stromelysin 1 (MMP-3; EC 3.4.24.17), stromelysin 2 (MMP-10; EC 3.4.24.22), proteoglycanase, matrilysin (MMP-7), gelatinase A (MMP-2, 72kDa gelatinase, basement membrane collagenase; EC 3.4.24.24), 20 gelatinase B (MMP-9, 92kDa gelatinase; EC 3.4.24.35), stromelysin 3 (MMP-11), metalloelastase (MMP-12, HME, human macrophage elastase) and membrane MMP (MMP-14). MMP is an abbreviation or acronym representing the term Matrix Metalloprotease with the attached 25 numerals providing differentiation between specific members of the MMP group.

The uncontrolled breakdown of connective tissue by metalloproteases is a feature of many pathological conditions. Examples include rheumatoid 30 arthritis, osteoarthritis, septic arthritis; corneal, epidermal or gastric ulceration; tumor metastasis, invasion or angiogenesis; periodontal disease; proteinuria; Alzheimers Disease; coronary thrombosis and bone disease. Defective injury repair processes 35 also occur. This can produce improper wound healing leading to weak repairs, adhesions and scarring. These latter defects can lead to disfigurement and/or

- 3 -

permanent disabilities as with post-surgical adhesions.

Matrix metalloproteases are also involved in the biosynthesis of tumor necrosis factor (TNF), and inhibition of the production or action of TNF and related compounds is an important clinical disease treatment mechanism. TNF- $\alpha$ , for example, is a cytokine that at present is thought to be produced initially as a 28 kD cell-associated molecule. It is released as an active, 17 kD form that can mediate a large number of deleterious effects *in vitro* and *in vivo*. For example, TNF can cause and/or contribute to the effects of inflammation, rheumatoid arthritis, autoimmune disease, multiple sclerosis, graft rejection, fibrotic disease, cancer, infectious diseases, malaria, mycobacterial infection, meningitis, fever, psoriasis, cardiovascular/pulmonary effects such as post-ischemic reperfusion injury, congestive heart failure, hemorrhage, coagulation, hyperoxic alveolar injury, radiation damage and acute phase responses like those seen with infections and sepsis and during shock such as septic shock and hemodynamic shock. Chronic release of active TNF can cause cachexia and anorexia. TNF can be lethal.

TNF- $\alpha$  convertase is a metalloprotease involved in the formation of active TNF- $\alpha$ . Inhibition of TNF- $\alpha$  convertase inhibits production of active TNF- $\alpha$ . Compounds that inhibit both MMPs activity and TNF- $\alpha$  production have been disclosed in WIPO International Publication Nos. WO 94/24140, WO 94/02466 and WO 97/20824. Compounds that inhibit MMPs such as collagenase, stromelysin and gelatinase have been shown to inhibit the release of TNF (Gearing et al. *Nature* 376, 555-557 (1994), McGeehan et al., *Nature* 376, 558-561 (1994)). There remains a

- 4 -

need for effective MMP and TNF- $\alpha$  convertase inhibiting agents.

MMPs are involved in other biochemical processes in mammals as well. Included is the control of ovulation, post-partum uterine involution, possibly implantation, cleavage of APP ( $\beta$ -Amyloid Precursor Protein) to the amyloid plaque and inactivation of  $\alpha_1$ -protease inhibitor ( $\alpha_1$ -PI).

Control of fertility and the treatment or prevention of Alzheimers Disease. In addition, increasing and maintaining the levels of an endogenous or administered serine protease inhibitor drug or biochemical such as  $\alpha_1$ -PI supports the treatment and prevention of diseases such as emphysema, pulmonary diseases, inflammatory diseases and diseases of aging such as loss of skin or organ stretch and resiliency.

Inhibition of selected MMPs can also be desirable in other instances. Treatment of cancer and/or inhibition of metastasis and/or inhibition of angiogenesis are examples of approaches to the treatment of diseases wherein the selective inhibition of stromelysin, gelatinase, or collagenase III are the relatively most important enzyme or enzymes to inhibit especially when compared with collagenase I (MMP-1). A drug that does not inhibit collagenase I can have a superior therapeutic profile. Osteoarthritis, another prevalent disease wherein it is believed that cartilage degradation in inflamed joints is at least partially caused by MMP-13 released from cells such as stimulated chondrocytes, may be best treated by administration of drugs one of whose modes of action is inhibition of MMP-13. See, for example, Mitchell et al., *J. Clin. Invest.*, 97:761-768 (1996) and Reboul et al., *J. Clin. Invest.*, 97:2011-2019 (1996).

- 5 -

Inhibitors of metalloproteases are known. Examples include natural biochemicals such as tissue inhibitor of metalloproteinase (TIMP),  $\alpha_2$ -macroglobulin and their analogs or derivatives.

5 These are high molecular weight protein molecules that form inactive complexes with metalloproteases. A number of smaller peptide-like compounds that inhibit metalloproteases have been described. Mercaptoamide peptidyl derivatives have shown ACE

10 inhibition *in vitro* and *in vivo*. Angiotensin converting enzyme (ACE) aids in the production of angiotensin II, a potent pressor substance in mammals and inhibition of this enzyme leads to the lowering of blood pressure. Thiol group-containing amide or

15 peptidyl amide-based metalloprotease (MMP) inhibitors are known as is shown in, for example, WO95/12389, WO96/11209 and U.S. 4,595,700.

It is recognized that a compound that inhibits a known member of the MMP group of enzymes

20 can inhibit members in that group and also new, yet to be discovered, enzymes. Therefore, the skilled person will presume that the novel inhibitors of this invention can be useful in the treatment of the diseases in which known and new MMP enzymes are

25 implicated.

#### Summary of the Invention

The present invention is directed to a process for treating a mammal having a condition

30 associated with pathological matrix metalloprotease (MMP) activity, as well as to molecules that particularly inhibit the activity of MMP-13.


Briefly, therefore, one embodiment of the present invention is directed to a process for

35 treating a mammal having a condition associated with pathological matrix metalloprotease activity that comprises administering a metalloprotease inhibitor

- 6 -


in an effective amount to a host having such a condition. The administered enzyme inhibitor corresponds in structure to one of formulas (I), (II) or (III), below

5




(I)

10



(II)

or



(III)

15

wherein

each of x and y independently is zero, 1 or 2;

20 W is oxygen or sulfur;

A contemplated R<sup>10</sup> group is an alkyl, aryl, alkoxy, cycloalkyl, aryloxy, aralkoxy, aralkyl,

- 7 -

aminoalkyl, heteroaryl and N-monosubstituted or N,N-disubstituted aminoalkyl group wherein the substituent(s) on the nitrogen are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, 5 aralkoxycarbonyl, alkoxy carbonyl, and alkanoyl, or wherein the nitrogen and two substituents attached thereto form a 5- to 8-membered heterocyclic or heteroaryl ring;

A contemplated R<sup>1</sup> group is linked to the 10 SO<sub>2</sub> portion of an inhibitor is an aryl (carbocyclic) or heteroaryl group. That SO<sub>2</sub>-linked substituent can be an aralkanoylalkyl, arylcarbonylalkyl, aralkylaryl, aryloxyalkylaryl, aralkoxyaryl, arylazoaryl, arylhydrazinoaryl, alkylthioaryl, 15 arylthioalkyl, alkylthioaralkyl, aralkylthioalkyl, or aralkylthioaryl group, the sulfoxide or sulfone of any of those thio substituents, alkylthioalkyl, and can have a fused ring structure comprising two or three 5- or 6-membered aryl rings that can be 20 carbocyclic or heterocyclic rings. The SO<sub>2</sub>-linked substituent is preferably aryl or heterocyclic (heteroaryl) ring having a single aromatic ring such as a single-ringed aralkyl, heteroaralkyl, aralkoxyalkyl, or aryloxyalkyl group. The aryl 25 (carbocyclic) and heteroaryl substituents of which R<sup>1</sup> can be comprised are unsubstituted or substituted with one or two substituents independently selected from among halo, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, nitro, cyano, perfluoroalkyl, trifluoromethylalkyl, hydroxy, 30 thiol, hydroxycarbonyl, aryloxy, arylthio, arylamino, aralkyl, arylcarboxamido, heteroarylcarboxamido, azoaryl, azoheteroaryl, aryl, heteroaryloxy, heteroarylthio, heteroarylarnino, heteroaralkyl, cycloalkyl, heterocyclooxy, heterocyclothio, 35 heterocycloamino, cycloalkyloxy, cycloalkylthio, cycloalkylamino, heteroaralkoxy, heteroaralkylthio,

heteroaralkylamino, aralkoxy, aralkylthio,  
aralkylamino, heterocyclic, heteroaryl, arylazo,  
hydroxycarbonylalkoxy, alkoxy carbonylalkoxy,  
5 alkanoyl, arylcarbonyl, aralkanoyl, alkanoyloxy,  
aralkanoyloxy, hydroxyalkyl, hydroxyalkoxy,  
alkylthio, alkoxyalkylthio, alkoxy carbonyl,  
aryloxyalkoxyaryl, arylthioalkylthioaryl,  
aryloxyalkylthioaryl, arylthioalkoxyaryl,  
hydroxycarbonylalkoxy, hydroxycarbonylalkylthio,  
10 alkoxy carbonylalkoxy, alkoxy carbonylalkylthio, amino,  
alkanoylamino, arylcarbonylamino, aralkanoylamino,  
heteroarylcarbonylamino, heteroaralkanoylamino, and  
N-monosubstituted or N,N-disubstituted aminoalkyl  
wherein the substituent(s) on the nitrogen are  
15 selected from the group consisting of alkyl, aryl,  
aralkyl, cycloalkyl, aralkoxycarbonyl,  
alkoxycarbonyl, and alkanoyl, or wherein the nitrogen  
and two substituents attached thereto together form a  
5- to 8-membered heterocyclo or heteroaryl ring.

20 Contemplated R<sup>2</sup> and R<sup>3</sup> substituents can  
independently be hydrogen (hydrido), an alkyl, aryl,  
aralkyl, heteroaryl, heteroaralkyl, alkynylalkyl,  
alkenylalkyl, thioalkyl, cycloalkyl, cycloalkylalkyl,  
heterocycloalkylalkyl, alkoxyalkyl, aralkoxyalkyl,  
25 aminoalkyl, alkoxyalkoxyalkyl, aryloxyalkyl,  
hydroxyalkyl, hydroxycarbonylalkyl,  
hydroxycarbonylaralkyl, or N-monosubstituted or N,N-  
disubstituted aminoalkyl group wherein the  
substituent(s) on the nitrogen are selected from the  
30 group consisting of alkyl, aralkyl, cycloalkyl and  
alkanoyl, or wherein R<sup>2</sup> and another substituent (R<sup>2</sup>  
and R<sup>4</sup>, or R<sup>2</sup> and R<sup>6</sup>, or R<sup>2</sup> and R<sup>8</sup>) together with the  
atoms to which they are attached form a 4- to  
8-membered ring.

35 Contemplated R<sup>4</sup> and R<sup>5</sup> groups are  
independently selected. Those substituents can be

- 9 -

hydrogen (hydrido), an alkyl, cycloalkyl,  
cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl,  
aryloxyalkyl, aralkoxyalkyl, aralkyl, aryl,  
heteroaryl, heteroaralkyl, hydroxycarbonylalkyl,  
5 alkoxycarbonylalkyl, aralkoxycarbonylalkyl,  
hydroxycarbonyl, alkoxycarbonyl, perfluoroalkyl,  
trifluoromethylalkyl, thioalkyl, alkylthioalkyl,  
arylthioalkyl, aralkylthioalkyl,  
heteroaralkylthioalkyl, or a sulfoxide or sulfone of  
10 any of the thio substituents, aminocarbonyl,  
aminocarbonylalkyl, N-monosubstituted or N,N-  
disubstituted aminocarbonyl or aminocarbonylalkyl  
group wherein the substituent(s) on the nitrogen are  
independently selected from among alkyl, aralkyl,  
15 cycloalkyl and alkanoyl, or wherein the nitrogen and  
two substituents attached thereto together form a 5-  
to 8-membered heterocyclo or heteroaryl ring that can  
contain one additional heteroatom, or R<sup>2</sup> and R<sup>4</sup>  
together with the atoms to which they are attached  
form a 4- to 8-membered ring (as above), or R<sup>4</sup> and R<sup>5</sup>  
20 together with the atom to which they are attached  
form a 3- to 8-membered ring, or R<sup>4</sup> and R<sup>8</sup> together  
with the atoms to which they are attached form a 5-  
to 8-membered ring.  
25 R<sup>6</sup> and R<sup>7</sup> substituents are also  
independently selected. R<sup>6</sup> and R<sup>7</sup> substituents can  
be a substituent that constitutes R<sup>4</sup> and R<sup>5</sup>, or R<sup>6</sup>  
and R<sup>4</sup> together with atoms to which they are attached  
form a 4- to 8-membered ring, or R<sup>6</sup> and R<sup>2</sup> together  
30 with the atoms to which they are attached form a 5-  
to 8-membered ring (as above), or R<sup>6</sup> and R<sup>8</sup> together  
with the atoms to which they are attached form a 4-  
to 8-membered ring, or R<sup>6</sup> and R<sup>7</sup> together with atom  
to which they are attached form a 3- to 8-membered  
35 ring.


-10-

Contemplated R<sup>8</sup> and R<sup>9</sup> substituents are also independently selected. R<sup>8</sup> and R<sup>9</sup> substituents can also be a substituent that constitutes R<sup>3</sup> and R<sup>4</sup>, or R<sup>8</sup> and R<sup>2</sup> together with the atoms to which they are attached form a 6- to 8-membered ring (as above), or R<sup>8</sup> and R<sup>9</sup> together with the atom to which they are attached form a 3- to 8-membered ring, or R<sup>8</sup> and R<sup>4</sup> together with the atom to which they are attached form a 5- to 8-membered ring (as above), or R<sup>8</sup> and R<sup>6</sup> together with the atoms to which they are attached form a 4- to 8-membered ring (as above).


A provision to the above definitions is that no carbon atom is geminally substituted with more than one sulphydryl group. Additionally, a starred substituent "R\*" groups, "y\*" and "x\*" of formula III are the same as or different from the unstarred "R" groups, "y" and "x".

The present invention is also directed to a more preferred sub-set of molecules of formulas I, II, and III, above. Here, x is zero so that R<sup>8</sup> and R<sup>9</sup> and their bonded carbon atom are absent, y is one, the mercapto group is bonded directly to the carbon atom that bears the R<sup>6</sup> substituent radical, when present, with the R<sup>7</sup> radical of formulas I-III being hydrido, as are R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup>. Here, also, R<sup>1</sup> is a substituted aryl (carbocyclic aryl), or substituted heteroaryl group containing one 5- or 6-membered ring; i.e., R<sup>1</sup> is other than a fused ring substituted aryl or heteroaryl group, and a compound of formula III is a homodimer. These preferred compounds are depicted by formulas Ia, IIa, and IIIa, below, and the substituent "R" groups and W are discussed hereinafter.

- 11 -




(I a)



(II a)

5

or




(III a)


10 In most preferred practice, a contemplated inhibitor compound constitutes another sub-set of the compounds of formulas I, II and III. Here, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> of formulas I-III are hydrido, only one of R<sup>2</sup> and R<sup>6</sup> is present unless bonded together in a ring,  
 15 the SO<sub>2</sub>-linked R<sup>1</sup> substituent is a 4-substituted phenyl group (PhR<sup>11</sup>), and W is O. These most preferred compounds are depicted by formulas Ib, IIb and IIIb, below. Specifics of the depicted "R" groups are discussed hereinafter.

20

- 12 -




(I b)



(II b)

5

or



(III b)

10

Among the several benefits and advantages of the present invention are the provision of compounds and compositions effective as inhibitors of matrix metalloproteinase activity, the provision of such compounds and compositions that are effective for the inhibition of metalloproteinases implicated in diseases and disorders involving uncontrolled breakdown of connective tissue.

More particularly, a benefit of this invention is the provision of a compound and composition effective for inhibiting metalloproteinases, particularly MMP-13, associated

-13-

with pathological conditions such as, for example, rheumatoid arthritis, osteoarthritis, septic arthritis, corneal, epidermal or gastric ulceration, tumor metastasis, invasion or angiogenesis,  
5 periodontal disease, proteinuria, Alzheimer's Disease, coronary thrombosis and bone disease.

An advantage of the invention is the provision of a method for preparing such compositions. Another benefit is the provision of a  
10 method for treating a pathological condition associated with abnormal matrix metalloproteinase activity.

Another advantage is the provision of compounds, compositions and methods effective for  
15 treating such pathological conditions by selective inhibition of a metalloproteinase, MMP-13, associated with such conditions with minimal side effects resulting from inhibition of other proteinases whose activity is necessary or desirable for normal body  
20 function.

Still further benefits and advantages of the invention will be apparent to the skilled worker from the disclosure that follows.

25 Description of the Preferred Embodiments


In accordance with the present invention, it has been discovered that certain thiol sulfones are effective for inhibition of matrix metalloproteinases ("MMPs") believed to be associated  
30 with uncontrolled or otherwise pathological breakdown of connective tissue. In particular, it has been found that these certain thiolsulfonamides are effective for inhibition of collagenase III (MMP-13), which can be particularly destructive to tissue if  
35 present or generated in abnormal quantities or concentrations, and thus exhibit a pathological activity.

- 14 -

Moreover, it has been discovered that many of these thiol sulfones are selective in the inhibition of MMP-13, as well as other MMPs associated with diseased conditions without excessive 5 inhibition of those collagenases essential to normal bodily function such as tissue turnover and repair. More particularly, it has been found that particularly preferred the thiol sulfones useful in the invention are particularly active in inhibiting 10 of MMP-13, while being selective for MMP-13, in having a limited or minimal effect on MMP-1. This point is discussed in detail hereinafter and is illustrated in several examples.


One embodiment of the present invention is 15 directed to a process for treating a mammal having a condition associated with pathological matrix metalloprotease activity. That process comprises administering a metalloprotease inhibitor in an effective amount to a host having such a condition. 20 The administered enzyme inhibitor corresponds in structure to one of formulas (I), (II) or (III), below

25




(I)

- 15 -



or



5

wherein

each of x and y independently is zero,

1 or 2;

10           W is oxygen or sulfur;

A contemplated R<sup>10</sup> group is an alkyl, aryl, alkoxy, cycloalkyl, aryloxy, aralkoxy, aralkyl, aminoalkyl, heteroaryl and N-monosubstituted or N,N-disubstituted aminoalkyl group wherein the  
15 substituent(s) on the nitrogen are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, aralkoxycarbonyl, alkoxy carbonyl, and alkanoyl, or wherein the nitrogen and two substituents attached thereto form a 5- to 8-membered heterocyclic or  
20 heteroaryl ring;

A contemplated R<sup>1</sup> group is linked to the SO<sub>2</sub> portion of an inhibitor is an aryl (carbocyclic) or heteroaryl group. That SO<sub>2</sub>-linked substituent can be an aralkanoylalkyl, arylcarbonylalkyl, aralkylaryl, aryloxyalkylaryl, aralkoxyaryl, arylazoaryl, arylhydrazinoaryl, alkylthioaryl,

arylthioalkyl, alkylthioaralkyl, aralkylthioalkyl, or aralkylthioaryl group, the sulfoxide or sulfone of any of those thio substituents, alkylthioalkyl, and can have a fused ring structure comprising two or

5 three 5- or 6-membered aryl rings that can be carbocyclic or heterocyclic rings. The SO<sub>2</sub>-linked substituent is preferably aryl or heterocyclic (heteroaryl) ring having a single aromatic ring such as a single-ringed aralkyl, heteroaralkyl,

10 aralkoxyalkyl, or heteroaryloxyalkyl group. The aryl (carbocyclic) and heteroaryl substituents of which R<sup>1</sup> can be comprised are unsubstituted or substituted with one or two substituents independently selected from among halo, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, nitro,

15 cyano, perfluoroalkyl, trifluoromethylalkyl, hydroxy, thiol, hydroxycarbonyl, aryloxy, arylthio, arylamino, aralkyl, arylcarboxamido, heteroarylcarboxamido, azoaryl, azoheteroaryl, aryl, heteroaryloxy, heteroarylthio, heteroarylarnino, heteroaralkyl,

20 cycloalkyl, heterocyclooxy, heterocyclothio, heterocycloamino, cycloalkyloxy, cycloalkylthio, cycloalkylamino, heteroaralkoxy, heteroaralkylthio, heteroaralkylamino, aralkoxy, aralkylthio, aralkylamino, heterocyclic, heteroaryl, arylazo,

25 hydroxycarbonylalkoxy, alkoxycarbonylalkoxy, alkanoyl, arylcarbonyl, aralkanoyl, alkanoyloxy, aralkanoyloxy, hydroxyalkyl, hydroxyalkoxy, alkylthio, alkoxyalkylthio, alkoxycarbonyl, aryloxyalkoxyaryl, arylthioalkylthioaryl,

30 aryloxyalkylthioaryl, arylthioalkoxyaryl, hydroxycarbonylalkoxy, hydroxycarbonylalkylthio, alkoxycarbonylalkoxy, alkoxycarbonylalkylthio, amino, alkanoylamino, arylcarbonylamino, aralkanoylamino, heteroarylcarbonylamino, heteroaralkanoylamino, and

35 N-monosubstituted or N,N-disubstituted aminoalkyl wherein the substituent(s) on the nitrogen are selected from the group consisting of alkyl, aryl,

-17-

aralkyl, cycloalkyl, aralkoxycarbonyl, alkoxycarbonyl, and alkanoyl, or wherein the nitrogen and two substituents attached thereto together form a 5- to 8-membered heterocyclo or heteroaryl ring.

Contemplated R<sup>2</sup> and R<sup>3</sup> substituents can independently be hydrogen (hydrido), an alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkynylalkyl, alkenylalkyl, thioalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, alkoxyalkyl, aralkoxyalkyl, aminoalkyl, alkoxyalkoxyalkyl, aryloxyalkyl, hydroxyalkyl, hydroxycarbonylalkyl, hydroxycarbonylaralkyl, or N-monosubstituted or N,N-disubstituted aminoalkyl group wherein the substituent(s) on the nitrogen are selected from the group consisting of alkyl, aralkyl, cycloalkyl and alkanoyl, or wherein R<sup>2</sup> and another substituent (R<sup>2</sup> and R<sup>4</sup>, or R<sup>2</sup> and R<sup>6</sup>, or R<sup>2</sup> and R<sup>8</sup>) together with the atoms to which they are attached form a 4- to 8-membered ring.

Contemplated R<sup>4</sup> and R<sup>5</sup> groups are independently selected. Those substituents can be hydrogen (hydrido), an alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, aryloxyalkyl, aralkoxyalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, hydroxycarbonyl, alkoxycarbonyl, perfluoroalkyl, trifluoromethylalkyl, thioalkyl, alkylthioalkyl, arylthioalkyl, aralkylthioalkyl, heteroaralkylthioalkyl, or a sulfoxide or sulfone of any of the thio substituents, aminocarbonyl, aminocarbonylalkyl, N-monosubstituted or N,N-disubstituted aminocarbonyl or aminocarbonylalkyl group wherein the substituent(s) on the nitrogen are independently selected from among alkyl, aralkyl, cycloalkyl and alkanoyl, or wherein the nitrogen and two

-18-

substituents attached thereto together form a 5- to 8-membered heterocyclo or heteroaryl ring that can contain one additional heteroatom, or R<sup>2</sup> and R<sup>4</sup> together with the atoms to which they are attached 5 form a 4- to 8-membered ring (as above), or R<sup>4</sup> and R<sup>5</sup> together with the atom to which they are attached form a 3- to 8-membered ring, or R<sup>4</sup> and R<sup>8</sup> together with the atoms to which they are attached form a 5- to 8-membered ring.

10           R<sup>6</sup> and R<sup>7</sup> substituents are also independently selected. R<sup>6</sup> and R<sup>7</sup> substituents can be a substituent that constitutes R<sup>4</sup> and R<sup>5</sup>, or R<sup>6</sup> and R<sup>4</sup> together with atoms to which they are attached form a 4- to 8-membered ring, or R<sup>6</sup> and R<sup>2</sup> together 15 with the atoms to which they are attached form a 5- to 8-membered ring (as above), or R<sup>6</sup> and R<sup>8</sup> together with the atoms to which they are attached form a 4- to 8-membered ring, or R<sup>6</sup> and R<sup>7</sup> together with atom 20 to which they are attached form a 3- to 8-membered ring.

Contemplated R<sup>8</sup> and R<sup>9</sup> substituents are also independently selected. R<sup>8</sup> and R<sup>9</sup> substituents can also be a substituent that constitutes R<sup>3</sup> and R<sup>4</sup>, or R<sup>8</sup> and R<sup>2</sup> together with the atoms to which they 25 are attached form a 6- to 8-membered ring (as above), or R<sup>8</sup> and R<sup>9</sup> together with the atom to which they are attached form a 3- to 8-membered ring, or R<sup>8</sup> and R<sup>4</sup> together with the atom to which they are attached form a 5- to 8-membered ring (as above), or R<sup>8</sup> and R<sup>6</sup> 30 together with the atoms to which they are attached form a 4- to 8-membered ring (as above).

A provision to the above definitions is that no carbon atom is geminally substituted with more than one sulfhydryl group. Additionally, a

-19-

starred substituent groups (R\*), as well as "y\*" and "x\*" of formula III are the same as or different from the unstarred "R" groups, "y" and "x".

In generally increasing order of preference, the following paragraphs summarize the substituents that can most advantageously constitute each of R<sup>1</sup> through R<sup>4</sup>, as well as w, x and y.

R<sup>1</sup> represents a substituted aryl or heteroaryl ring that is substituted by one or more of the following substituents: C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy, heteroaralkoxy, C<sub>1</sub>-C<sub>10</sub> alkylthio, arylthio, heteroarylthio.

R<sup>1</sup> represents a substituted aryl or heteroaryl ring that is substituted by one or more of the following substituents: C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, arylcarboxamido, heteroarylcarboxamido, arylazo, heteroarylazo, aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy, heteroaralkoxy, C<sub>1</sub>-C<sub>6</sub> alkylthio, arylthio, heteroarylthio in which each ring-containing substituent itself contains a single ring.

R<sup>1</sup> represents a 6-membered substituted aryl ring that is substituted in the para-position (4-position) by one of the following substituents: C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, arylcarboxamido, heteroarylcarboxamido, arylazo, heteroarylazo, aryloxy, heteroaryloxy, aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy, heteroaralkoxy, C<sub>1</sub>-C<sub>6</sub> alkylthio, arylthio, heteroarylthio in which each ring-containing substituent itself contains a single ring.

R<sup>1</sup> represents a 6-membered substituted aryl ring that is substituted in the 4- or para-position

- 20 -

by C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy arylcarboxamido, arylazo, aryloxy, arylthio and aryl in which each ring-containing substituent itself contains a single ring.

5 R<sup>1</sup> represents substituted phenyl, wherein the phenyl ring is substituted in the para-position by n-propyl, n-butyl, n-pentyl, n-hexyl, isobutyl, isoamyl, ethoxy, n-propyloxy, n-butoxy, n-pentyloxy, n-hexyloxy, isobutoxy, phenoxy, thiophenoxy (phenylthio), phenyl, azophenyl or benzamido, in  
10 which the para-substituted R<sup>1</sup> phenyl substituent can itself optionally contain a para-substituent containing one atom or a chain of no more than five atoms other than hydrogen, or in the meta- and para-  
15 positions by a methylenedioxy moiety.

R<sup>2</sup> and R<sup>3</sup> Preferences:

R<sup>2</sup> and R<sup>3</sup> are independently hydrogen (hydrido), C<sub>1</sub>-C<sub>6</sub> alkyl, aralkyl, heteroaralkyl,  
20 cycloalkylalkyl having 4-8 carbons in the ring and 1-3 carbons in the alkyl chain, heterocycloalkylalkyl in which 4-8 atoms are in the ring, one or two of which atoms can be nitrogen, oxygen or sulfur and in which the alkyl chain contains 1-3 carbons, C<sub>1</sub>-C<sub>5</sub>  
25 alkyl substituted by hydroxycarbonyl, amino, mono-substituted amino and di-substituted amino, wherein the substituents on nitrogen are chosen from C<sub>1</sub>-C<sub>4</sub> alkyl, aralkyl, C<sub>5</sub>-C<sub>8</sub> cycloalkyl and C<sub>1</sub>-C<sub>6</sub> alkanoyl groups, or wherein the two substituents and the  
30 nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring.

R<sup>2</sup> and R<sup>3</sup> are independently hydrogen (hydrido), C<sub>1</sub>-C<sub>6</sub> alkyl, aralkyl, heteroaralkyl,  
35 cycloalkylalkyl having 4-8 carbons in the ring and 1-

-21-

3 carbons in the alkyl chain, heterocycloalkylalkyl in which 4-8 atoms are in the ring, one or two of which atoms can be nitrogen, oxygen or sulfur and in which the alkyl chain contains 1-3 carbons.

5           R<sup>2</sup> represents hydrogen (hydrido) or C<sub>1</sub>-C<sub>6</sub> alkyl and R<sup>3</sup> is hydrogen.

R<sup>2</sup> represents hydrogen (hydrido), methyl, ethyl, n-propyl, n-butyl, or isobutyl and R<sup>3</sup> is hydrogen.

10          R<sup>2</sup> represents hydrogen (hydrido) benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-thiazolylmethyl, 4-thiazolylmethyl, or 5-thiazolylmethyl and R<sup>3</sup> is hydrogen.

15          R<sup>4</sup> and R<sup>5</sup> Preferences:

R<sup>4</sup> and R<sup>5</sup> independently are hydrogen (hydrido) hydroxy, amino, alkanoylamino, aralkanoylamino, arylcarbonylamino, heteroarylcarbonylamino, hydroxycarbonyl, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub> alkyl, aralkyl aryl heteroaryl, cycloalkyl, heteroaralkyl, or alkylcycloalkyl.

R<sup>4</sup> and R<sup>5</sup> independently are hydrogen (hydrido) hydroxy, amino, hydroxycarbonyl, aminocarbonyl, or C<sub>1</sub>-C<sub>6</sub> alkyl.

25          R<sup>4</sup> and R<sup>5</sup> independently are hydrogen (hydrido) hydroxy, or amino.

R<sup>4</sup> and R<sup>5</sup> independently are hydrogen (hydrido) methyl, ethyl, propyl or butyl.

30          R<sup>4</sup> and R<sup>5</sup> independently are hydrogen (hydrido) aryl or heteroaryl.

R<sup>4</sup> and R<sup>5</sup> independently are hydrogen (hydrido) benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-thiazolylmethyl, 4-thiazolylmethyl or 5-thiazolylmethyl.

- 22 -

R<sup>4</sup> and R<sup>5</sup> independently are hydrogen (hydrido) alkanoylamino, aralkanoylamino, or heteroarylcarbonylamino.

R<sup>4</sup> and R<sup>5</sup> are both hydrogen (hydrido).

5

R<sup>6</sup> and R<sup>7</sup> Preferences:

R<sup>6</sup> and R<sup>7</sup> independently are hydrido or a radical selected from the group consisting of an cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, C<sub>1</sub>-C<sub>6</sub> alkyl group, a carboxyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, an amino C<sub>1</sub>-C<sub>6</sub> alkanoyl group, a carboxamide group where the amido nitrogen is (i) unsubstituted or substituted with (ii) a C<sub>1</sub>-C<sub>4</sub> alkyl substituted by amino, mono-substituted amino or di-substituted amino, wherein the substituent on the amino nitrogen is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>5</sub>-C<sub>8</sub> cycloalkyl and C<sub>1</sub>-C<sub>6</sub> alkanoyl groups, or wherein two amino nitrogen substitutents and the nitrogen to which they are bonded together form a 5- to 8-membered heterocyclic or heteroaryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur or (iii) the amido nitrogen is the amine of an amino acid.

R<sup>6</sup> and R<sup>7</sup> independently are hydrogen and hydroxycarbonyl.

R<sup>6</sup> and R<sup>7</sup> independently are hydrogen, aryl, and heteroaryl.

R<sup>6</sup> and R<sup>7</sup> independently are hydrogen, aralkyl, and heteroaralkyl.

R<sup>6</sup> and R<sup>7</sup> independently are hydrogen, benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-thiazolylmethyl, 4-thiazolylmethyl or 5-thiazolylmethyl.

R<sup>6</sup> and R<sup>7</sup> are both hydrogen.

- 23 -

R<sup>7</sup> is hydrogen (hydrido) and R<sup>6</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl group, a carboxyl group, a carboxamide group where the amido nitrogen is (i) unsubstituted or substituted with (ii) a C<sub>1</sub>-C<sub>4</sub> alkyl substituted by 5 amino, mono-substituted amino or di-substituted amino, wherein the substituents on nitrogen are chosen from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>5</sub>-C<sub>8</sub> cycloalkyl and C<sub>1</sub>-C<sub>6</sub> alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken 10 together form a 5- to 8-membered heterocyclo or heterozryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur or (iii) the amido nitrogen is the amine of an amino acid, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl or an amino C<sub>1</sub>-C<sub>6</sub> 15 alkanoyl group, or R<sup>2</sup> and R<sup>6</sup> together with the atoms to which they are bonded form a 5- or 6-membered ring. These latter ring compounds are discussed separately hereinafter.

20 R<sup>8</sup> and R<sup>9</sup> Preferences:

R<sup>8</sup> and R<sup>9</sup> independently are hydrogen, hydroxycarbonyl, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.

25 R<sup>8</sup> and R<sup>9</sup> independently are hydrogen and hydroxycarbonyl.

R<sup>8</sup> and R<sup>9</sup> independently are hydrogen and C<sub>1</sub>-C<sub>6</sub> alkyl.

R<sup>8</sup> and R<sup>9</sup> independently are hydrogen, aryl, or heteroaryl.

30 R<sup>8</sup> and R<sup>9</sup> independently are hydrogen, aralkyl, or heteroaralkyl.

R<sup>8</sup> and R<sup>9</sup> independently are hydrogen, benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl,

- 24 -

2-thiazolylmethyl, 4-thiazolylmethyl, or 5-thiazolylmethyl.

R<sup>8</sup> and R<sup>9</sup> are both hydrogen

5 R<sup>10</sup> Preferences:

R<sup>10</sup> is alkyl, cycloalkyl, aryl, alkoxy, heteroaryl, aminoalkyl, N-monosubstituted aminoalkyl and N,N-disubstituted aminoalkyl, wherein the substituents on nitrogen are selected from the group consisting of alkyl, aralkyl, cycloalkyl and alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring.

15 R<sup>10</sup> is alkyl, aryl, alkoxy, heteroaryl, aminoalkyl, N-monosubstituted aminoalkyl, and N,N-disubstituted aminoalkyl, wherein the substituents on nitrogen are selected from the group consisting of alkyl, aralkyl, cycloalkyl and alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring.

20 R<sup>10</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, alkoxy, or heteroaryl.

25 R<sup>10</sup> is methyl, ethyl, n-propyl, n-butyl, isopropyl, or isobutyl.

R<sup>10</sup> is a 3- to 8-membered cycloalkyl ring.

R<sup>10</sup> is cyclohexyl and cyclopentyl.

30 R<sup>10</sup> is aryl or heteroaryl having a single ring.

R<sup>10</sup> is phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, thiophene-2-yl, or 3-thiophene-3-yl.

R<sup>10</sup> is C<sub>1</sub>-C<sub>6</sub> alkoxy.

35 R<sup>10</sup> is methoxy and ethoxy.

-25-

Starred substituents, R\*, y\* and x\* are preferably the same as unstarred substituents, R, y and x so that a compound of formula III is homodimer.

In particularly preferred practice, a chain 5 of three carbon atoms separates the SO<sub>2</sub> portion of a SO<sub>2</sub>-linked R<sup>1</sup> substituent and the mercapto group so that x is zero and y is 1. An SO<sub>2</sub>-linked R<sup>1</sup> substituent is a substituted aryl or heteroaryl group that is a 5- or 6-membered single-ring; i.e., the 10 aryl or heteroaryl group is not a fused ring radical, and is itself substituted with one other single-ringed aryl or heteroaryl group or, with an alkyl or alkoxy group containing an chain of 2 to about 7 carbon atoms, a phenoxy group, a thiophenoxy 15 [C<sub>6</sub>H<sub>5</sub>-S-] group, a phenylazido [C<sub>6</sub>H<sub>5</sub>-N<sub>2</sub>-] group or a benzamido [-NHC(O)C<sub>6</sub>H<sub>5</sub>] group. The SO<sub>2</sub>-linked 20 single-ringed aryl or heteroaryl R<sup>1</sup> group is substituted at its own 4-position when a 6-membered ring, and at its own 3-position when a 5-membered ring.

The R<sup>1</sup> group's substituent single-ringed aryl or heteroaryl, phenoxy, thienyl, thiophenoxy, phenylazo or benzamido group is unsubstituted or can 25 itself be substituted at the 4-position, and sometimes at both the 3- and 4-positions, when a 6-membered ring or the 3-position when a 5-membered ring. The 4- and 3-positions of rings discussed here are numbered from the sites of substituent bonding as compared to formalized ring numbering positions used 30 in heteroaryl nomenclature. Here, single atoms such as halogen moieties or substituents that contain one to a chain of about five atoms other than hydrogen such as C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy or carboxyethyl groups can be used. Exemplary substituted SO<sub>2</sub>-linked 35 R<sup>1</sup> substituents include biphenyl, 4-phenoxyphenyl,

4-thiophenoxyphenyl, 4-butoxyphenyl, 4-methoxyphenyl, 4-pentylphenyl, 4-(4'-dimethylaminophenyl)azophenyl, 4-(3,4-methylenedioxy)phenoxy and 2-[(2-pyridyl)-5-thienyl].

5 When examined along its longest chain of atoms, an R<sup>1</sup> substituent including its own substituent has a total length of greater than a saturated chain of six carbon atoms and less than a saturated chain of about 18 and preferably about 12  
10 carbon atoms, even though many more atoms may be present in ring structures or substituents. This length requirement is discussed further below.

Looked at more generally, and aside from specific moieties from which it is constructed, a  
15 particularly preferred R<sup>1</sup> radical (group or moiety) has a length greater than about that of a pentyl group, e.g., 4-ethylphenyl or 4-methoxyphenyl. Such an R<sup>1</sup> radical also has a length that is less than that of a stearyl (octadecyl) group. That is to say  
20 that a particularly preferred R<sup>1</sup> group is a radical having a length greater than about that of a saturated six carbon chain, and shorter than that of a saturated eighteen carbon chain. More preferably, the radical has a length greater than that of a hexyl  
25 group and less than that of a lauryl group.

The radical chain lengths are measured along the longest linear atom chain in the radical, and each atom in the chain is presumed to be carbon for ease in calculation. Such lengths can be readily  
30 determined by using published bond angles, bond lengths and atomic radii, as needed, to draw and measure a staggered chain, or by building models using commercially available kits whose bond angles, lengths and atomic radii are in accord with accepted,  
35 published values. For example, a phenyl group has a length of about a butyl group. Radical lengths can also be determined somewhat less exactly by assuming


- 27 -


that all atoms have bond lengths of saturated carbon,  
 that unsaturated bonds have the same lengths as  
 saturated bonds and that bond angles for unsaturated  
 bonds are the same as those for saturated bonds,  
 5 although the above-mentioned modes of measurement are  
 preferred.

In addition, a particularly preferred R<sup>1</sup>  
 group when rotated about an axis drawn through the  
 SO<sub>2</sub>-bonded 1-position and the 4-position of a  
 10 6-membered ring, or the SO<sub>2</sub>-bonded position and  
 substituent-bonded 3- or 5-position of a 5-membered  
 ring defines a three-dimensional volume whose widest  
 dimension has the width of about one phenyl ring to  
 about three phenyl rings in a direction transverse to  
 15 that axis to rotation.

As a consequence of these length and width  
 requirements, R<sup>1</sup> substituents such as  
 4-(phenyl)phenyl [biphenyl],  
 4-(4'-methoxyphenyl)phenyl, 4-(phenoxy)phenyl,  
 20 4-(thiophenyl)phenyl [4-(phenylthio)phenyl],  
 4-(azophenyl)phenyl and 4-(benzamido)phenyl are  
 particularly preferred R<sup>1</sup> substituents. Those  
 substituents can themselves also be substituted in  
 the second ring from the SO<sub>2</sub> group at the meta- or  
 25 para-position or both with a single atom or a  
 substituent containing a longest chain of up to five  
 atoms, excluding hydrogen.

One sub-set of particularly preferred MMP-  
 30 13 inhibitor compounds useful in a before-described  
 process has structures depicted by formulas Ia, IIa  
 and IIIa, below.






(II a)

or

5



(III a)


In the above particularly preferred MMP-13  
 10 inhibitor compounds useful herein, R<sup>1</sup> is as described  
 immediately above. W is preferably oxygen (O) in  
 these compounds, but can be sulfur (S). R<sup>10</sup> is as  
 discussed before, but is preferably aryl or  
 heteroaryl having a single ring or C<sub>1</sub>-C<sub>6</sub> alkoxy.

15 R<sup>2</sup> and R<sup>3</sup> are radicals that are  
 independently selected from the group consisting of  
 hydrido, C<sub>1</sub>-C<sub>6</sub> alkyl, single-ringed aralkyl or  
 heteroaralkyl having 1-3 carbons in the alkyl chain,  
 cycloalkylalkyl having 4-8 carbons in the ring and 1-  
 20 3 carbons in the alkyl chain, and  
 heterocycloalkylalkyl in which 4-8 atoms are in the  
 ring, one or two of which atoms are nitrogen, oxygen  
 or sulfur and in which the alkyl chain contains 1-3  
 carbons, or wherein R<sup>2</sup> and R<sup>6</sup> together with the atoms  
 25 to which they are bonded form a 5- or 6-membered  
 ring.

-29-


$R^6$  is a radical selected from the group consisting of an  $C_1$ - $C_6$  alkyl group, a carboxyl group, a  $C_1$ - $C_6$  alkoxy carbonyl group, an amino  $C_1$ - $C_6$  alkanoyl group, a carboxamide group where the amido nitrogen is (i) unsubstituted or substituted with (ii) a  $C_1$ - $C_4$  alkyl substituted by amino, mono-substituted amino or di-substituted amino, wherein the substituent on the amino nitrogen is selected from the group consisting of  $C_1$ - $C_6$  alkyl,  $C_5$ - $C_8$  cycloalkyl and  $C_1$ - $C_6$  alkanoyl groups, or wherein two amino nitrogen substitutents and the nitrogen to which they are bonded together form a 5- to 8-membered heterocyclic or heteroaryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur or (iii) the amido nitrogen is the amine of an amino acid.  $R^2$  and  $R^6$  can also form a 5- or 6-membered ring together with the atoms to which they are bonded, as noted above. A 6-membered ring is preferred and that ring can be aromatic.

A most preferred MMP-13 inhibitor sub-set of compounds useful in a before-described process corresponds to the structures depicted by formulas I<sub>b</sub>, II<sub>b</sub> and III<sub>b</sub>, below.



(I b)


25



(II b)

- 30 -

or



(III b)



5

In an inhibitor compound of formulas Ib, IIb, or IIIb, R<sup>2</sup> and R<sup>6</sup> are as discussed immediately above, except that only one of R<sup>2</sup> or R<sup>6</sup> is present, unless R<sup>2</sup> and R<sup>6</sup> together with the atoms to which they are bonded form a 5- or 6-membered ring. R<sup>10</sup> is also as discussed immediately above. The phenyl ring (Ph) of a PhR<sup>11</sup> group is substituted at its para-position by an R<sup>11</sup> group that can be another single-ringed aryl or heteroaryl group or, with a C<sub>2</sub>-C<sub>6</sub> alkyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, a phenoxy group, a thiophenoxy [C<sub>6</sub>H<sub>5</sub>-S-] group, a phenylazido [C<sub>6</sub>H<sub>5</sub>-N<sub>2</sub>-] group or a benzamido [-NHC(O)C<sub>6</sub>H<sub>5</sub>] group. In one embodiment of a most preferred inhibitor compound, an R<sup>11</sup> substituent is phenoxy and is itself substituted at its own para-position with a moiety that is selected from the group consisting of a halogen, a C<sub>1</sub>-C<sub>4</sub> alkoxy group, a C<sub>1</sub>-C<sub>4</sub> alkyl group, a dimethylamino group, a C<sub>1</sub>-C<sub>3</sub> alkyl carboxyl group, a C<sub>1</sub>-C<sub>3</sub> alkylcarbonyl C<sub>1</sub>-C<sub>4</sub> alkoxy group and a C<sub>1</sub>-C<sub>3</sub> alkyl carboxamido group, or is substituted at the meta- and para-positions by a methylenedioxy group.

Compounds in which R<sup>2</sup> and R<sup>6</sup> together with the atoms to which they are bonded form a 5- or a 6-

- 31 -

membered ring correspond to formulas IVa, IVb, Va, and Vb, below:



5

The following preferences apply to the inhibitor compounds of formulas IVa, IVb, Va and Vb:

R<sup>1</sup> preferences:

- 10 R<sup>1</sup> is a radical that is selected from the group consisting of aryl, heteroaryl, alkyl, alkylthioalkyl, arylthioalkyl, heteroarylthioalkyl, aralkylthioalkyl, heteroaralkylthioalkyl; the sulfone or sulfoxide of any of those thio substituents. The  
 15 aryl or heteroaryl groups can be substituted at one, two, or three positions by a radical selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy, heteroaralkoxy, C<sub>1</sub>-C<sub>10</sub> alkylthio, arylthio,  
 20 heteroarylthio, cycloalkylthio, heterocyclo, cycloalkyl, amino, alkanoylamino, aralkanoylamino, arylcarbonylamino, heteroaralkanoyl, heteroarylcarbonylamino.

- R<sup>1</sup> represents, C<sub>1</sub>-C<sub>10</sub> alkyl, aryl, heteroaryl, wherein the aryl or heteroaryl can optionally be substituted by one or more of the following substituents: C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy,

- 32 -

aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy,  
heteroaralkoxy, C<sub>1</sub>-C<sub>10</sub> alkylthio, arylthio,  
heteroarylthio, arylamino, heteroaryl amino.

R<sup>1</sup> represents aryl, wherein the aryl can  
5 optionally be substituted by one or more of the  
following substituents; C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy,  
aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy,  
heteroaralkoxy, C<sub>1</sub>-C<sub>6</sub> alkylthio, arylthio,  
heteroarylthio.

10 R<sup>1</sup> represents aryl, wherein the aryl is  
optionally substituted in the para-position by one of  
the following substituents; C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub>  
alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl,  
aralkoxy, heteroaralkoxy C<sub>1</sub>-C<sub>6</sub> alkylthio, arylthio,  
15 heteroarylthio or benzamido.

R<sup>1</sup> represents aryl, wherein the aryl is  
substituted in the para-position by C<sub>1</sub>-C<sub>6</sub> alkyl or  
C<sub>1</sub>-C<sub>6</sub> alkoxy.

20 R<sup>1</sup> represents aryl, wherein the aryl is  
substituted in the para-position by n-propyl, n-  
butyl, n-pentyl, n-hexyl, isobutyl, isoamyl, thoxy,  
n-propyloxy, n-butoxy, n-pentyloxy, n-hexyloxy,  
isobutoxy.

25 R<sup>1</sup> represents aryl, wherein the aryl is  
substituted in the para-position by n-butyl, n-  
pentyl, n-hexyl, n-butoxy, n-pentyloxy, isobutoxy.

30 R<sup>1</sup> represents single-ringed aryl, wherein  
the aryl is substituted in the para-position by  
aryloxy, phenyl, phenylazo, benzamido or  
heteroaryloxy.

R<sup>1</sup> represents single-ringed aryl, wherein  
the aryl is substituted in the para-position by a  
phenoxy group.

-33-

R<sup>1</sup> represents single-ringed aryl, wherein the aryl is substituted in the para-position by aryl or heteroaryl.

5 R<sup>1</sup> represents single-ringed aryl, wherein the aryl is substituted in the para-position by phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl.

R<sup>1</sup> represents single-ringed aryl, wherein the aryl is substituted in the para-position by phenyl.

10 R<sup>1</sup> represents single-ringed aryl, wherein the aryl is substituted in the para-position by C<sub>1</sub>-C<sub>6</sub> alkylthio.

15 R<sup>1</sup> represents single-ringed aryl, wherein the aryl is substituted in the para-position by methylthio, n-propylthio, n-butylthio.

R<sup>1</sup> represents single-ringed aryl, wherein the aryl is substituted in the para-position by arylthio and heteroarylthio.

20 R<sup>1</sup> represents single-ringed aryl, wherein the aryl is substituted in the para-position by phenylthio.

R<sup>10</sup> preferences:

25 R<sup>10</sup> is a radical selected from the group consisting of alkyl, aryl, alkoxy, heteroaryl, cycloalkyl, aminoalkyl, N-monosubstituted aminoalkyl and N,N-disubstituted aminoalkyl, wherein the substituents on nitrogen are chosen from alkyl, aralkyl, cycloalkyl and alkanoyl, or wherein the two 30 substituents and the nitrogen to which they are attached together form a 5 to 8 membered heterocyclo or heteroaryl ring.

R<sup>10</sup> represents C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, C<sub>1</sub>-C<sub>6</sub> alkoxy, or heteroaryl.

- 34 -

R<sup>10</sup> represents methyl, ethyl, n-propyl, n-butyl, isopropyl, or isobutyl.

R<sup>10</sup> represents a 3- to 8-membered cycloalkyl ring.

5 R<sup>10</sup> represents cyclohexyl and cyclopentyl.

R<sup>10</sup> represents aryl or heteroaryl.

R<sup>10</sup> represents phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, thiophene-2-yl, 3-thiophene-3-yl.


R<sup>10</sup> represents C<sub>1</sub>-C<sub>6</sub> alkoxy.

10 R<sup>10</sup> represents methoxy and ethoxy.

Particularly preferred and most preferred R<sup>1</sup> and R<sup>10</sup> substituents of inhibitor compounds of formulas IVa, IVb, Va and Vb are as discussed before for compounds of formulas Ia-IIIa and Ib-IIIb, respectively.

Another group of compounds in which R<sup>4</sup> and R<sup>6</sup> or R<sup>6</sup> and R<sup>8</sup> together with the atoms to which they are bonded form a 6-membered ring are those in which the formed ring is aromatic. Exemplary compounds 20 correspond to formulas VIa, VIb, VIIa, and VIIb, below. In those formulas, it is seen that inhibitor compounds of formulas VIa and VIb are compounds of formulas I and II in which y is zero and x is one, whereas compounds of formulas VIIa and VIIb are 25 compounds of formulas I and II in which y is one and x is one.

- 35 -



The following preferences apply for  
 5 preferred compounds of the above formulas.

R<sup>1</sup> preferences:

R<sup>1</sup> is a radical that is selected from the group consisting of aryl, heteroaryl, alkyl,  
 10 alkylthioalkyl, arylthioalkyl, heteroarylthioalkyl, aralkylthioalkyl, heteroaralkylthioalkyl; the sulfone or sulfoxide of any of said thio substituents. The aryl or heteroaryl groups can be substituted at one, two, or three positions by a radical selected from  
 15 the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy, heteroaralkoxy, C<sub>1</sub>-C<sub>10</sub> alkylthio, arylthio, heteroarylthio, cycloalkylthio, heterocyclo, cycloalkyl, amino, alkanoylamino, aralkanoylamino,  
 20 arylcarbonylamino, heteroaralkanoyl, heteroarylcarbonylamino.

R<sup>1</sup> is a radical that is aryl, heteroaryl, C<sub>1</sub>-C<sub>10</sub> alkyl, wherein the aryl or heteroaryl can optionally be substituted by one or more of the following substituents: C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy,

- 36 -

aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy,  
heteroaralkoxy, C<sub>1</sub>-C<sub>10</sub> alkylthio, arylthio,  
heteroarylthio, arylamino, heteroarylaminio.

R<sup>1</sup> is a radical that is aryl, wherein the  
5 aryl can optionally be substituted by one or more of  
the following substituents: C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub>  
alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl,  
aralkoxy, heteroaralkoxy, C<sub>1</sub>-C<sub>6</sub> alkylthio, arylthio,  
heteroarylthio.

10 R<sup>1</sup> is a radical that is single-ringed aryl,  
wherein the aryl is optionally substituted in the  
para-position by one of the following substituents:  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, aryloxy, heteroaryloxy,  
aryl, heteroaryl, aralkoxy, heteroaralkoxy, C<sub>1</sub>-C<sub>6</sub>  
15 alkylthio, arylthio, heteroarylthio.

R<sup>1</sup> is a radical that is single-ringed aryl,  
wherein the aryl is substituted in the para-position  
by C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> alkoxy.

20 R<sup>1</sup> is a radical that is single-ringed aryl,  
wherein the aryl is substituted in the para-position  
by n-propyl, n-butyl, n-pentyl, n-hexyl, isobutyl,  
isoamyl, t-butoxy, n-propyloxy, n-butoxy, n-  
pentyloxy, n-hexyloxy, isobutoxy.

25 R<sup>1</sup> is a radical that is single-ringed aryl,  
wherein the aryl is substituted in the para-position  
by n-butyl, n-pentyl, n-hexyl, n-butoxy, n-pentyloxy,  
isobutoxy.

30 R<sup>1</sup> is a radical that is single-ringed aryl,  
wherein the aryl is substituted in the para-position  
by aryloxy or heteroaryloxy.

R<sup>1</sup> is a radical that is single-ringed aryl,  
wherein the aryl is substituted in the para-position  
by a phenoxy group.

-37-

R<sup>1</sup> is a radical that is single-ringed aryl, wherein the aryl is substituted in the para-position by aryl or heteroaryl.

5 R<sup>1</sup> is a radical that is single-ringed aryl, wherein the aryl is substituted in the para-position by phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl.

R<sup>1</sup> is a radical that is single-ringed aryl, wherein the aryl is substituted in the para-position by phenyl.

10 R<sup>1</sup> is a radical that is single-ringed aryl, wherein the aryl is substituted in the para-position by C<sub>1</sub> to C<sub>6</sub> alkylthio.

15 R<sup>1</sup> is a radical that is single-ringed aryl, wherein the aryl is substituted in the para-position by methylthio, n-propylthio, n-butylthio.

R<sup>1</sup> is a radical that is single-ringed aryl, wherein the aryl is substituted in the para-position by arylthio and heteroarylthio.

20 R<sup>1</sup> is a radical that is single-ringed aryl, wherein the aryl is substituted in the para-position by phenylthio.

R<sup>10</sup> preferences:

25 R<sup>10</sup> is a radical that is selected from the group consisting of alkyl, aryl, alkoxy, heteroaryl, cycloalkyl, aminoalkyl, N-monosubstituted aminoalkyl and N,N-disubstituted aminoalkyl, wherein the substituents on nitrogen are chosen from alkyl, aralkyl, cycloalkyl and alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5 to 8 membered heterocyclo or heteroaryl ring.

30 R<sup>10</sup> is a radical that is C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, C<sub>1</sub>-C<sub>6</sub> alkoxy, or heteroaryl.

- 38 -

R<sup>10</sup> is a radical that is methyl, ethyl, n-propyl, n-butyl, isopropyl, or isobutyl.

R<sup>10</sup> is a radical that is a 3- to 8-membered cycloalkyl ring.

5 R<sup>10</sup> is a radical that is cyclohexyl or cyclopentyl.

R<sup>10</sup> is a radical that is aryl or heteroaryl.

10 R<sup>10</sup> is a radical that is phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, thiophene-2-yl, or 3-thiophene-3-yl.

R<sup>10</sup> is a radical that is C<sub>1</sub>-C<sub>6</sub> alkoxy.

R<sup>10</sup> is a radical that is methoxy and ethoxy.

15 Particularly preferred and most preferred R<sup>1</sup> and R<sup>10</sup> substituents of inhibitor compounds of formulas VIa, VIb, VIIa and VIIb are as discussed before for compounds of formulas Ia-IIIA and Ib-IIIb, respectively.

20 The compounds described herein are useful in a process described herein in that such compounds can inhibit the activity of MMP-13. A particularly preferred compound inhibits the enzyme with an IC<sub>50</sub> value of about 1000 nm or less in the *in vitro* assay 25 discussed hereinafter. A most preferred compound exhibits an IC<sub>50</sub> value in that assay of about 30 nm or less, with some compounds exhibiting values of about 1 nm or less.

In addition, while being highly active 30 against MMP-13, selectivity of inhibitory activity toward MMP-1 is also exhibited by many of these particularly preferred and most preferred compounds. That is, many compounds exhibit little or no inhibition in the *in vitro* assay against MMP-1 so 35 that IC<sub>50</sub> values are often found to be several

thousand to greater than 10,000 nm toward MMP-1. Exemplary ratios of IC<sub>50</sub> values toward MMP-1 and MMP-13 (IC<sub>50</sub> MMP-1/IC<sub>50</sub> MMP-13) can range from about 5 to about 25,000, with most preferred compounds 5 exhibiting ratios of about 500 to about 25,000. Inhibition data for several exemplary compounds are provided in a table hereinafter.

A contemplated inhibitor compound is used for treating a host mammal such as a mouse, rat, 10 rabbit, dog, horse, primate such as a monkey, chimpanzee or human that has a condition associated with pathological matrix metalloprotease activity.

Also contemplated is use of a contemplated metalloprotease inhibitor compound in the treatment 15 of a disease states that can be affected by the activity of metalloproteases. An example of such disease states is those affected by the activity of TNF- $\alpha$  convertase. Exemplary of such disease status are the acute phase responses of shock and sepsis, 20 coagulation responses, hemorrhage and cardiovascular effects, fever and inflammation, anorexia and cachexia.

In treating a disease condition associated with pathological matrix metalloproteinase activity, 25 a contemplated MMP inhibitor compound can be used in the form of an amine salt derived from an inorganic or organic acid. Exemplary salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, 30 bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 35 nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate,

- 40 -

pionate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate and undecanoate.

Also, a basic nitrogen-containing group can be quaternized with such agents as lower alkyl  
5 halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl  
10 halides like benzyl and phenethyl bromides, and others to provide enhanced water-solubility. Water or oil-soluble or dispersible products are thereby obtained as desired. The salts are formed by combining the basic compounds with the desired acid.

15 Other compounds useful in this invention that are acids can also form salts. Examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases or basic quaternary ammonium  
20 salts.

In some cases, the salts can also be used as an aid in the isolation, purification or resolution of the compounds of this invention.

Total daily dose administered to a host  
25 mammal in single or divided doses can be in amounts, for example, for 0.001 to 30 mg/kg body weight daily and more usually 0.01 to 10 mg. Dosage unit compositions can contain such amounts or submultiples thereof to make up the daily dose. A suitable dose  
30 can be administered, in multiple sub-doses per day. Multiple doses per day can also increase the total daily dose should this be desired by the person prescribing the drug.

The dosage regimen for treating a disease  
35 condition with a compound and/or composition of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet

-41-

and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of  
5 the particular compound employed, whether a drug delivery system is utilized and whether the compound is administered as part of a drug combination. Thus, the dosage regimen actually employed can vary widely and therefore can deviate from the preferred dosage  
10 regimen set forth above.

A compound useful in the present invention can be formulated as a pharmaceutical composition. Such a composition can then be administered orally, parenterally, by inhalation spray, rectally, or  
15 topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration can also involve the use of transdermal administration such as transdermal  
20 patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, for example, Hoover, John E.,  
25 Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania; 1975 and Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980.

Injectable preparations, for example,  
30 sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a  
35 nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be

-42-

employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland  
5 fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents,  
10 polyethylene glycols can be used. Mixtures of solvents and wetting agents such as those discussed above are also useful.

Suppositories for rectal administration of the drug can be prepared by mixing the drug with a  
15 suitable nonirritating excipient such as cocoa butter, synthetic mono- di- or triglycerides, fatty acids and polyethylene glycols that are sold at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and  
20 release the drug.

Solid dosage forms for oral administration can include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds of this invention are ordinarily combined with one or  
25 more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium  
30 stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or  
35 tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of

- 43 -

capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be 5 prepared with enteric coatings.

For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and 10 suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds can be dissolved in water, polyethylene glycol, propylene glycol, 15 ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Liquid dosage forms for oral administration 20 can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and 25 suspending agents, and sweetening, flavoring, and perfuming agents.

The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the 30 mammalian host treated and the particular mode of administration.

Certain compounds of this invention can serve as prodrugs to other compounds of this invention. Prodrugs are drugs that can be chemically 35 converted *in vivo* or *in vitro* by biological systems into an active derivative or derivatives. An example from this invention are drugs of formula II (IIa or













- 44 -

IIb) where the acyl group is hydrolyzed to a compound of formula I (Ia or Ib). An additional example is where a disulfide of this invention is reduced to its thiol product or, in some cases, converted into an active mixed disulfide.

Table 1 through Table 40, below, show several compounds useful in a process of this invention. Each group of compounds is illustrated by a generic formula, or formulae, followed by a series of preferred moieties or groups that constitute various substituents that can be attached at the position clearly shown in the generic structure. The generic symbols, e.g., R<sup>1</sup>, R<sup>2</sup> and the like, are as defined before. This system is well known in the chemical communication arts and is widely used in scientific papers and presentations. For example in Table 2, R<sup>1</sup> is the variable group with the structural variables that can substitute for R<sup>1</sup> shown in the balance of the table. There are 30 R<sup>1</sup> groups (including hydrogen) shown that are used to represent, in a non-limiting manner, 30 distinct compounds that can be prepared for use in the invention.


- 45 -

Table 1




- 46 -

Table 2



- 47 -


Table 3



$\text{R}^1$			


- 48 -

Table 4





- 49 -

Table 5




- 50 -

Table 6




- 51 -

Table 7




- 52 -

Table 8




- 53 -

Table 9
















- 54 -

Table 10

 $\text{--R}^1$ 


- 55 -

Table 11

 $\text{--R}^1$ 

- 56 -

Table 12

$\text{R}^2$	Chemical Structure			
- H				
- CH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>				
- CH <sub>2</sub> Ph				
- CH <sub>2</sub> CH <sub>2</sub> Ph				
- CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>				
- CH <sub>2</sub> CF <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> OCH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> OH				
- CH <sub>2</sub> CO <sub>2</sub> H				
- CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H				


-57-

Table 13















- 58 -

Table 14




- 59 -

Table 15




- 60 -

Table 16

 $\text{R}^1$ 

- 61 -

Table 17




- 62 -

Table 18

$\text{R}^2$				
- H				
- CH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>				
- CH <sub>2</sub> Ph				
- CH <sub>2</sub> CH <sub>2</sub> Ph				
- CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>				
- CH <sub>2</sub> CF <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> OCH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> OH				
- CH <sub>2</sub> CO <sub>2</sub> H				
- CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H				


- 63 -

Table 19




- 64 -

Table 20



- 65 -

Table 21



$\text{R}^1$		


- 66 -

Table 22

$- R^2$				
- H				
- CH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>				
- CH <sub>2</sub> Ph				
- CH <sub>2</sub> CH <sub>2</sub> Ph				
- CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>				
- CH <sub>2</sub> CF <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> OCH <sub>3</sub>				
- CH <sub>2</sub> CH <sub>2</sub> OH				
- CH <sub>2</sub> CO <sub>2</sub> H				
- CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H				
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H				


- 67 -

Table 23



- 68 -

Table 24















- 69 -

Table 25

$\text{HS}-\text{CH}_2-\text{CH}(\text{R}^2)-\text{S}(=\text{O})-\text{C}_6\text{H}_4-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_3$	- R <sup>2</sup> -		
- H			
- CH <sub>3</sub>			
- CH <sub>2</sub> CH <sub>3</sub>			
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>			
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>			
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>			
- CH <sub>2</sub> Ph			
- CH <sub>2</sub> CH <sub>2</sub> Ph			
- CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>			
- CH <sub>2</sub> CF <sub>3</sub>			
- CH <sub>2</sub> CH <sub>2</sub> OCH <sub>3</sub>			
- CH <sub>2</sub> CH <sub>2</sub> OH			
- CH <sub>2</sub> CO <sub>2</sub> H			
- CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H			
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H			
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H			
- CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H			


- 70 -

Table 26




- 71 -

Table 27




- 72 -

Table 28




- 73 -

Table 29




- 74 -

Table 30




- 75 -

Table 31



- 76 -

Table 32











- 77 -

Table 33

<th data-cs="6" data-kind="parent"> </th> <th data-kind="ghost"></th> <th data-kind="ghost"></th> <th data-kind="ghost"></th> <th data-kind="ghost"></th>					
<th data-cs="6" data-kind="parent"> </th> <th data-kind="ghost"></th> <th data-kind="ghost"></th> <th data-kind="ghost"></th> <th data-kind="ghost"></th>					


- 78 -

Table 34

	$\text{R}^4$			
$\text{CH}_3$				
$\text{CH}_2\text{CH}_3$				
				
				
				
				
				


- 79 -

Table 35




- 80 -

Table 36




- 81 -

Table 37




- 82 -

Table 38




- 83 -

Table 39



- 84 -

Table 40



<chem>Cc1ccccc1CCCCC</chem>	<chem>Cc1ccccc1I</chem>	<chem>Cc1ccccc1Cl</chem>	<chem>Cc1ccccc1COCCC=O</chem>
<chem>Cc1ccccc1CCCCC</chem>	<chem>Cc1ccccc1Br</chem>	<chem>Cc1ccccc1F</chem>	<chem>Cc1ccccc1COCC#C</chem>
<chem>Cc1ccccc1CC</chem>	<chem>Cc1ccccc1O</chem>	<chem>Cc1ccccc1NC(=O)C(F)(F)F</chem>	<chem>Cc1ccccc1NC(=O)C(C)C</chem>
<chem>Cc1ccccc1CC</chem>	<chem>Cc1ccsc1</chem>	<chem>Cc1ccccc1C(=O)O</chem>	<chem>Cc1ccccc1NC(=O)CCC</chem>
<chem>Cc1ccccc1CH3</chem>	<chem>Cc1ccsc1</chem>	<chem>Cc1ccccc1Cc2ccncc2S=C=O</chem>	<chem>Cc1ccccc1NC(=O)CC</chem>
<chem>Cc1ccccc1CH3</chem>	<chem>Cc1ccsc1</chem>	<chem>Cc1ccccc1C(=O)OCC</chem>	<chem>Cc1ccccc1NC(=O)CCCC</chem>
<chem>Cc1ccccc1CH3</chem>	<chem>Cc1ccsc1</chem>	<chem>Cc1ccccc1Cc2ccncc2NHC(=O)c3ccccc3</chem>	<chem>Cc1ccccc1NC(=O)CCPh</chem>
<chem>Cc1ccccc1CH3</chem>	<chem>Cc1ccsc1</chem>	<chem>Cc1ccccc1Cc2ccncc2NHC(=O)c3ccccc3</chem>	<chem>Cc1ccsc1C(=O)C(=O)c2ccncc2</chem>
<chem>Cc1ccccc1OCCN(C)C</chem>	<chem>Cc1ccccc1OCCN(C)C</chem>	<chem>Cc1ccccc1OCCN(c1ccccc1)C</chem>	<chem>Cc1ccsc1C(=O)C(=O)c2ccncc2</chem>

In the written descriptions of molecules and groups, molecular descriptors can be combined to produce words or phrases that describe structural groups or are combined to describe structural groups.

5 Such descriptors are used in this document. Common illustrative examples include such terms as aralkyl (or arylalkyl), heteroaralkyl, heterocycloalkyl, cycloalkylalkyl, aralkoxyalkoxycarbonyl and the like. A specific example of a compound encompassed with the 10 latter descriptor aralkoxyalkoxycarbonyl is C<sub>6</sub>H<sub>5</sub>-CH<sub>2</sub>-CH<sub>2</sub>-O-CH<sub>2</sub>-O-(C=O)- wherein C<sub>6</sub>H<sub>5</sub>- is phenyl. It is also to be noted that a structural group can have more than one descriptive word or phrase in the art, for example, heteroaryloxyalkylcarbonyl can also be 15 termed heteroaryloxyalkanoyl. Such combinations are used above in the description of the compounds and compositions of this invention and further examples are described below. The following list is not intended to be exhaustive or drawn out but provide 20 further illustrative examples of such words or phrases.

As utilized herein, the term "alkyl", alone or in combination, means a straight-chain or branched-chain alkyl radical containing 1 to about 12 carbon atoms, preferably 1 to about 10 carbon atoms, and more preferably 1 to about 6 carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl and the 30 like.

The term "alkenyl", alone or in combination, means a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing 2 to about 12 carbon atoms preferably 35 2 to about 10 carbon atoms, and more preferably, 2 to about 6 carbon atoms. Examples of suitable alkenyl radicals include ethenyl (vinyl), 2-propenyl, 3-

propenyl, 1,4-pentadienyl, 1,4-butadienyl, 1-butenyl, 2-butenyl, 3-butenyl, decenyl and the like.

The term "alkynyl", alone or in combination, means a straight-chain hydrocarbon radical having one or more triple bonds and containing 2 to about 12 carbon atoms, preferably 2 to about 10 carbon atoms, and more preferably, 2 to about 6 carbon atoms. Examples of alkynyl radicals include ethynyl, 2-propynyl, 3-propynyl, decynyl, 1-butynyl, 2-butynyl, 3-butynyl, and the like.

The term "carbonyl", alone or in combination, means a -C(=O)- group wherein the remaining two bonds (valences) can be independently substituted. The term "thiol" or "sulfhydryl", alone or in combination, means a -SH group. The term "thio" or "thia", alone or in combination, means a thiaether group; i.e., an ether group wherein the ether oxygen is replaced by a sulfur atom.

The term "amino", alone or in combination, means an amine or -NH<sub>2</sub> group whereas the term mono-substituted amino, alone or in combination, means a substituted amine -N(H)(substituent) group wherein one hydrogen atom is replaced with a substituent, and disubstituted amine means a -N(substituent)<sub>2</sub> wherein two hydrogen atoms of the amino group are replaced with independently selected substituent groups.

Amines, amino groups and amides are compounds that can be designated as primary (I°), secondary (II°) or tertiary (III°) or unsubstituted, 30 mono-substituted or di-substituted depending on the degree of substitution of the amino nitrogen. Quaternary amine (ammonium) (IV°) means a nitrogen with four substituents [-N<sup>+</sup>(substituent)<sub>4</sub>] that is positively charged and accompanied by a counter ion, 35 whereas N-oxide means one substituent is oxygen and

the group is represented as  $[-N^+(\text{substituent}), -O^-]$ ; i.e., the charges are internally compensated.

The term "cyano", alone or in combination, means a -C-triple bond-N ( $-C\equiv N$ ) group. The term 5 "azido", alone or in combination, means a -N-triple bond-N ( $-N\equiv N$ ) group. The term "hydroxyl", alone or in combination, means a -OH group. The term "nitro", alone or in combination, means a  $-NO_2$  group. The term "azo", alone or in combination, means a  $-N=N-$  10 group wherein the bonds at the terminal positions can be independently substituted.

The term "hydrazino", alone or in combination, means a -NH-NH- group wherein the depicted remaining two bonds (valences) can be 15 independently substituted. The hydrogen atoms of the hydrazino group can be replaced, independently, with substituents and the nitrogen atoms can form acid addition salts or be quaternized.

The term "sulfonyl", alone or in 20 combination, means a  $-SO_2-$  group wherein the depicted remaining two bonds (valences) can be independently substituted. The term "sulfoxido", alone or in combination, means a  $-SO-$  group wherein the remaining two bonds (valences) can be independently 25 substituted.

The term "sulfone", alone or in combination, means a  $-SO_2-$  group wherein the depicted remaining two bonds (valences) can be independently substituted. The term "sulfide", alone or in 30 combination, means a  $-SON=$  group wherein the remaining three depicted bonds (valences) can be independently substituted. The term "sulfenamide", alone or in combination, means a  $-S-$  group wherein the remaining two bonds (valences) can be 35 independently substituted.

The term "alkoxy", alone or in combination, means an alkyl ether radical wherein the term alkyl is as defined above. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, 5 isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like.

The term "cycloalkyl", alone or in combination, means a cyclic alkyl radical that contains 3 to about 8 carbon atoms. The term 10 "cycloalkylalkyl" means an alkyl radical as defined above that is substituted by a cycloalkyl radical containing 3 to about 8, preferably 3 to about 6, carbon atoms. Examples of such cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, 15 cyclohexyl and the like.

The term "aryl", alone or in combination, means a 5- or 6-membered aromatic ring-containing moiety or a fused ring system containing two or three rings that have all carbon atoms in the ring; i.e., a 20 carbocyclic aryl radical, or a heteroaryl radical containing one or more heteroatoms such as sulfur, oxygen and nitrogen in the ring(s). Exemplary carbocyclic aryl radicals include phenyl, indenyl and naphthyl radicals. Examples of such heterocyclic or 25 heteroaryl groups are pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, pyrrolyl, imidazolyl (e.g., imidazol-4-yl, 1-benzyloxycarbonylimidazol-4-yl, and the like), pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, furyl, 30 tetrahydrofuryl, thienyl, triazolyl, oxazolyl, oxadiazoyl, thiazolyl, thiadiazoyl, indolyl (e.g., 2-indolyl, and the like), quinolinyl, (e.g., 2-quinolinyl, 3-quinolinyl, 1-oxido-2-quinolinyl, and the like), isoquinolinyl (e.g., 1-isoquinolinyl, 35 3-isoquinolinyl, and the like), tetrahydroquinolinyl (e.g., 1,2,3,4-tetrahydro-2-quinolyl, and the like), 1,2,3,4-tetrahydroisoquinolinyl (e.g., 1,2,3,4-

tetrahydro-1-oxo-isoquinolinyl, and the like), quinoxalinyl,  $\beta$ -carbolinyl, 2-benzofurancarbonyl, benzothiophenyl, 1-, 2-, 4- or 5-benzimidazolyl, and the like.

5 An aryl ring group optionally carries one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro and the like, such as phenyl, p-tolyl, 4-methoxyphenyl, 4-(tert-butoxy)phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 1-naphthyl, 2-naphthyl; and the like.

10 The term "aralkyl", alone or in combination, means an alkyl radical as defined above in which one hydrogen atom is replaced by an aryl radical as defined above, such as benzyl, 2-phenylethyl and the like.

15 The term "aralkoxycarbonyl", alone or in combination, means a radical of the formula -C(O)-O-aralkyl in which the term "aralkyl" has the significance given above. An example of an 20 aralkoxycarbonyl radical is benzyloxycarbonyl.

The term "aryloxy" means a radical of the formula aryl-O- in which the term aryl has the significance given above.

25 The terms "alkanoyl" or "alkylcarbonyl", alone or in combination, means an acyl radical derived from an alkanecarboxylic acid, examples of which include acetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, and the like.

30 The term "cycloalkylcarbonyl" means an acyl group derived from a monocyclic or bridged cycloalkanecarboxylic acid such as cyclopropanecarbonyl, cyclohexanecarbonyl, adamantanecarbonyl, and the like, or from a benz-fused monocyclic cycloalkanecarboxylic acid that is 35 optionally substituted by, for example, alkanoylamino, such as 1,2,3,4-tetrahydro-2-

naphthoyl, 2-acetamido-1,2,3,4-tetrahydro-2-naphthoyl.

The terms "aralkanoyl" or "aralkylcarbonyl" mean an acyl radical derived from an aryl-substituted alkane carboxylic acid such as phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, 4-aminohydrocinnamoyl, 4-methoxyhydrocinnamoyl and the like.

The terms "aroyle" or "arylcarbonyl" means an acyl radical derived from an aromatic carboxylic acid. Examples of such radicals include aromatic carboxylic acids, an optionally substituted benzoic or naphthoic acid such as benzoyl, 4-chlorobenzoyl, 4-carboxybenzoyl, 4-(benzyloxycarbonyl)benzoyl, 1-naphthoyl, 2-naphthoyl, 6-carboxy-2-naphthoyl, 6-(benzyloxycarbonyl)-2-naphthoyl, 3-benzyloxy-2-naphthoyl, 3-hydroxy-2-naphthoyl, 3-(benzyloxyformamido)-2-naphthoyl, and the like.

The heterocyclic (heterocyclo) or heterocycloalkyl portion of a heterocyclocarbonyl, heterocyclooxy carbonyl, heterocycloalkoxy carbonyl, or heterocycloalkyl group or the like is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle that contains one or more hetero atoms selected from nitrogen, oxygen and sulphur. Such a moiety can be optionally substituted on one or more carbon atoms by halogen, alkyl, alkoxy, oxo, and the like, and/or on a secondary nitrogen atom (i.e., -NH-) by alkyl, aralkoxy carbonyl, alkanoyl, aryl or arylalkyl or on a tertiary nitrogen atom (i.e., =N-) by oxido and that is attached via a carbon atom. The tertiary nitrogen atom with three substituents can also attached to form a N-oxide [=N(O)-] group.

The term "cycloalkylalkoxy carbonyl" means an acyl group of the formula cycloalkylalkyl-O-CO-

wherein cycloalkylalkyl has the significance given above. The term "aryloxyalkanoyl" means an acyl radical of the formula aryl-O-alkanoyl wherein aryl and alkanoyl have the significance given above. The 5 term "heterocyclooxy carbonyl" means an acyl group having the formula heterocyclo-O-CO- wherein heterocyclo is as defined above.

The term "heterocycloalkanoyl" is an acyl radical of the formula heterocyclo-substituted alkane 10 carboxylic acid wherein heterocyclo has the significance given above. The term "heterocycloalkoxycarbonyl" means an acyl radical of the formula heterocyclo-substituted alkane-O-CO- wherein heterocyclo has the significance given above. 15 The term "heteroaryloxy carbonyl" means an acyl radical represented by the formula heteroaryl-O-CO- wherein heteroaryl has the significance given above.

The term "aminocarbonyl" alone or in combination, means an amino-substituted carbonyl 20 (carbamoyl) group derived from an amino-substituted carboxylic acid (carboxamide) wherein the amino (amido nitrogen) group can be a primary or secondary amino group containing substituents selected from hydrogen, and alkyl, aryl, aralkyl, cycloalkyl, 25 cycloalkylalkyl radicals and the like.

The term "aminoalkanoyl" means an acyl group derived from an amino-substituted alkanecarboxylic acid wherein the amino group can be a primary or secondary amino group containing 30 substituents independently selected from hydrogen, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like.

The term "halogen" means fluoride, chloride, bromide or iodide. The term "haloalkyl" 35 means an alkyl radical having the significance as defined above wherein one or more hydrogens are replaced with a halogen. Examples of such haloalkyl

- 92 -

radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and the like.

The term perfluoroalkyl means an alkyl  
5 group wherein each hydrogen has been replaced by a fluorine atom. Examples of such perfluoroalkyl groups, in addition to trifluoromethyl above, are perfluorobutyl, perfluoroisopropyl, perfluorododecyl and perfluorodecyl.

10 The term "aromatic ring" in combinations such as substituted-aromatic ring sulfone or substituted-aromatic ring sulfoxide means aryl or heteroaryl as defined above.

M utilized in the reaction schemes that  
15 follow represents a leaving group such as halogen, phosphate ester or sulfate ester.

#### Preparation of Useful Compounds

20 Schemes 1 through 7 illustrate procedures with examples of chemical transformations that can be used for the preparation of compounds useful in this invention, e.g., compounds of formulas I-III, Ia-IIIa, or Ib-IIIb. The R<sup>1</sup> through R<sup>10</sup> groups shown in  
25 the schemes have been defined previously in this document.

This discussion is not intended to be exhaustive as is readily noted that additional or alternative methods, conditions, reactions or systems  
30 can be identified and used by a chemist of ordinary skill to obtain the compounds shown. Optically active as well as non-optically active isomers are included, e.g., RS isomers, enantiomers, diastereomers, racemates, E isomers, Z isomers, syn-  
35 isomers, anti- isomers and the like.

These syntheses, as with all of the reactions discussed herein, can be carried out under

a dry inert atmosphere such a nitrogen or argon if desired. Selected reactions known to those skilled in the art are carried out under a dry atmosphere such as dry air, whereas other synthetic steps, for example, aqueous acid or base ester or amide hydrolyses are carried out with a reaction solution in contact with laboratory air.

Scheme 1

The first reaction in Scheme 1 is a Michael reaction of a thiol, compound 1, with an unsaturated aldehyde (when R<sup>6</sup> is H) or ketone, compound 2, to form a sulfide aldehyde or ketone, compound 3. Unsaturated esters, amides and acids are also substrates for the Michael reaction wherein the corresponding sulfide esters, amides or acids are prepared.

A Michael reaction can be base-mediated by the use of catalytic amounts of some bases, carried out with an equivalent or more of a base, or by the use of an additional reagent. Alternatively, the thiol reagent can be a preformed thiol base salt.

Bases that can be used include, for example, metal hydroxides such as sodium, potassium, lithium or magnesium hydroxide; oxides such as those of sodium, potassium, lithium, calcium or magnesium; metal carbonates such as those of sodium, potassium, lithium, calcium or magnesium; metal bicarbonates such as sodium bicarbonate or potassium bicarbonate; hindered primary organic amines or secondary tertiary organic amines such as alkyl amines, arylalkyl amines, alkylarylalkyl amines, heterocyclic amines or heteroaryl amines; ammonium hydroxide or quaternary ammonium hydroxides.

As non-limiting examples, such amines that can be used as a base mediator of the Michael reaction in Scheme 1 can include triethylamine,

trimethylamine, diisopropylamine,  
methyldiisopropylamine, diazabicyclononane,  
tribenzylamine, dimethylbenzylamine,  
N-methylmorpholine, N,N'-dimethylpiperazine,  
5 N-ethylpiperidine, 2,2,6,6-tetramethylpiperidine,  
dimethylaminopyridine, pyridine, quinoline,  
tetramethylethylenediamine, diazabicyclononane and  
the like.

Non-limiting examples of ammonium

10 hydroxides, (usually made from amines and water) that  
can be used as a base mediator, can include ammonium  
hydroxide, triethylammonium hydroxide,  
trimethylammonium hydroxide,  
methyldiisopropylammonium hydroxide,  
15 tribenzylammonium hydroxide, dimethylbenzylammonium  
hydroxide, N-methylmorpholinium hydroxide,  
N,N'-dimethylpiperazinium hydroxide,  
N-ethylpiperidinium hydroxide, and the like.

Non-limiting examples of quaternary

20 ammonium hydroxides that can be used as a base  
mediator include tetraethylammonium hydroxide,  
tetramethylammonium hydroxide,  
dimethyldiisopropylammonium hydroxide,  
benzylmethyldiisopropylammonium hydroxide,  
25 methyldiazabicyclononylammonium hydroxide,  
methyltribenzylammonium hydroxide,  
N,N-dimethylmorpholinium hydroxide, N,N,N',N',-  
tetramethylpiperazinium hydroxide, and N-ethyl-N'-  
hexylpiperidinium hydroxide and the like.

30 Metal hydrides, amide or alcoholates such  
as calcium hydride, sodium hydride, potassium  
hydride, lithium hydride, sodium methoxide, potassium  
tert-butoxide, calcium ethoxide, magnesium ethoxide,  
sodium amide, potassium diisopropyl amide and the  
35 like may also be suitable reagents for use as a base  
mediator.

Organometallic deprotonating agents such as alkyl or aryl lithium reagents such as methyl lithium, phenyl lithium, tert-butyl lithium, lithium acetylide or butyl lithium, Grignard reagents such as 5 methylmagnesium bromide or methylmagnesium chloride, organocadmium reagents such as dimethylcadmium and the like can also serve as bases for causing thiolate salt formation or catalyzing the reaction.

Quaternary ammonium hydroxides or mixed 10 salts are also useful for aiding phase transfer couplings or serving as phase transfer reagents.

The reaction medium can be a single solvent, mixed solvents of the same or different classes or serve as a reagent in a single or mixed 15 solvent system. The solvents can be protic, non-protic or dipolar aprotic.

Non-limiting examples of protic solvents for the Michael reaction include water, methanol (MeOH), ethanol (EtOH; denatured, 95% or absolute), 20 isopropanol and the like. Typical non-protic solvents include acetone, tetrahydrofuran (THF), dioxane, diethyl ether, tert-butylmethyl ether (TBME), aromatic solvents such as xylene, toluene, or benzene, ethyl acetate (EA), methyl acetate, butyl 25 acetate, trichloroethane, methylene chloride, ethylenedichloride (EDC), hexane, heptane, isooctane, cyclohexane and the like. Dipolar aprotic solvents include compounds such as dimethylformamide (DMF), dimethylacetamide (DMAc), acetonitrile, 30 dimethylsulfoxide (DMSO), hexamethylphosphoric triamide (HMPA), nitromethane, tetramethylurea, N-methylpyrrolidone and the like.

Non-limiting examples of reagents that can be used as solvents or as part of a mixed solvent 35 system for the Michael reaction include organic or inorganic mono- or multi-protic acids or bases such as hydrochloric acid, phosphoric acid, sulfuric acid,

- 96 -

acetic acid, formic acid, citric acid, succinic acid, triethylamine, morpholine, N-methylmorpholine, piperidine, pyrazine, piperazine, pyridine, potassium hydroxide, sodium hydroxide, alcohols or amines for

- 5 making esters or amides or thiols for making the products of this invention and the like.

Room temperature or less, or moderate warming (-10°C to 60°C) are the preferred temperatures of the Michael reaction. If desired, 10 the reaction temperature can be about -76°C to the reflux point of the reaction solvent or solvents.

The sulfide compound 3, an electrophile that is the product of the Michael reaction, can be oxidized to a sulfone, compound 7, in one step using 15 two equivalents of oxidizing agent. Oxidizing agents for this process, in a non-limiting example, include peroxyomonosulfate (OXONE®), hydrogen peroxide, meta-chloroperbenzoic acid, perbenzoic acid, percamphoric acid, peracetic acid, perlactic acid, tert-butyl 20 peroxide, tert-butyl hydroperoxide, tert-butyl hypochlorite, sodium hypochlorite, hypochlorous acid, sodium meta-periodate, periodic acid, and the like.

25 Protic, non-protic, dipolar aprotic solvents, either pure or mixed, can be used for the oxidation reaction, such as methanol/water.

The oxidation can be carried out at temperature of about -78° to about 50° degrees centigrade and preferable about -10°C to about 40°C.

Preparation of the sulfone can also be 30 carried out via a two-step process wherein a sulfoxide, compound 6, is prepared in the first step. The synthesis of a sulfoxide starting with a sulfide requires the use of only about one equivalent of one of the above oxidizing agents with a preferred 35 temperature of about zero °C.

The use of a protected thiol group can be desired by one skilled in the art as an aid in

selectivity and as a supplement to the exploitation of the usual steric and electronic factors. The solvents listed above for use with the Michael reaction can be used with these selective sulfoxide preparations with, for example, methanol or methanol/water being preferred along with a reaction temperature of about -10°C to about 30°C. It can be desirable in the case of more active oxidizing agents, but not required, that the reactions be carried out under an inert gas atmosphere with or without degassed solvents.

A formed sulfoxide, compound 6 or compound 9, can then be oxidized to a sulfone, if desired, and with or without prior isolation and characterization of the sulfoxide by the use of the oxidation procedures discussed above. In addition, optically active sulfoxides can be prepared using optically active oxidizing agents such as per-camphoric acid.

Scheme 1 also illustrates the conversion of compound 3, into an alcohol compound 4. Compound 3 can be an aldehyde (when R<sup>6</sup> is H) or ketone, or in some instances an acid (when R<sup>6</sup> is O), ester (when R<sup>6</sup> is OR), or amide (where R<sup>6</sup> is N). The useful process for this conversion is treatment of the electrophile compound 3 with an organometallic reagent such as a lithium reagent, magnesium reagent (Grignard reagent), zinc reagent, cadmium reagent, sodium reagent or potassium reagent. Where H is required on the oxygen, the carbonyl compound can be reduced by well known methods such as the use of sodium borohydride, lithium aluminum hydride or the like. Such reactions of carbonyl compounds with organometallic reagents are well known in the art to produce alcohols such as compound 4 or, depending on reagent and starting material, new carbonyl compounds.

These conversion reactions are usually carried out under an inert atmosphere such as N<sub>2</sub> or Ar at a temperature of about -80°C to about 50°C in a inert non-polar or dipolar aprotic solvent or mixture of solvents. The alcohol compound **4** can be oxidized to a sulfone such as compound **7** or a sulfoxide such as compound **6** using methods as outline above. The alcohol can also converted into a sulfide derivative such as compound **5** wherein W is oxygen or sulfur.

10 Non-limiting examples of such are the thioacetate [-S(C=O)CH<sub>3</sub>] or dithioacetate groups [-S(C=S)CH<sub>3</sub>].

Conversion of compounds **7** to **8**, **6** to **9** or **4** to **5** in Scheme 1 can be carried out by an activated azo process wherein a phosphine such as triphenyl phosphine and an azo compound such as diisopropyl azodicarboxylate (DIAD) or diethyl azodicarboxylate (DEAD) and the starting alcohol are treated with a thiocarboxylic acid or dithiocarboxylic acid. The reaction is usually carried out under an inert atmosphere at about -40°C to about room temperature in an inert solvent such as methylene chloride, THF or others listed above.

Scheme 2

25 Scheme 2 shows the same overall conversion of compounds **7** to **8**, **6** to **9** or **4** to **5** using an alternative process that proceeds through via hydroxyl activation or replacement to provide intermediate compounds **10** (sulfide), **11** (sulfone) or **12** (sulfoxide).

In the Schemes, M represents groups such as halides (Cl, Br, I), fluorides (aromatic), tosylate (OTs), mesylate (OMs) and triflate (OTf) groups and the like. M can also represent groups such as -SH (thiol) or, following treatment with base or as a pre-formed salt, an -S<sup>-</sup> (thiolate) group. The

- 99 -

nonthiols are prepared from alcohols by standard methods such as treatment with HCl, HBr, thionyl chloride or bromide, phosphorus trihalide, phosphorus pentahalide, tosylchloride or methanesulfonyl 5 chloride and the like.

The hydroxyl activation or replacement reactions are usually carried out at a temperature of about -25°C to solvent reflux under an inert atmosphere such as nitrogen or argon.

10 The solvent or solvent mixture can vary widely depending upon reagents and other conditions and can include polar or dipolar aprotic solvents as listed before or mixtures of those solvents. In some cases, bases such as triethyl amine, pyridine or 15 other non-reactive bases can serve as reagents and/or solvents and/or cosolvents. The preparations of sulfate esters and/or organic halides are well known in the art.

In some instances, in the reactions in 20 these Schemes, protecting groups are used in other parts of a molecule(s) at locations that is(are) not desired to be reactive centers. Such protecting groups can include acyl groups, carbamoyl groups, ethers, alkoxyalkyl ethers, cycloalkyloxy ethers, 25 arylalkyl groups, silyl groups as well as trisubstituted silyl groups and the like. Examples of such protecting groups include acetyl, THP, benzyl, benzoyl, tert-butyldimethylsilyl (TBDMS) or MEM groups. The preparation of such protected 30 compounds as well as removal of the protecting groups are well known in the art.

Reaction of compounds 10, 11 and 12 in Scheme 2 shows the second step in the preparation of compounds 5, 8 and 9. This method of synthesis of 35 sulfur-containing compounds; i.e., use of the SN<sub>2</sub> class of reactions, is commonly called nucleophilic substitution.

-100-

A bimolecular nucleophilic substitution ( $SN_2$ ) reaction is illustrated in the step so named wherein group M is displaced by a thiol compound or the salt of a thiol compound producing compounds of formula I or formula II or a compound of formula I via conversion of formula II to I. The opposite procedure is also possible. Compounds of formulas I and II are also intermediates in the preparation of compounds of formula III. Compounds of formula III can also be converted into those of formulas I or II.

Non-limiting examples of thiol compounds or their salts are hydrogen sulfide ( $H_2S$ ), sodium sulfide ( $NaSH$ ), thiolacetic acid [ $HS(C=O)CH_3$ ], sodium thiolacetate [ $NaS(C=O)CH_3$ ], dithioacetic acid [ $[HS(C=S)CH_3]$ ] and sodium dithiolacetate [ $NaS(C=S)CH_3$ ]. Thiols are shown at other points in the Schemes.

As with the Michael reaction discussed along with Scheme 1, the thiol anion can be derived from a preformed salt or the salt can be formed in situ via addition of a base. The bases and solvents discussed with regard to Scheme 1, the Michael reaction, are applicable to this step. Preferred bases are those that are hindered such as tertiary amines so that competition with thiolate anion in a two stage reaction is minimized. The solvents, solvent mixtures or solvent/reagent mixtures discussed above are satisfactory but non-protic or dipolar aprotic solvents such as acetone, acetonitrile, DMF, acetonitrile and the like are examples of a preferred class. Bases can also be used as solvents as well as reagents. Mixtures of the above solvents or with a solvent and a base such as pyridine or triethylamine are also useful. Again, procedures involving nucleophilic substitution reactions are well known in the art.

The generalized oxidation/reduction sequence illustrated in Scheme 2 is also well known

-101-

in the art. Hydrolysis by base, preferably aqueous as discussed above, reaction of the C=W group with a organometallic reagent or its reductive removal can provide an -SH (thiol) compound of formula I.

5         This thiol compound that is not shown per se in Schemes 1 or 2 can then be oxidized, if desired, using, for example, air, oxygen, hypohalide reagents, sodium plumbite, or oxidation agents listed above. Non-oxidizable solvents and a basic or  
10 slightly basic pH value are preferred and the atmosphere of the reaction can be air or another gas mentioned above. Preferred temperature is zero°C to 40°C but lower or higher temperatures can be used. Mixed disulfides can be made if the starting  
15 materials have different structures.

Reversal of the oxidation process *ex vivo* requires reduction of the disulfide bond to the thiol of formula II followed by acylation with a reagent such as a derivative of HO(C=W)R<sup>10</sup>. Such a  
20 derivative can be an activated carbonyl compound prepared using activation reagents well known in the art including the peptide and protein synthesis and amino acid coupling or conjugation art. Examples of such activation reagents are thionyl chloride, oxalyl  
25 chloride, phosphorus oxychloride, HOBT (hydroxybenzotriazole), isobutylchloroformate, carbodiimide, azodicarboxylate compounds and the like all of which are well known and established in the art. Reduction of the disulfide to the corresponding  
30 thiol can be carried out by, for example, treatment with hydride reagents such as lithium aluminum hydride, aluminum hydride, metal borohydrides, sodium cyanoborohydride and the like.

35         Scheme 3

Scheme 3 illustrates an alternative sequence for the preparation of intermediates and

-102-

products of this invention. A thiol such as compound 1 can be reacted with an alpha-substituted aldehyde, ketone, acid, acid salt, ester or amide, wherein M is the alpha substituent. This  $SN_2$  reaction is carried  
5 out as previously discussed preferably at the lower end of the permissible temperature range. This reaction produces the sulfide compound 17, which can be reduced or treated with an organometallic reagent to produce alcohol compound 18. Both processes have  
10 been discussed above.

Compound 18 can also be made via a double bond containing feedstock that is, for example, converted into an epoxide compound 19 that can be ring-opened via the  $SN_2$  process using a thiolate anion ( $R^1S^-$ ). In this case, the reagent can be a hydrogen sulfide anion ( $HS^-$ ) and the product can then be reacted with, for example, a  $R^1-M$  reagent to form compound 18 in a two step procedure. These processes have been presented in association with earlier  
15 Schemes.  
20

Step 4 shows the conversion of an alcohol into a sulfoxide or sulfone followed by the preparation of the activated intermediate compounds 23 and 24. These two compounds can then be converted  
25 into the compounds of formula I (Ia or Ib) (M converted into -SH) or formula II (IIa or IIb) directly or into formula II (IIa or IIb) thence back into formula I (Ia or Ib) via a hydrolysis or reduction [-S(C=W)R<sup>10</sup> group reduction to -SH]  
30 procedure. These procedures were presented earlier. Note the same processes can be used with the sulfides such as compounds 22 and 25 to produce the sulfone compounds 26 or sulfoxides compound 27 by oxidation (discussed above) as indicated by the reaction  
35 arrows.

Scheme 4

Scheme 4 illustrates methods that can be used to create a compound of this invention from the thiol function. Compound **28** and compound **33** both contain a double bond. The double bond can be converted into an epoxide that can be used as discussed above.

Reagents such as hydrogen peroxide, peracetic acid, per-trifluoroacetic acid can accomplish the conversion to an epoxide directly, whereas halohydrins such as sodium hypochlorite, hypochlorous acid can be used to produce an intermediate hydroxyhalide that can be converted into the epoxide with a hindered base if desired.

Hypoalide compounds can be converted into hydroxy sulfide compounds first if desired. The halides can then be converted into organometallic reagents if the hydroxy group is first either protected or converted into a protected thiol function.

Step 2 shows the conversion of an epoxide into a protected thiol directly using, for example, the methods of Step 3 in Scheme 3. The hydroxy function can be converted into a halide (M group) as discussed earlier, and thence to an organometallic reagent. Addition of the organometallic reagent to the intermediate epoxide compound **34**, prepared as discussed above, provides the hydroxide derivative compound **35**.

The former conversions are repeated in Steps 7 through 9 to give as products of compounds of this invention of formula II and, following hydrolysis and oxidation, compounds of formula I and/or III. Preparation of the M derivatives compound **36**, formation of the R<sup>1</sup>S- bonds and oxidation to a sulfoxide compound **38** (n=1) or sulfone compound

-104-

38 (n=2) are processes presented in several places above.

Scheme 5

5 Compound 22, which can be prepared by the methods shown in Scheme 3, serves as a starting material in Scheme 5 that illustrates further alternative synthetic pathways starting from the R<sup>1</sup>S- bond side of compounds of formulas I-III, Ia-IIIa or 10 Ib-IIIb. In one process, the activated M-carbon bond is converted into an organometallic reagent compound 39 that is reacted with an epoxide compound 29. The product alcohol compound 40 containing the two additional backbone carbon atoms is converted into an 15 activated intermediate compound 41 (carbon-M bond formed) that is reacted in an S<sub>N</sub>2 manner with, for example sodium sulfide or sodium thioacetate or other reagents discussed above, to provide compound 37. This intermediate or pro-drug can then be oxidized, 20 in one step or two steps, as shown on the continuation of Scheme 5 to the protected compound 38. Compound 38 can be hydrolyzed or reduced to a compound of formula I, Ia or Ib.

It is noted that one skilled in the art can 25 also choose to perform conversions into sulfoxides or sulfones as is shown on the left side of this scheme.

In this instance, the oxidized sulfur- and M-containing intermediate compound 42 is converted in 30 to an organometallic reagent compound 43 that is reacted with the epoxide compound 29. The resulting compound, 44, is then converted into another M-containing intermediate, compound 45, that is reacted via an S<sub>N</sub>2 reaction as before to form compound 38.

-105-

Scheme 6

Scheme 6 illustrates further the preparation of the compounds of formulas I-III, Ia-IIIa or Ib-IIIb that are useful in this invention.

5      R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, M, W and -METAL are as defined hereinbefore. R<sup>2</sup> is defined as before with R<sup>2</sup>-M<sup>2</sup> being a subset of R<sup>2</sup> wherein the R<sup>2</sup> group is part of an electrophilic reagent. In an

10     electrophilic reagent M<sup>2</sup> serves as an halide (F, Cl, Br, I) or organosulfate such as tosylate, triflate or mesylate. Another type of M<sup>2</sup> electrophilic reagent is represented by esters, amides, anhydrides, acid halides, mixed anhydrides, aldehydes, ketones, carbonates, carbamates, ureas, sulfonyl halides,

15     sulfonic esters and the like.

Step 1 represents a nucleophilic substitution (SN<sub>2</sub>) reaction as discussed in, for example, Scheme 2. A formed sulfide such as compound 46 can be readily oxidized in one or two steps as discussed in earlier Schemes to form the sulfone compound 47 shown here. Removal of a hydrogen alpha to a sulfonyl group provides an anion intermediate such as compound 48. Hydrogen removal is accomplished through the use of a strong base such as those discussed above. Such bases are usually organometallic bases or hydride bases such as hindered Grignard reagents, lithium alkyls such as tert-butyl lithium, hydrides such as potassium hydride, metal amides such as sodium amide and the like. Anion formation is usually carried out under an inert atmosphere such as nitrogen or argon at temperature of about -100°C to about 30°C. A preferred temperature range is from about -80°C to about zero°C.

35     The solvent for such reactions are usually neutral non-protic solvents, dipolar aprotic solvents

-106-

or as mixtures or parts of mixtures. Ammonia or amines can be used also especially with, for example, sodium amide or sodium diisopropyl amide.

Once the anion is available, Step 4 can be  
5 carried out to provide compound 50. The type of SN<sub>2</sub> or electrophilic addition reaction shown in Step 4 has been discussed above. Alkylating agents include epoxides, halides, sulfate esters and the like. Aryl fluoro compounds can be in this class also.

10 Electrophilic addition to various double bond compounds is also a common method of adding groups as is well known in the art. Reagents can include esters, amides, anhydrides, acid halides, mixed anhydrides, ketones, aldehydes, carbonates,  
15 carbamates, ureas, sulfonyl halides, sulfonic acid esters and the like as discussed above. Generally, these reactions are carried out in the same solvent as anion formation under the same atmosphere and at the same temperature. As is known in the art, it can  
20 be desirable to carry out anion formation at a higher or lower temperature than the reaction with an electrophilic reagent. One skilled in the art chooses the temperature for anion formation and that for reaction electrophilic reagent depending upon the  
25 characteristics of the starting material, the acidity of the proton being removed and activity of the electrophilic reagent as is well known. Ammonia and amines are solvents that are often removed following anion preparation.

30 Compound 50 can then be transformed into compound 51 following the procedures discussed before for transforming a hydroxyl group into a thiol or thiolate. Thus, compound 50 can be transformed into compound 52 as described in Scheme 2 for transforming  
35 compounds 6 or 7 into compounds 12 or 11. Reaction of compound 52 with sodium sulfide or sodium hydrogen

sulfide can be used to form compound 55. Similarly, activated azo coupling can be used to transform compound 50 into compound 51. The product compounds 51 and 53 are subsets of the compounds of formulas 5 II, IIa or IIb and I, Ia or Ib, respectively.

Scheme 7

Thiol sulfones having R<sup>6</sup> substituents of the type shown in Tables 13 and 19 hereinabove can be synthesized via a ring-opening addition reaction, as shown in Scheme 7. A thiol compound 1 is reacted with a 2,4-dihydroxybutanoic acid anhydride ( $\alpha$ -hydroxy- $\gamma$ -butyrolactone) 51 to produce a sulfide having a hydroxy group 3 carbons away from the sulfide group and an R<sup>6</sup> substituent -COOH, compound 52. The reaction can be base-mediated by the use of catalytic or equivalent amounts of a base-mediator described as useful for the Michael reaction of Scheme 1, using substantially identical solvent and reaction conditions to the Michael reaction. Oxidation of the sulfide compound 52 to the sulfone compound 53 can be carried out by the one-step or two-step process, as described for the Michael reaction product in Scheme 1 hereinabove.

The alpha hydroxyl group can be converted to a thiol group using the hydroxyl activation or replacement process as shown in Scheme 2, where the leaving group M is substituted by a thiol group in a nucleophilic substitution reaction. The -COOH R<sup>6</sup> substituent compound 53 can be derivitized before or after conversion of the alpha hydroxyl group to a thiol group. Derivitization prior to forming the thiol is shown in Scheme 7. The -COOH R<sup>6</sup> substituent can be derivitized by esterification or amidation by methods well known in the art, preferably using base

mediation. Amidation of compound 53 to compound 54 with N-(2-aminoethyl)morpholine is shown in Scheme 7, followed by hydroxyl activation or replacement to form compound 55. A compound of the invention can be 5 made by nucleophilic substitution of compound 55 followed by hydrolysis of the product to form compound 56.

In an exemplary synthesis of a compound prepared by the reaction sequence shown in Scheme 7, 10 the initial thiol-containing compound 1 can be prepared as illustrated below where R<sup>1</sup> of the thiol compound 1 is 4-(benzamido)-phenyl.

To a solution of chlorotriphenylmethane (trityl chloride; 5.00 g, 39.94 mmol) in 5% 15 trifluoroacetic acid/dichloromethane was added a solution of 4-aminothiophenol (9.28 g, 33.28 mmol) dropwise, at room temperature. The resulting mixture is stirred at room temperature for 0.5 hours. The mixture is then diluted with water, neutralized with 20 2.5 N NaOH. The organic layer is washed further with water, dried, filtered and concentrated. The yellow solid is then triturated with diethyl ether to give a trityl-protected 4-aminothiophenolate (10.2 g, 69%) as an off-white solid, m/z = 368 (M + H).

25 To a solution of the trityl-protected 4-aminothiophenolate (10.2 g, 27.70 mmol) and triethylamine (5.70 mL, 41.55 mmol) in dichloromethane are added benzoyl chloride (3.54 mL, 30.47 mmol). After 1 hour at room temperature, the 30 mixture is diluted with dichloromethane. The reaction mixture is then washed with water, dried, filtered and concentrated. The resulting solid is triturated with diethyl ether to give a trityl-protected 4-(benzamido)-thiophenolate (23.9 g, 99%) 35 as a white solid, m/z = 472 (M + H).


To a solution of the trityl-protected 4-(benzamido)-thiophenolate (7.82 g, 16.58 mmol) in dichloromethane are added triisopropylsilane (16.98 mL, 82.91 mmol) and trifluoroacetic acid (25 mL).  
5 The mixture is stirred at room temperature for 0.5 hour and then concentrated. Hexanes are added and the resulting solid was collected to give the de-protected 4-(benzamido)-thiophenol (3.69 g, 97%) as a yellow solid, m/z = 230 (M + H). The 4-(phenoxy)-  
10 thiophenol can be made in a similar manner.

The foregoing steps have been presented as part of Scheme 1 through Scheme 7. The terms and reactions ACTIVATED AZO COUPLING, ELECTROPHILIC SUBSTITUTION, NUCLEOPHILIC SUBSTITUTION and  
15 HYDROLYSIS utilized in those schemes are well known steps in the art.

The chemical reactions described above are generally disclosed in terms of their broadest application to the preparation of the compounds of  
20 this invention. Occasionally, the reactions may not be applicable as described to each compound included within the disclosed scope or may be unsafe in a particular instance. The compounds for which this occurs will be readily recognized by those skilled in  
25 the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional  
30 reagents, by routine modification of reaction conditions, and the like, or other reactions disclosed herein or otherwise conventional, will be applicable to the preparation of the corresponding compounds of this invention. In all preparative  
35 methods, all starting materials are known or readily preparable from known starting materials.


- 110 -

SCHEME 1




- 111 -

SCHEME 2




- 112 -

SCHEME 3




- 113 -

SCHEME 4




- 114 -

SCHEME 5




- 115 -

SCHEME 5  
continued


-116-

SCHEME 6



- 117 -

SCHEME 7




-118-

Best Mode for Carrying Out the Invention

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its 5 fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

- 10 Example 1: Preparation of (R,S) 1-[(4-methoxyphenyl)-sulfonyl]propane-2-thiol




15 Part A: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 3.4 g *p*-methoxybenzenethiol, 1.95 mL (R,S)-propylene oxide (1.15 eq), 370 mg potassium carbonate (1.15 eq) in 60 mL MeOH. The reaction was 20 stirred 30 minutes at room temperature at this point HPLC analysis showed no starting material. The reaction was filtered and the filtrate was concentrated *in vacuo*. The crude sulfide was dissolved in 125 mL MeOH and 100 mL H<sub>2</sub>O and reacted 25 with 45 g (3.0 eq) OXONE®. The reaction was stirred overnight, filtered, and the filtrate was concentrated to 1/2 the original volume. The reaction mixture was partitioned between ethyl acetate and water and the organic phase was washed 30 with water, brine, dried over sodium sulfate and then concentrated *in vacuo* to 5.0 g of (R,S) 1-[(4-methoxyphenyl)sulfonyl]propane-2-ol.

-119-

Part B: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 1.3 g alcohol, 1.63 g triphenylphosphine (1.1 eq) in 40 mL THF. The reaction mixture was 5 cooled to zero °C and 1.25 mL DIAD was added. After 2 minutes 0.42 mL thioacetic acid was added and the reaction was stirred 1 hour. After standard work up the crude reaction mixture was chromatographed on silica gel (30 % ethyl acetate/hexanes, 50 % ethyl 10 acetate/hexanes) to afford mostly the olefin and a fraction of 100 mg of desired alcohol contaminated with olefin. This material was used without further purification.

15 Part C: A 100 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with the crude product from part B in 15 mL MeOH. To this was added 1.5 mL 25 % aqueous ammonium hydroxide. The reaction was stirred 2 hours then 20 quenched with dry ice. The reaction mixture was partitioned between ethyl acetate/water and the organic phase was concentrated *in vacuo* to afford 75 mg crude oil. Flash chromatography on silica gel (100 % MeCl) yielded 15 mg pure (R,S) 1-[{4- 25 methoxyphenyl}sulfonyl]propane-2-thiol.

Example 2: Preparation of (R,S)- 4-[{(4-methoxyphenyl)-sulfonyl] butane-2-thiol}



30

Part A: To a solution of 25.0 g (178 mmol) of 4-methoxybenzenethiol in 250 mL of anhydrous DMF,

-120-

was added 16.4 mL (18.5 g, 196 mmol) of 3-chloro-1-propanol. After nitrogen gas was bubbled through the solution for 15 min., 74.0 g (535 mM) of powdered potassium carbonate was added. After 16 hours, the  
5 DMF was removed *in vacuo*, ethyl acetate and water were added, the organic layer separated and washed 3xs with brine, dried with magnesium sulfate, filtered and concentrated to afford 36.0 g of crude sulfide suitable for use in the next reaction.

10

Part B: To a solution of 36.0 g (181 mmol) of sulfide from Part A in 800 mL of methanol and 160 mL of water, was added 351 g (571 mmol) of potassium peroxyomonosulfate (OXONE®). After 15 hours, the  
15 reaction was filtered, the filter cake was washed with methanol and the filtrate concentrated *in vacuo*, ethyl acetate and water were added, the layers were separated and the aqueous layer was extracted 2 xs with ethyl acetate. The 3 organic extracts were  
20 combined and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 40.0 g of crude product, identified as 3-[(4-methoxyphenyl)sulfonyl] propan-1-ol, m/e = ?? (M+H).

25

Part C: To a solution of 5.0 g (22 mmol) of 4-[(4-methoxyphenyl)sulfonyl] propan-1-ol from part B and 12.1 mL (8.8 g, 87 mmole) of triethylamine in 25 mL of methylene chloride at zero °C, was added  
30 a solution of 13.8 g (87 mmol) of sulfur trioxide-pyridine complex in 25 mL of DMSO. After 1 hour, the reaction mixture was added to 300 mL of ice, ethyl acetate was added, the organic layer was separated and washed with water, 5 % potassium hydrogen sulfate  
35 solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 4.1 g of 3-[(4-

- 121 -

methoxyphenyl)sulfonyl] propan-1-al suitable for the next reaction.

Part D: A 100 mL round bottom flask  
5 equipped with magnetic stir bar, addition funnel, and N<sub>2</sub> inlet was charged with 2.87 mL of 3.0 M MeMgBr in Et<sub>2</sub>O (2.0 eq) in 15 mL THF. The reaction mixture was cooled to 0°C and a solution of 1.0 g crude aldehyde from part C in 5 mL THF was added dropwise. After 1  
10 hour at zero °C the reaction was quenched with aqueous saturated ammonium chloride. The reaction mixture was partitioned between ethyl acetate/aq KHSO<sub>4</sub> and the organic phase was washed with saturated sodium bicarbonate, brine then concentrated *in vacuo*  
15 to afford the crude alcohol. Flash chromatography on silica gel (50 % ethyl acetate-hexanes, 100 % ethyl acetate) yielded 360 mg pure (R,S)-4-[(4-methoxyphenyl)-sulfonyl] butane-2-ol.


Part E: A 100 mL round bottom flask  
20 equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 360 mg alcohol from part D in 5 mL THF. The solution was cooled to zero °C and reacted with 444 mg triphenylphosphine (1.15 eq) then 0.27 mL DEAD  
25 (1.15 eq). After stirring 5 minutes the reaction was treated with 0.12 mL thioacetic acid. The reaction was stirred 1 hour then concentrated *in vacuo*. The residue was slurried in 5 mL MeCl<sub>2</sub> at -78°C filtered to remove impurities, and the filtrate was  
30 chromatographed on silica gel (30 % ethyl acetate-hexanes) 200 mg of 90 % pure thioacetate that was used without further purification.

Part F: A 100 mL round bottom flask  
35 equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 200 mg crude thioacetate from part E in

-122-

20 mL MeOH. The solution was cooled to zero °C and 2.0 eq NaOMe was added. After 20 minutes the reaction was partitioned between ethyl acetate and H<sub>2</sub>O. The organic phase was dried and concentrated in vacuo to crude product. Chromatography on silica gel (100 % MeCl<sub>2</sub> to 10 %ethyl acetate-MeCl<sub>2</sub>) yielded 87 mg pure (R,S)- 4-[(4-methoxyphenyl)-sulfonyl] butane-2-thiol.

10 Example 3: Preparation of 3-[(4-methoxyphenyl)-sulfonyl]-2(S)-methylpropanethiol



15 Part A: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 1.3 g 3-bromo-2(S)-methylpropanol, 2.28 mL p-methoxybenzenethiol, 7.7 g potassium carbonate (3.0 eq) in 60 mL MeOH. After 6 hours at room temperature HPLC analysis indicated complete reaction. The reaction mixture was filtered and the filtrate was concentrated in vacuo and the residue was partitioned between ethyl acetate-H<sub>2</sub>O.

20 The organic phase was washed with brine, dried and concentrated in vacuo to yield the crude sulfide. The sulfide was dissolved in 150 mL MeOH and added to a slurry of 36 g (3.0 eq) OXONE® in a 150 mL H<sub>2</sub>O. The reaction was stirred overnight at room temperature then filtered and concentrated to 30 1/2 original volume. After ethyl acetate extraction followed by concentration in vacuo afforded 2.9 g pure 3-[(4-methoxyphenyl)sulfonyl]-2(S)-methylpropanol.


- 123 -

Part B: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 2.9 g 3-[{4-methoxyphenyl}sulfonyl]-2(S)-methylpropanol in 50 mL THF. The solution was cooled to zero°C and 3.42 g triphenylphosphine (1.15 eq) then 2.1 mL DEAD (1.15 eq). After stirring 5 minutes the reaction was treated with 0.85 mL thioacetic acid. The reaction was stirred 1 hour then concentrated *in vacuo*. The residue was slurried in 25 mL MeCl<sub>2</sub> at -78°C then filtered to remove impurities and the filtrate was chromatographed on silica gel (50 % Et<sub>2</sub>O-H/ 80 % Et<sub>2</sub>O-H) to yield 2.0 g pure thioacetate.

15

Part C: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 1.2 g thioacetate in 35 mL MeOH. The reaction mixture was treated with 1.0 mL 25 % NaOMe in MeOH. After 30 minutes the reaction was quenched with 1N HCl and partitioned between ethyl acetate-H<sub>2</sub>O. The organic phase was dried and concentrated *in vacuo* to crude product. Chromatography on silica gel (50 % ethyl acetate-hexanes) yielded 400 mg of 3-[{(4-methoxyphenyl)sulfonyl}-2(S)-methylpropane-thiol.

Example 4: Preparation of 3-[{(4-{3-phenylpropyloxy)-phenyl}sulfonyl]-propanethiol



30

- 124 -

Part A: To a solution of 10.0 g (79 mmol) of 4-hydroxybenzenethiol in 100 mL of anhydrous DMF, was added 7.3 mL (8.2 g, 87 mmol) of 3-chloro-1-propanol. After nitrogen gas was bubbled through the  
5 solution for 15 min., 33.0 g (238 mM) of powdered potassium carbonate was added. After 17 hours, the DMF was removed *in vacuo*, ethyl acetate and water were added, the organic layer separated and washed 3xs with brine, dried with magnesium sulfate,  
10 filtered and concentrated to afford 16 g of crude product, m/z = 183 (M-H).

Part B: To a solution of 2 g (10.6 mmol) of product from Part A in 20 mL of anhydrous DMF, was  
15 added 4.5 g (31.8 mmol) of powdered potassium carbonate, followed by 2.1 g (10.6 mM) of 1-bromo-3-phenylpropane. After 24 hours, ethyl acetate and water were added, the organic layer separated and washed 3xs with brine, dried with magnesium sulfate,  
20 filtered and concentrated to afford 3.3 g of crude product that was dissolved in 100 mL MeOH and added to 20 g OXONE® in 80 mL H<sub>2</sub>O. The reaction was stirred overnight at room temperature, filtered and concentrated to 1/2 volume. Extraction with ethyl acetate followed by drying and concentration *in vacuo*  
25 gave 3.3 g of the sulfone alcohol.


Part C: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was  
30 charged with 3.6 g alcohol from part B in 50 mL THF. The solution was cooled to zero °C and 2.8 g triphenylphosphine then 1.7 mL DEAD. After stirring 5 minutes the reaction was treated with 0.8 mL thioacetic acid. The reaction was stirred 1 hour  
35 then concentrated *in vacuo*. The residue was slurried in 25 mL MeCl<sub>2</sub> at -78°C then filtered to remove

-125-

impurities and the filtrate was chromatographed on silica gel (30 % ethyl acetate-hexanes/ 50 % ethyl acetate-hexanes) to yield 1.4 g pure thioacetate.

5               Part D: A 100 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 655 mg thioacetate in 50 mL MeOH. The reaction mixture was treated with 1.1 mL 25 % NaOMe in MeOH. After 30 minutes the reaction was quenched 10 with 1N HCl and partitioned between ethyl acetate-H<sub>2</sub>O. The organic phase was dried and concentrated in vacuo to crude product. Chromatography on silica gel (50 % ethyl acetate-hexanes) yielded 420 mg pure 3-[(4-(3-phenylpropyloxy)phenyl)sulfonyl]-propanethiol.

15              Example 5 : Preparation of



20              Part A: To a solution of 2.1 g of product from Ex. 4 Part A in 50 mL of anhydrous DMF, was added 4.75 g (3 eq) of powdered potassium carbonate, followed by 2.25 g of t-butyl bromoacetate. After 4 hours, ethyl acetate and water were added, the 25 organic layer separated and washed 3xs with brine, dried with magnesium sulfate, filtered and concentrated to afford 3.4 g of crude product that was dissolved in 80 mL MeCl<sub>2</sub> and reacted with 8.2 g MCPBA (2.5 eq). The reaction was stirred overnight 30 at room temperature, quenched with sodium sulfite, and washed 2XS with saturated sodium bicarbonate. The organic phase was filtered thru CELITE®, dried and concentrated in vacuo gave 3.9 g of the crude sulfone


-126-

alcohol which was filtered thru a short plug of alumina (10 % ethanol-ethyl acetate) to remove MCPBA to yield 3.5 g pure product.

5           Part B: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 3.5 g alcohol from part A in 50 mL THF. The solution was cooled to zero °C and 2.8 g triphenylphosphine, then 1.67 mL DEAD. After 10 stirring 5 minutes, the reaction was treated with 0.76 mL thioacetic acid. The reaction was stirred 1 hour then concentrated in vacuo. The residue was slurried in 15 mL MeCl<sub>2</sub> at -78°C then filtered to remove impurities and the filtrate was 15 chromatographed on silica gel (30 % ethyl acetate-hexanes/ 50 % ethyl acetate-hexanes) to yield 2.1 g pure thioacetate.

20           Part C: A 100 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 382 mg thioacetate in 15 mL MeOH. The reaction mixture was treated with 0.46 mL 25 % NaOMe in MeOH. After 30 minutes the reaction was quenched with 1N HCl and partitioned between ethyl acetate-H<sub>2</sub>O. The organic phase was dried and concentrated in 25 vacuo to crude product. Chromatography on silica gel (50 % ethyl acetate-hexanes) yielded 250 mg pure product.

30           Example 6: Preparation of




-127-

Part A: A 100 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 1.65 g thioacetate from Ex.5 part B in 5 10 mL 4NHCl-Dioxane. The reaction was stirred at room temperature overnight. Concentration *in vacuo* followed by Et<sub>2</sub>O trituration yielded 1.0 g pure acid.

Part B : A 100 mL round bottom flask 10 equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 382 mg thioacetate in 15 mL MeOH. The reaction mixture was treated with 0.39 mL (3.0 eq) 25 % NaOMe in MeOH. After 15 minutes the reaction was quenched with 1N HCl and partitioned between ethyl 15 acetate-H<sub>2</sub>O. The organic phase was dried and concentrated *in vacuo* to crude product that was a 65-35 mixture of thiol to disulfide.

Example 7: Preparation of (R,S) trans-3-[ (4-methoxyphenyl)sulfonyl] cyclohexanethiol 20



Part A: A 250 mL round bottom flask 25 equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 4.6 g cyclohexenone, 6.7 g p-methoxy benzenethiol in 50 mL degassed MeOH. To the stirring solution was added 6.8 g triethylamine. The reaction was stirred 30 minutes then concentrated *in vacuo* to 30 remove triethylamine. The crude product was dissolved in 65 mL MeOH, cooled to zero ° and treated with 3.6 g NaBH<sub>4</sub> cautiously. The reaction was

-128-

stirred 90 minutes at zero°C then quenched with 1N HCl and partitioned between ethyl acetate-H<sub>2</sub>O. The combined organics were washed with brine, dried, and concentrated *in vacuo* to crude product that was  
5 dissolved in 200 mL MeOH and added to a slurry of 86 g OXONE® in 200 mL H<sub>2</sub>O. After 4 hours HPLC analysis indicated complete reaction and the reaction mixture was filtered and concentrated *in vacuo* to 1/2 original volume. After extraction with ethyl acetate  
10 the organic phase was washed with H<sub>2</sub>O, brine, dried, and concentrated *in vacuo* to yield 8.9 g of a 3:1 diastereomeric mixture of alcohols.


Part B: A 250 mL round bottom flask  
15 equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 1.2 g alcohol from part A in 20 mL THF. The solution was cooled to zero °C and 1.16 g triphenylphosphine then 0.7 mL DEAD. After stirring 5 minutes the reaction was treated with 0.35 mL  
20 thioacetic acid. The reaction was stirred 1 hour then concentrated *in vacuo*. HPLC analysis indicated a 6 : 1 ratio of diastereomers. The residue was slurried in 10 mL MeCl<sub>2</sub> at -78°C then filtered to remove impurities and the filtrate was  
25 chromatographed on silica gel (30 % ethyl acetate-hexanes/ 50 % ethyl acetate-hexanes) to yield 0.4 g pure thioacetate which was analysed by HPLC and found to be > 30 : 1 ratio of diastereomers.

30 Part C: A 100 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 395 mg thioacetate in 15 mL MeOH. The reaction mixture was treated with 0.78 mL 25 % NaOMe in MeOH. After 30 minutes the reaction was quenched  
35 with 1N HCl and partitioned between ethyl acetate-

- 129 -

H<sub>2</sub>O. The organic phase was dried and concentrated *in vacuo* to yield 320 mg pure (R,S)-3-[(4-methoxyphenyl)sulfonyl] cyclohexanethiol, whose 300 MHz proton NMR was suggestive of a trans relationship 5 between the sulfone and thiol.

Example 8: Preparation of (R,S) 3-butyl-3-[(4-methoxyphenyl)sulfonyl] cyclohexanethiol



10

Part A: A 100 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 2.5 g of alcohol from Example 7 part A 15 in 25 mL THF. The solution was cooled to -78°C and treated with 2.65 mL (2.5 eq) DMPU, then 1.93 mL (2.2 eq) 10M nBuLi in Hexanes. The dianion was stirred 30 minutes at -78°C then reacted with 0.94 mL butyl bromide. 20 The reaction was stirred at room temperature overnight then quenched with saturated ammonium chloride. The reaction was partitioned between ethyl acetate-H<sub>2</sub>O. The organic phase was dried and concentrated *in vacuo* to crude product that was 25 chromatographed (70 % ethyl acetate-hexanes) to yield 120 mg faster moving isomer and 480 mg slower moving isomer.

Part B: A 100 mL round bottom flask 30 equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 0.48 g alcohol from part A in 8 mL THF.


-130-

The solution was cooled to zero °C and 0.41 g triphenylphosphine then 0.25 mL DEAD. After stirring 5 minutes the reaction was treated with 0.12 mL thioacetic acid. The reaction was stirred 1 hour 5 then concentrated *in vacuo*. The residue was slurried in 5 mL MeCl<sub>2</sub> at -78 °C then filtered to remove impurities and the filtrate was chromatographed on silica gel (25 % ethyl acetate-hexanes/ 50 % ethyl acetate-hexanes) to yield 132 mg thioacetate 10 contaminated with olefin.

The crude thioacetate was used without further purification.

Part C: A 100 mL round bottom flask 15 equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 132 mg crude thioacetate in 4 mL MeOH. The reaction mixture was treated with 0.14 mL 25 % NaOMe in MeOH. After 30 minutes the reaction was quenched with 1N HCl and partitioned between ethyl 20 acetate-H<sub>2</sub>O. The organic phase was dried and concentrated *in vacuo* to a crude product that was chromatographed (25 % ethyl acetate-hexanes) to yield 55 mg thiol.

25 Example 9: Preparation of



Part A: A 250 mL round bottom flask 30 equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 5.2 g cyclopentenone, 8.9 g p-methoxy benzenethiol in 75 mL degassed MeOH. To the stirring

-131-

solution was added 8.9 mL triethylamine. The reaction was stirred 30 minutes then concentrated *in vacuo* to remove triethylamine. The crude product was dissolved in 100 mL MeOH, cooled to zero °C and 5 treated with 4.8 g NaBH<sub>4</sub> cautiously. The reaction was stirred 90 minutes at zero °C then quenched with 1N HCl and partitioned between ethyl acetate-H<sub>2</sub>O. The combined organics were washed with brine, dried, and concentrated *in vacuo* to 14.8 g crude product 10 that was dissolved in 250 mL MeOH and added to a slurry of 117 g OXONE® in 250 mL H<sub>2</sub>O. After 12 hours HPLC analysis indicated complete reaction and the reaction mixture was filtered and concentrated *in vacuo* to 1/2 original volume. After extraction with 15 ethyl acetate the organic phase was washed with H<sub>2</sub>O, brine, dried, and concentrated *in vacuo* to yield 15.5 g of a 3:1 diastereomeric mixture of alcohols.


Part B: A 250 mL round bottom flask 20 equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 3.0 g alcohol from part A in 50 mL THF. The solution was cooled to zero °C and 3.0 g triphenylphosphine then 1.78 mL DEAD. After stirring 5 minutes the reaction was treated with 0.98 mL 25 thioacetic acid. The reaction was stirred 1 hour then concentrated *in vacuo*. The residue was slurried in 20 mL MeCl<sub>2</sub> at -78°C then filtered to remove 30 impurities and the filtrate was chromatographed on silica gel (30 % ethyl acetate-hexanes/ 50 % ethyl acetate-hexanes) to yield 780 mg thioacetate which was analysed by HPLC and found to be 2.6 : 1 ratio of diastereomers.

Part C: A 100 mL round bottom flask 35 equipped with magnetic stir bar and N<sub>2</sub> inlet was

-132-

charged with 780 mg thioacetate in 15 mL MeOH. The reaction mixture was treated with 0.78 mL 25 % NaOMe in MeOH. After 30 minutes the reaction was quenched with 1N HCl and partitioned between ethyl acetate-H<sub>2</sub>O. The organic phase was dried and concentrated *in vacuo* to yield 500 mg crude thiol that was submitted without further purification.

Example 10: Preparation of (R,S)-Methyl-4-[ (4-methoxyphenyl)sulfonyl]-2-mercaptopbutanoate



Part A: A 100 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 1.0 g 3-[ (4-methoxyphenyl)sulfonyl] propan-1-al in 35 mL MeCl<sub>2</sub>. The reaction was cooled to zero °C and charged with 700 mg (1.2 eq) trimethylsilyl cyanide and 1.1 g (1.1 eq) zinc bromide and stirred at room temperature overnight. The reaction mixture was concentrated *in vacuo* and partitioned between ethyl acetate-H<sub>2</sub>O. The residue was treated with 5 mL acetic acid and 15 mL 6N HCl and heated to reflux for 3 hours. The reaction mixture was concentrated *in vacuo* and partitioned between ethyl acetate-H<sub>2</sub>O. The crude hydroxy acid (435 mg) was dissolved in 15 mL MeOH and treated with 0.18 mL thionyl chloride and stirred at room temperature overnight. The reaction mixture was concentrated *in vacuo* and partitioned between ethyl acetate-H<sub>2</sub>O. The crude ester was chromatographed on silica gel (50 % ethyl acetate-hexanes/ 100 % ethyl


- 133 -

acetate) to yield 360 mg pure (R,S)-methyl-4-[(4-methoxyphenyl)sulfonyl]-2-hydroxybutanoate.

Part B: A 100 mL round bottom flask  
5 equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 250 mg alcohol from part A in 5 mL THF. The solution was cooled to zero °C and 250 mg triphenylphosphine then 0.14 mL DEAD. After stirring 5 minutes the reaction was treated with 0.1 mL 10 thioacetic acid. The reaction was stirred 1 hour then concentrated *in vacuo*. The residue was slurried in 5 mL MeCl<sub>2</sub> at -78°C then filtered to remove 15 impurities and the filtrate was chromatographed on silica gel (30 % ethyl acetate-hexanes/ 50 % ethyl acetate-hexanes) to yield 100 mg clear oil.

Part C: A 100 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 100 mg thioacetate in 10 mL MeOH. The 20 reaction mixture was treated with 0.2 mL 25 % NaOMe in MeOH. After 30 minutes the reaction was quenched with 1N HCl and partitioned between ethyl acetate-H<sub>2</sub>O. The organic phase was dried and concentrated *in vacuo* to yield 70 mg crude thiol that was filtered 25 thru a plug of silica gel with MeCl<sub>2</sub> to yield 45 mg pure (R,S)-methyl-4-[(4-methoxyphenyl)-sulfonyl]-2-mercaptobutanoate.

Example 11: Preparation of (R,S)-3-[(4-methoxybenzyl)-sulfonyl]propane thiol  
30



- 134 -

Part A: To a solution of 4.1 g of benzyl mercaptan in 40 mL of anhydrous DMF, was added 3.0 g of 3-chloro-1-propanol. After nitrogen gas was bubbled through the solution for 15 min., 8.7 g of 5 powdered potassium carbonate was added. After 16 hours, the DMF was removed *in vacuo*, ethyl acetate and water were added, the organic layer separated and washed 3xs with brine, dried with magnesium sulfate, filtered and concentrated to afford 5.6 g of a rose 10 colored liquid that was dissolved in 100 mL MeOH and added to a slurry of 58 g (3.0 eq) OXONE® in 100 mL H<sub>2</sub>O. The reaction was stirred 3 hours and the reaction mixture was filtered and concentrated *in vacuo* to 1/2 original volume. After extraction with 15 ethyl acetate the organic phase was washed with H<sub>2</sub>O, brine, dried, and concentrated *in vacuo* to yield 3.55 g white solid.


Part B: A 100 mL round bottom flask 20 equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 1.0 g alcohol from part A in 10 mL THF. The solution was cooled to zero °C and 1.25 g triphenylphosphine then .82mL DEAD. After stirring 5 minutes the reaction was treated with 0.36 mL 25 thioacetic acid. The reaction was stirred 1 hour then concentrated *in vacuo*. The residue was slurried in 10 mL MeCl<sub>2</sub> at -78°C then filtered to remove 30 impurities and the filtrate was chromatographed on silica gel (50 % ethyl acetate-hexanes) to yield 210 mg clear oil.

Part C: A 100 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 210 mg thioacetate in 3 mL MeOH. The 35 reaction mixture was treated with 0.5 mL NH<sub>4</sub>OH in

- 135 -

MeOH. After 60 minutes the reaction was quenched with 1N HCl and partitioned between ethyl acetate-H<sub>2</sub>O. The organic phase was dried and concentrated in vacuo to yield 170 mg crude thiol that was triturated 5 with Et<sub>2</sub>O to yield 150 mg pure thiol.

Example 12: Preparation of 3-[(4-methoxyphenyl)-sulfonyl]propan-1-ol.



10


Part A: To a solution of 7.1 g (50 mmol) of 4-methoxybenzenethiol in 100 mL of anhydrous DMF, was added 4.4 mL (5.0 g, 53 mmol) of 3-chloro-1-propanol. After nitrogen gas was bubbled through the 15 solution for 15 min., 21.0 g (151 mM) of powdered potassium carbonate was added. After 30 minutes, the DMF was removed in vacuo, ethyl acetate and water were added, the organic layer separated and washed 3xs with brine, dried with magnesium sulfate, 20 filtered and concentrated to afford 10.3 g of product suitable for the next reaction.

Part B: To a solution of 10.0 g (50 mmol) of product from Part A in 200 mL of methanol and 20 mL of water, was added 93 g (151 mmol) of potassium peroxyomonosulfate (OXONE®). After 2 hours, the reaction was filtered, the filter cake was washed with methanol and the filtrate concentrated in vacuo, ethyl acetate and water were added, the layers were 25 separated and the aqueous layer was extracted 2xs with ethyl acetate. The 3 organic extracts were combined and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, 30

-136-

filtered and concentrated to afford 11.8 g of pure 3-[*(4-methoxyphenyl)sulfonyl*]-propan-1-ol, m/z = 237 (M+Li).

5 Example 13: Preparation of 3-[*(4-methoxyphenyl)sulfonyl*]propane-1-thiol.



10 Part A: To a solution of 2.8 g (9 mmol) of 3-[*(4-methoxyphenyl)sulfonyl*]propan-1-ol from Example 13 in 20 mL of methylene chloride at zero °C, was added 1.3 mL (1.0 g, 9 mmol) of triethylamine, followed by 0.7 mL (1.0 g, 9 mM) of methanesulfonyl chloride. After 16 hours, the reaction was concentrated *in vacuo*, ethyl acetate and water were added, the organic layer was separated and washed with 5% potassium hydrogen sulfate solution, saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to yield 2.7 g of product suitable for the next reaction.

25 Part B: To a solution of 2.8 g (9 mmol) of product from Part A in 20 mL of anhydrous DMF, was added 1.4 mL (1.0 g, 10 mmol) of triethylamine, and 0.7 mL (0.8 g, 10 mM) of thiolacetic acid. After 16 hours, the reaction was concentrated *in vacuo*, ethyl acetate and water were added, the organic layer was separated and washed with 5% potassium hydrogen sulfate solution, saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to yield 2.6 g of crude product. This was chromatographed on silica gel


-137-

using 20%-40% ethyl acetate/hexane to yield 1.8 g of pure thioacetate, m/z = 295 (M+Li).

Part C: To a solution of 0.9 g (3 mmol) of 5 thioacetate, from Part B, in 20 mL of anhydrous methanol, was added 0.3 g (12 mmol) of sodium metal. After 1 hour, the reaction was quenched with dry ice, ethyl acetate and 5% potassium hydrogen sulfate were added, the organic layer was separated and washed 10 with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 0.5 g of crude product. This was chromatographed on silica gel using 20%-30% ethyl acetate/hexane to yield 0.4 g of pure 3-[(4- 15 methoxyphenyl)sulfonyl]-propane-1-thiol, m/z= 253 (M+Li).

Example 14: Preparation of 3-[(4-methoxyphenyl)-sulfonyl]-2R-methylpropane-1-thiol.

20



Part A: To a solution of 4.4 g (31 mmol) of 4-methoxybenzenethiol in 100 mL of anhydrous DMF, 25 was added 3.4 mL (5.0 g, 33 mmol) of (R)-(-)-3-bromo-2-methyl-1-propanol. After nitrogen gas was bubbled through the solution for 15 min., 12.9 g (93 mM) of powdered potassium carbonate was added. After 1 hour, the DMF was removed *in vacuo*, ethyl acetate and 30 water were added, the organic layer separated and washed 3xs with brine, dried with magnesium sulfate, filtered and concentrated to afford 7.4 g of product suitable for the next reaction.

-138-

Part B: To a solution of 6.6 g (31 mmol) of product from Part A in 150 mL of methanol and 15 mL of water, was added 67 g (108 mmol) of potassium peroxyomonosulfate (OXONE®). After 3 hours, the 5 reaction was filtered, the filter cake was washed with methanol and the filtrate concentrated in vacuo, ethyl acetate and water were added, the layers were separated and the aqueous layer was extracted 2xs with ethyl acetate. The 3 organic extracts were 10 combined and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 7.3 g of the crude product. This was chromatographed on silica gel using 20%-60% ethyl acetate/hexane to yield 5.9 g 15 of pure 3-[(4-methoxyphenyl)sulfonyl]-2R-methylpropan-1-ol, m/z = 251 (M+Li).


Part C: To a solution of 5.9 g (24 mmol) of 3-[(4-methoxyphenyl)sulfonyl]-2R-methylpropan-1-ol 20 from Part B and 6.9 g (26 mmole) of triphenylphosphine in 100 mL of anhydrous THF at zero °C, was added 4.2 mL (4.3 g, 21 mmol) of diisopropylazodicarboxylate, followed after 5 min. by 1.9 mL (2.0 g, 26 mM) of thiolacetic acid. After 1 25 hour, the reaction was concentrated and the residue was chromatographed on silica gel using 20%-30% ethyl acetate/hexane to yield 8.6 g which was chromatographed again on silica gel using methylene chloride to yield 4.0 g of pure thioacetate, m/z = 30 309 (M+Li).

Part D: To a solution of 1.4 g (5 mmol) of thioacetate, from Part C, in 40 mL of anhydrous methanol, was added 0.4 g (17 mmol) of sodium metal. 35 After 1 hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and water, the organic layer was separated and washed

-139-

with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product. This was chromatographed on silica gel using 15%-25% ethyl acetate/hexane to yield 0.6 g of pure 3-[(4-methoxyphenyl)sulfonyl]-2R-methylpropane-1-thiol, m/z= 267 (M+Li).

Example 15: Preparation of 3-[(4-methoxyphenyl)sulfonyl]-2,2-dimethylpropane-1-thiol.



Part A: To a solution of 5.0 g (36 mmol) of 4-methoxybenzenethiol in 50 mL of anhydrous DMF, was added 4.6 mL (6.3 g, 37 mmol) of 3-bromo-2,2-dimethyl-1-propanol. After nitrogen gas was bubbled through the solution for 15 min., 14.8 g (107 mM) of powdered potassium carbonate was added. After 67 hours, the DMF was removed *in vacuo*, ethyl acetate and water were added, the organic layer separated and washed 3xs with brine, dried with magnesium sulfate, filtered and concentrated to afford 8.4 g of product suitable for the next reaction.

25

Part B: To a solution of 8.1 g (36 mmol) of product from Part A in 150 mL of methanol and 15 mL of water, was added 77 g (125 mmol) of potassium peroxyomonosulfate (OXONE®). After 3 hours, the reaction was filtered, the filter cake was washed with methanol and the filtrate concentrated *in vacuo*, ethyl acetate and water were added, the layers were separated and the aqueous layer was extracted 2xs with ethyl acetate. The 3 organic extracts were

- 140 -

combined and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 8.3 g of the crude product. This was chromatographed on silica gel using 20%-50% ethyl acetate/hexane to yield 6.6 g of pure 3-[(4-methoxyphenyl)sulfonyl]-2,2-dimethylpropan-1-ol, m/z = 265 (M+Li).


Part C: To a solution of 5.0 g (19 mmol) of 3-[(4-methoxyphenyl)sulfonyl]-2,2-dimethylpropan-1-ol from Part B and 5.6 g (21 mmole) of triphenylphosphine in 80 mL of anhydrous THF at zero °C, was added 3.4 mL (3.7 g, 21 mmol) of diethylazodicarboxylate, followed after 5 min. by 1.5 mL (1.6 g, 21 mM) of thiolacetic acid. After 16 hours, the reaction was concentrated and the residue was chromatographed on silica gel using 15%-25% ethyl acetate/hexane to yield 3.9 g of pure thioacetate, m/z = 334 (M+NH<sub>4</sub>).

20

Part D: To a solution of 2.0 g (6 mmol) of thioacetate from Part C in 60 mL of anhydrous methanol, was added 0.5 g (23 mmol) of sodium metal. After 1 hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.7 g of crude product. This was chromatographed on silica gel using 10%-20% ethyl acetate/hexane to yield 1.3 g of pure 3-[(4-methoxyphenyl)sulfonyl]-2,2-dimethylpropane-1-thiol, m/z= 292 (M+NH<sub>4</sub>).

35 Example 16: Preparation of 3-[(4-methoxyphenyl)-sulfonyl]-pentane-1-thiol.

- 141 -




Part A: To a solution of 4.6 g (20 mmol) of 3-[(4-methoxyphenyl)sulfonyl]propane-1-ol from example 13 and 6 mL of DMPU in 60 mL of anhydrous THF at -70°C under nitrogen, was added 5.8 mL (2.8 g, 44 mmol) of a 10.0 M solution of n-butyllithium in hexane. After stirring for 30 min. at -70°C, 1.6 mL (2.4 g, 22 mmole) of 1-bromoethane was added. After 2 hours, the reaction mixture was cooled to zero °C and 25 mL of saturated ammonium chloride solution was added, followed by ethyl acetate and water, the layers were separated and the aqueous layer was extracted 2 xs with ethyl acetate. The 3 organic layers were combined and washed with brine, dried with magnesium sulfate, filtered and concentrated to afford 4 g of crude product. This was chromatographed on silica gel using 40%-55% ethyl acetate/hexane to yield 2.4 g of pure 3-[(4-methoxyphenyl)sulfonyl]-pentan-1-ol, m/z= 265 (M+Li).

Part B: To a solution of 3.1 g (12 mmole) of triphenylphosphine in 100 mL of anhydrous THF at zero C, was added 1.9 mL (2.0 g, 12 mmol) of diethylazodicarboxylate, followed after 15 min. by a solution of 2.4 g (9 mmol) of 3-[(4-methoxyphenyl)-sulfonyl]-pentan-1-ol from Part A and 0.9 mL (0.9 g, 12 mM) of thiolacetic acid. After 1 hour, the reaction was concentrated and the residue was chromatographed on silica gel using 15%-25% ethyl acetate/hexane to yield 1.5 g of pure thioacetate, m/z = 323 (M+Li).

-142-

Part C: To a solution of 1.5 g (5 mmol) of thioacetate from Part B in 20 mL of anhydrous methanol, was added 0.4 g (18 mmol) of sodium metal. After 1 hour, the reaction was cooled, 1N HCl  
5 solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with water and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.4 g of crude product. This was chromatographed on silica gel  
10 using 10%-20% ethyl acetate/hexane to yield 0.6 g of pure 3-[(4-methoxyphenyl)sulfonyl]-pentane-1-thiol, m/z= 281 (M+Li).

Example 17: Preparation of 3-[(4-methoxyphenyl)-  
15 sulfonyl]-dodecane-1-thiol.



Part A: To a solution of 4.7 g (20 mmol) of 3-[(4-methoxyphenyl)sulfonyl]propan-1-ol from example 13 and 6 mL of DMPU in 100 mL of anhydrous THF at -70°C under nitrogen, was added 5.9 mL (2.9 g, 45 mmol) of a 10.0 M solution of n-butyllithium in hexane. After stirring for 30 min. at -70°C, 4.3 mL (4.7 g, 22 mmole) of 1-bromononane was added. After 25 16 hours, the reaction mixture was cooled to zero °C and 25 mL of saturated ammonium chloride solution was added, followed by ethyl acetate and water, the layers were separated and the aqueous layer was extracted 2xs with ethyl acetate. The 3 organic 30 layers were combined and washed with brine, dried with magnesium sulfate, filtered and concentrated to afford 11 g of crude product. This was chromatographed on silica gel using 30%-50% ethyl acetate/hexane to yield 4.2 g of pure 3-[(4-


- 143 -

methoxyphenyl)sulfonyl]-dodecan-1-ol, m/z = 363 (M+Li).

Part B: To a solution of 4.2 g (12 mmol) of 3-[(4-methoxyphenyl)sulfonyl]-dodecan-1-ol from Part A and 4.6 g (18 mmole) of triphenylphosphine in 100 mL of anhydrous THF at 0°C, was added 2.8 mL (3.1 g, 18 mmol) of diethylazodicarboxylate, followed after 15 min. by 1.3 mL (1.3 g, 18 mM) of thiolacetic acid. After 1 hour, the reaction was concentrated and the residue was chromatographed on silica gel using 5%-15% ethyl acetate/hexane to yield 4.3 g of pure thioacetate, m/z = 421 (M+Li).

Part C: To a solution of 2.0 g (5 mmol) of thioacetate from Part B in 25 mL of anhydrous methanol, was added 0.4 g (18 mmol) of sodium metal. After 1 hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with water and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.7 g of crude product. This was chromatographed on silica gel using 5%-20% ethyl acetate/hexane to yield 1.2 g of pure 3-[(4-methoxyphenyl)sulfonyl]-dodecane-1-thiol, m/z = 379 (M+Li).

Example 18: Preparation of 3-[(4-methoxyphenyl)-sulfonyl]-4-phenylbutane-1-thiol.



30

Part A: To a solution of 5.0 g (22 mmol) of 3-[(4-methoxyphenyl)sulfonyl]propan-1-ol from

- 144 -

example 13 and 6 mL of DMPU in 100 mL of anhydrous THF at -70°C under nitrogen, was added 5.7 mL (2.8 g, 43 mmol) of a 10.0 M solution of n-butyllithium in hexane. After stirring for 30 min. at -70°C, 2.3 mL (3.3 g, 20 mmole) of benzyl bromide was added. After 5 18 hours, the reaction mixture was cooled to zero °C and 25 mL of saturated ammonium chloride solution was added, followed by ethyl acetate and water, the layers were separated and the aqueous layer was 10 extracted 2xs with ethyl acetate. The 3 organic layers were combined and washed with brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product. This was chromatographed 15 on silica gel using 35%-45% ethyl acetate/hexane to yield 5.3 g of pure 3-[(4-methoxyphenyl)sulfonyl]-4-phenylbutan-1-ol, m/z= 327 (M+Li).

Part B: To a solution of 5.3 g (17 mmol) of 3-[(4-methoxyphenyl)sulfonyl]-4-phenylbutan-1-ol 20 from Part A and 6.5 g (25 mmole) of triphenylphosphine in 100 mL of anhydrous THF at zero °C, was added 3.9 mL (4.3 g, 25 mmol) of diethylazodicarboxylate, followed after 15 min. by 1.8 mL (1.9 g, 25 mM) of thiolacetic acid. After 1 25 hour, the reaction was concentrated and the residue was chromatographed on silica gel using 15%-30% ethyl acetate/hexane to yield 5.5 g of pure thioacetate, m/z = 385 (M+Li).


30 Part C: To a solution of 2.9 g (8 mmol) of thioacetate, from Part B, in 35 mL of anhydrous methanol, was added 0.7 g (29 mmol) of sodium metal. After 1 hour, the reaction was cooled, 1N HCl 35 solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with water and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.9 g of crude

-145-

product. This was chromatographed on silica gel using 10%-20% ethyl acetate/hexane to yield 1.6 g of pure 3-[(4-methoxyphenyl)sulfonyl]-4-phenylbutane-1-thiol, m/z = 343 (M+Li).

5

Example 19: Preparation of 3-[(4-methoxyphenyl)sulfonyl]-butane-1-thiol.



10                 Part A: To a solution of 2.6 g (18 mmol) of 4-methoxybenzenethiol in 30 mL of methanol at zero °C, was added 2.2 mL (2.0 g, 20 mmol) of methyl methacrylate. After nitrogen gas was bubbled through the solution for 15 min., 2.8 mL (2.1 g, 20 mmole) of triethylamine was added. After 4.5 hours, 15 20 mL of methanol and 10 mL of water were added, followed by 36 g (59 mmol) of potassium peroxyomonosulfate (OXONE®). After 65 hours, the reaction was filtered, the filter cake was washed with methanol and the filtrate concentrated *in vacuo*, 20 ethyl acetate and water were added, the layers were separated and the aqueous layer was extracted 2xs with ethyl acetate. The 3 organic extracts were combined and washed with saturated sodium bicarbonate 25 solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 4.1 g of crude product. This was chromatographed on silica gel using 25%-35% ethyl acetate/hexane to yield 3.5 g of pure methyl 3-[(4-methoxyphenyl)sulfonyl]-butanoic acid, m/z = 279 (M+Li).

30                 Part B: To a solution of 3.5 g (13 mmol) of methyl 3-[(4-methoxyphenyl)sulfonyl]-butanoic acid from Part A in 50 mL of anhydrous THF at zero °C

-146-

under nitrogen, was added 14.2 mL (0.5 g, 13 mmol) of a 1.0 M solution of lithium aluminum hydride in THF. After 1.5 hours, the reaction mixture was cooled to zero°C and ~0.6 mL of water was added, followed by 5 0.6 mL of 2.5 N sodium hydroxide solution and 1.8 mL of water, the reaction was filtered, the filtrate concentrated in vacuo, ethyl acetate and 5% citric acid solution were added, the organic layer was separated and washed with saturated sodium 10 bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 2.7 grams of pure 3-[(4-methoxyphenyl)-sulfonyl]butan-1-ol, m/z = 251 (M+Li).


15 Part C: To a solution of 2.7 g (11 mmol) of 3-[(4-methoxyphenyl)sulfonyl]butan-1-ol from Part B and 3.6 g (14 mmole) of triphenylphosphine in 50 mL of anhydrous THF at zero °C, was added 2.2 mL (2.4 g, 14 mmol) of diethylazodicarboxylate, followed 20 after 15 min. by 1.0 mL (1.1 g, 14 mM) of thiolacetic acid. After 18 hours, the reaction was concentrated and the residue was chromatographed on silica gel using 15%-30% ethyl acetate/hexane to yield 2.8 g of pure 3-[(4-methoxyphenyl)sulfonyl]butane-1-thioacetate, m/z = 303 (M+H). 25

Part D: To a solution of 2.8 g (9 mmol) of 3-[(4-methoxyphenyl)sulfonyl]butane-1-thioacetate from Part C in 40 mL of anhydrous methanol, was added 30 0.8 g (34 mmol) of sodium metal. After 1 hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product. This was chromatographed on silica 35 gel using 10%-20% ethyl acetate/hexane to yield 1.8 g

-147-

of pure 3-[(4-methoxyphenyl)sulfonyl]butane-1-thiol,  
m/z= 261 (M+H) .

Example 20: Preparation of 3-[(4-methoxyphenyl)-  
5 sulfonyl]hexane-1-thiol.



Part A: To a solution of 2.8 g (20 mmol)  
of 4-methoxybenzenethiol in 40 mL of methanol at zero  
10 °C , was added 2.6 g (20 mmol) of methyl trans-2-  
hexenoate . After nitrogen gas was bubbled through  
the solution for 15 min., 3.0 mL (2.2 g, 21 mmole) of  
triethylamine was added. The reaction was heated at  
the reflux temperature for 16 hours, then  
15 concentrated in vacuo, ethyl acetate and water were  
added, the organic layer was separated and washed  
with 5% citric acid solution, saturated sodium  
bicarbonate solution and brine, dried with magnesium  
sulfate, filtered and concentrated to afford 5.1 g of  
20 product suitable for the next reaction.

Part B: To a solution of 5.1 g (17 mmol)  
of product from Part A in 50 mL of methanol and 10 mL  
of water, was added 40 g (65 mmol) of potassium  
25 peroxyomonosulfate (OXONE®) . After 2 hours, the  
reaction was filtered, the filter cake was washed  
with methanol and the filtrate concentrated in vacuo,  
ethyl acetate and water were added, the layers were  
separated and the aqueous layer was extracted 2xs  
30 with ethyl acetate. The 3 organic extracts were  
combined and washed with saturated sodium bicarbonate  
solution and brine, dried with magnesium sulfate,  
filtered and concentrated to afford 5.8 g of crude  
product. This was chromatographed on silica gel

- 148 -

using 15%-25% ethyl acetate/hexane to yield 4.4 g of pure methyl 3-[(4-methoxyphenyl)sulfonyl]hexanoic acid, m/z= 307 (M+Li) .

5           Part C: To a solution of 4.4 g (15 mmol) of methyl 3-[(4-methoxyphenyl)sulfonyl]hexanoic acid from Part B in 50 mL of anhydrous THF at zero °C under nitrogen, was added 16.2 mL (0.6 g, 15 mmol) of a 1.0 M solution of lithium aluminum hydride in THF.

10          After 1 hour, the reaction mixture was cooled to zero °C and 0.6 mL of water was added, followed by 0.6 mL of 2.5 N sodium hydroxide solution and 1.8 mL of water, the reaction was filtered, the filtrate concentrated *in vacuo*, ethyl acetate and 5% citric

15          acid solution were added, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 3.6 grams of pure 3-[(4-methoxyphenyl)sulfonyl]hexan-1-

20          ol, m/z= 273 (M+H) .

             Part D: To a solution of 3.6 g (12 mmol) of 3-[(4methoxyphenyl)sulfonyl]hexan-1-ol, from Part C and 3.8 g (15 mmole) of triphenylphosphine in 50 mL of anhydrous THF at zero °C , was added 2.3 mL (2.6 g, 15 mmol) of diethylazodicarboxylate, followed after 15 min. by 1.1 mL (1.1 g, 15 mM) of thiolacetic acid. After 15 hours, the reaction was concentrated and the residue was chromatographed on silica gel


25          30          using 10%-25% ethyl acetate/hexane to yield 3.3 g of pure thioacetate, m/z = 331 (M+H) .

             Part E: To a solution of 2.0 g (6 mmol) of thioacetate, from Part D, in 40 mL of anhydrous methanol, was added 0.5 g (23 mmol) of sodium metal. After 2 hours, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and

- 149 -

water, the organic layer was separated and washed with water and brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product. This was chromatographed on silica gel 5 using 5%-20% ethyl acetate/hexane to yield 1.0 g of pure 3-[(4-methoxyphenyl)sulfonyl]hexane-1-thiol, m/z= 289 (M+H) .

Example 21: Preparation of 3-[(4-methoxyphenyl)-  
10 sulfonyl]-3-phenylpropane-1-thiol.



Part A: To a solution of 3.0 g (21 mmol) of 4-methoxybenzenethiol in 40 mL of methanol at zero 15 °C , was added 3.5 g (21 mmol) of methyl trans-cinnamate . After nitrogen gas was bubbled through the solution for 15 min., 3.1 mL (2.3 g, 22 mM) of triethylamine was added. The reaction was heated at the reflux temperature for 16 hours, then 20 concentrated *in vacuo*, ethyl acetate and 5% citric acid solution were added, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 6.5 g of 25 product suitable for the next reaction.

Part B: To a solution of 6.5 g (21 mmol) of product from Part A in 100 mL of methanol and 20 mL of water, was added 42 g (68 mmol) of potassium 30 peroxymonosulfate (OXONE®) . After 19 hours, the reaction was filtered, the filter cake was washed with methanol and the filtrate concentrated *in vacuo*, ethyl acetate and water were added, the layers were

-150-

separated and the aqueous layer was extracted 2 xs with ethyl acetate. The 3 organic extracts were combined and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, 5 filtered and concentrated to afford 6.5 g of crude product. This was chromatographed on silica gel using 20%-35% ethyl acetate/hexane to yield 6.1 g of pure methyl 3-[(4-methoxyphenyl)sulfonyl]-3-phenylpropanoic acid, m/z= 341 (M+Li).

10

Part C: To a solution of 5.0 g (15 mmol) of methyl 3-[(4-methoxyphenyl)sulfonyl]-3-phenylpropanoic acid, from Part B in 60 mL of anhydrous THF at zero °C under nitrogen, was added 15 16.4 mL (0.6 g, 15 mmol) of a 1.0 M solution of lithium aluminum hydride in THF. After 2 hours, the reaction mixture was cooled to zero °C and 1.2 mL of water was added, followed by 1.2 mL of 2.5 N sodium hydroxide solution and 3.6 mL of water, the reaction 20 was filtered, the filtrate concentrated *in vacuo*, ethyl acetate and 5% citric acid solution were added, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and 25 concentrated to afford 3.9 grams of pure 3-[(4-methoxyphenyl)sulfonyl]-3-phenylpropan-1-ol, m/z= 313 (M+Li).


Part D: To a solution of 3.7 g (14 mmole) 30 of triphenylphosphine in 50 mL of anhydrous THF at zero °C, was added 2.2 mL (2.4 g, 14 mmol) of diethylazodicarboxylate, followed after 30 min. by a solution of 3.9 g (13 mmol) of 3-[(4-methoxyphenyl)sulfonyl]-3-phenylpropan-1-ol from Part 35 C and 1.0 mL (1.1 g, 14 mM) of thiolacetic acid. After 1 hour, the reaction was concentrated and the residue was chromatographed on silica gel using 15%-

- 151 -

30% ethyl acetate/hexane to yield 2.9 g of pure thioacetate, m/z = 371 (M+Li).

Part E: To a solution of 2.0 g (5 mmol) of  
 5 thioacetate, from Part D, in 60 mL of anhydrous methanol, was added 0.5 g (21 mmol) of sodium metal. After 1 hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and water, the organic layer was separated and washed  
 10 with water and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.8 g of crude product. This was chromatographed on silica gel using 15%-20% ethyl acetate/hexane to yield 1.1 g of pure 3-[(4-methoxyphenyl)sulfonyl]-3-phenylpropane-1-thiol, m/z= 329 (M+Li).  
 15

Example 22: Preparation of 3-[(4-methoxyphenyl)-sulfonyl]-octane-1-thiol.



20

Part A: To a solution of 2.7 g (19 mmol) of 4-methoxybenzenethiol in 40 mL of methanol at zero °C , was added 3.0 g (19 mmol) of methyl trans-2-octenoate . After nitrogen gas was bubbled through the solution for 15 min., 2.8 mL (2.0 g, 20 mM) of triethylamine was added. The reaction was heated at the reflux temperature for 16 hours, then concentrated *in vacuo*, ethyl acetate and 5% citric acid solution were added, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 5.7 g of product suitable for the next reaction.  
 25  
 30

- 152 -

Part B: To a solution of 5.7 g (19 mmol) of product from Part A in 120 mL of methanol and 20 mL of water, was added 38 g (62 mmol) of potassium peroxyomonosulfate (OXONE®). After 18 hours, the reaction was filtered, the filter cake was washed with methanol and the filtrate concentrated *in vacuo*, ethyl acetate and water were added, the layers were separated and the aqueous layer was extracted 2xs with ethyl acetate. The 3 organic extracts were combined and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 5.5 g of crude product. This was chromatographed on silica gel using 15%-25% ethyl acetate/hexane to yield 4.4 g of methyl 3-[(4-methoxyphenyl)sulfonyl]-octanoic acid, suitable for the next reaction.

Part C: To a solution of 4.4 g (13 mmol) of methyl 3-[(4-methoxyphenyl)sulfonyl]-octanoic acid from Part B in 60 mL of anhydrous THF at zero °C under nitrogen, was added 14.6 mL (0.5 g, 13 mmol) of a 1.0 M solution of lithium aluminum hydride in THF. After 2 hours, the reaction mixture was cooled to zero °C and 0.5 mL of water was added, followed by 0.5 mL of 2.5 N sodium hydroxide solution and 1.5 mL of water, the reaction was filtered, the filtrate concentrated *in vacuo*, ethyl acetate and 5% citric acid solution were added, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 3.3 grams of pure 3-[(4-methoxyphenyl)sulfonyl]-octan-1-ol, m/z= 307 (M+Li).

35

Part D: To a solution of 3.6 g (14 mmole) of triphenylphosphine in 50 mL of anhydrous THF at


- 153 -

zero °C , was added 2.2 mL (2.4 g, 14 mmol) of diethylazodi-carboxylate, followed after 15 min. by a solution of 3.3 g (11 mmol) of 3-[(4-methoxyphenyl)sulfonyl]-octan-1-ol from Part C and 5 1.0 mL (1.0 g, 14 mM) of thiolacetic acid. After 1 hour, the reaction was concentrated and the residue was chromatographed on silica gel using 10%-20% ethyl acetate/hexane to yield 2.4 g of pure thioacetate, m/z = 365 (M+Li).

10

Part E: To a solution of 2.0 g (6 mmol) of thioacetate, from Part D, in 25 mL of anhydrous methanol, was added 0.5 g (21 mmol) of sodium metal. After 1 hour, the reaction was cooled, 1N HCl 15 solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with water and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.7 g of crude product. This was chromatographed on silica gel 20 using 10%-15% ethyl acetate/hexane to yield 1.0 g of pure 3-[(4-methoxyphenyl)sulfonyl]-octane-1-thiol, m/z= 323 (M+Li).

Example 23: Preparation of 1-[(4-methoxyphenyl)-  
25 sulfonyl]-heptane-3-thiol.



Part A: To a solution of 5.0 g (22 mmol) of 3-[(4-methoxyphenyl)sulfonyl]propan-1-ol from 30 example 13 and 12.1 mL (8.8 g, 87 mmole) of triethylamine in 25 mL of methylene chloride at zero °C , was added a solution of 13.8 g (87 mmol) of sulfur trioxide-pyridine complex in 25 mL of DMSO. After 1 hour, the reaction mixture was added to 300

-154-

mL of ice, ethyl acetate was added, the organic layer was separated and washed with water, 5% potassium hydrogen sulfate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 4.1 g of 3-[(4-methoxyphenyl)sulfonyl]propan-1-al. suitable for the next reaction.

Part B: To 22.3 mL (4.3 g, 37 mM) of a 2.0 M butylmagnesium chloride solution in THF at zero °C , was added 4.1 g (18 mmol) of 3-[(4-methoxyphenyl)sulfonyl]propan-1-al from Part A in 30 mL of THF. After 3 hours, the reaction mixture was cooled to zero °C and 40 mL of saturated ammonium chloride solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with 5% potassium hydrogen sulfate solution, saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 4.7 grams of crude product. This was chromatographed on silica gel using 30%-40% ethyl acetate/hexane to yield 3.1 g of pure 1-[(4-methoxyphenyl)sulfonyl]-heptan-3-ol, m/z= 324 (M+NH<sub>4</sub>) .

Part C: To a solution of 3.1 g (11 mmol) of 1-[(4-methoxyphenyl)sulfonyl]-heptan-3-ol from Part B and 6.0 g (23 mmole) of triphenylphosphine in 50 mL of anhydrous THF at zero °C , was added 3.6 mL (4.0 g, 23 mmol) of diethylazodicarboxylate, followed after 1 hour by 1.7 mL (1.7 g, 23 mM) of thiolacetic acid. After 1 hour, the reaction was concentrated and the residue was chromatographed on silica gel using 10%-20% ethyl acetate/hexane to yield 1.2 g of thioacetate suitable for the next reaction.


35

Part D: To a solution of 1.2 g (3 mmol) of thioacetate, from Part C, in 40 mL of anhydrous

-155-

methanol, was added 0.3 g (13 mmol) of sodium metal. After 1 hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with water and brine, dried with magnesium sulfate, filtered and concentrated to afford 0.9 g of crude product. The crude product was chromatographed on silica gel using 10%-20% ethyl acetate/hexane to yield 0.6 g of pure 1-[(4-methoxyphenyl)sulfonyl]-heptane-3-thiol, m/z= 303 (M+H).

Example 24: Preparation of 3-[(4-methoxyphenyl)sulfonyl]-1-phenylpropane-1-thiol.



15

Part A: To a solution of 5.2 g (23 mmol) of 3-[(4-methoxyphenyl)sulfonyl]propan-1-ol from Example 13 and 12.6 mL (9.1 g, 90 mmole) of triethylamine in 25 mL of methylene chloride at zero °C, was added a solution of 14.4 g (90 mmol) of sulfur trioxide-pyridine complex in 25 mL of DMSO. After 1 hour, the reaction mixture was added to 200 mL of ice, ethyl acetate was added, the organic layer was separated and washed with water, 5% potassium hydrogen sulfate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 4.9 g of 3-[(4-methoxyphenyl)sulfonyl]propan-1-al suitable for the next reaction.

30

Part B: To 11.4 mL (3.2 g, 23 mM) of a 2.0 M phenylmagnesium chloride solution in THF at zero °C, was added 2.6 g (11 mmol) of 3-[(4-methoxyphenyl)sulfonyl]propan-1-al from Part A in 20

-156-


mL of THF. After 1.5 hours, the reaction mixture was cooled to zero °C and 20 mL of saturated ammonium chloride solution was added, followed by ethyl acetate and water, the organic layer was separated  
5 and washed with 5% potassium hydrogen sulfate solution, saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 2.7 grams of crude product. This was chromatographed on silica gel using 35%-40%  
10 ethyl acetate/hexane to yield 1.7 g of pure 3-[(4-methoxyphenyl)sulfonyl]-1-phenylpropan-1-ol, m/z= 324 (M+NH<sub>4</sub>) .

Part C: To a solution of 1.7 g (6 mmol) of  
15 product from Part B and 3.1 g (12 mmole) of triphenylphosphine in 40 mL of anhydrous THF at zero °C , was added 1.8 mL (2.0 g, 12 mmol) of diethylazodi-carboxylate, followed after 1 hour by 0.9 mL (0.9 g, 12 mM) of thiolacetic acid. After 16  
20 hours, the reaction was concentrated and the residue was chromatographed on silica gel using 15%-35% ethyl acetate/hexane to yield 0.8 g of thioacetate, suitable for the next reaction.

25 Part D: To a solution of 0.8 g (2 mmol) of thioacetate, from Part C, in 15 mL of anhydrous methanol, was added 0.2 g (8 mmol) of sodium metal. After 1 hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and  
30 water, the organic layer was separated and washed with water and brine, dried with magnesium sulfate, filtered and concentrated to afford 0.5 g of crude product. This was chromatographed on silica gel using 10%-30% ethyl acetate/hexane to yield 0.2 g of pure 3-[(4-methoxyphenyl)sulfonyl]-1-phenylpropane-1-thiol, m/z= 340 (M+NH<sub>4</sub>) .

-157-

Example 25: Preparation of 4-[(4-methoxyphenyl)sulfonyl]butane-1-thiol.



5           Part A: To a solution of 5.0 g (36 mmol) of 4-methoxybenzenethiol in 50 mL of anhydrous DMF, was added 4.4 mL (4.8 g, 44 mmol) of 3-chloro-1-propanol. After nitrogen gas was bubbled through the solution for 15 min., 17.3 g (125 mM) of powdered 10 potassium carbonate was added. After 66 hours, the DMF was removed *in vacuo*, ethyl acetate and water were added, the organic layer separated and washed 3xs with brine, dried with magnesium sulfate, filtered and concentrated to afford 8.2 g of product 15 suitable for the next reaction.

Part B: To a solution of 7.6 g (36 mmol) of product from Part A in 250 mL of methanol and 20 mL of water, was added 77 g (125 mmol) of potassium 20 peroxyomonosulfate (OXONE®). After 16 hours, the reaction was filtered, the filter cake was washed with methanol and the filtrate concentrated *in vacuo*, ethyl acetate and water were added, the layers were separated and the aqueous layer was extracted 2xs 25 with ethyl acetate. The 3 organic extracts were combined and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 8.3 g of the crude product. This was chromatographed on silica 30 gel using 50%-80% ethyl acetate/hexane to yield 5.8 g of pure 4-[(4-methoxyphenyl)sulfonyl]butan-1-ol, m/z = 251 (M+Li).


-158-

Part C: To a solution of 5.0 g (21 mmol) of 4-[(4-methoxyphenyl)sulfonyl]butan-1-ol from Part B and 5.9 g (23 mmole) of triphenylphosphine in 80 mL of anhydrous THF at zero °C, was added 3.5 mL (3.9 g, 23 mmol) of diethylazodicarboxylate, followed after 5 min. by 1.6 mL (1.7 g, 23 mM) of thiolacetic acid. After 65 hours, the reaction was concentrated and the residue was chromatographed on silica gel using 20%-30% ethyl acetate/hexane to yield 3.9 g of pure thioacetate, m/z = 320 (M+NH<sub>4</sub>).

Part D: To a solution of 2.0 g (7 mmol) of thioacetate, from Part C, in 60 mL of anhydrous methanol, was added 0.6 g (24 mmol) of sodium metal. After 1 hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.7 g of crude product. This was chromatographed on silica gel using 15%-25% ethyl acetate/hexane to yield 1.3 g of pure 4-[(4methoxyphenyl)sulfonyl]butane-1-thiol, m/z= 267 (M+Li).

25

Example 26: Preparation of 3-[(4-butoxyphenyl)-sulfonyl]propan-1-ol.



30 Part A: To a solution of 10.0 g (79 mmol) of 4-hydroxybenzenethiol in 100 mL of anhydrous DMF, was added 7.3 mL (8.2 g, 87 mmol) of 3-chloro-1-propanol. After nitrogen gas was bubbled through the solution for 15 min., 33.0 g (238 mM) of powdered

- 159 -


potassium carbonate was added. After 17 hours, the DMF was removed *in vacuo*, ethyl acetate and water were added, the organic layer separated and washed 3xs with brine, dried with magnesium sulfate, 5 filtered and concentrated to afford 16 g of crude product, m/z = 183 (M-H).

Part B: To a solution of 3 g (16 mmol) of product from Part A in 20 mL of anhydrous DMF, was 10 added 6.8 g (49 mmol) of powdered potassium carbonate, followed by 3.3 g (24 mM) of 1-bromobutane. After 65 hours, ethyl acetate and water were added, the organic layer separated and washed 3xs with brine, dried with magnesium sulfate, 15 filtered and concentrated to afford 3.9 g of crude product, m/z = 247 (M+Li).

Part C: To a solution of 3.9 g (16 mmol) of product from Part B in 50 mL of methanol and 10 mL of water, was added 32 g (52 mmol) of potassium peroxymonosulfate (OXONE®). After 16 hours, the reaction was filtered, the filter cake was washed with methanol and the filtrate concentrated *in vacuo*, ethyl acetate and water were added, the layers were 25 separated and the aqueous layer was extracted 2xs with ethyl acetate. The 3 organic extracts were combined and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 4.3 g of product, 30 identified as 3-[(4-butoxyphenyl)sulfonyl]propan-1-ol m/z = 279 (M+Li).

Example 27: Preparation of 3-[(4-butoxyphenyl)-sulfonyl]propane-1-thiol.


-160-



Part A: To a solution of 4.3 g (16 mmol) of 3-[(4-butoxyphenyl)sulfonyl]propan-1-ol from example 27 and 5.1 g (19 mmole) of triphenylphosphine in 50 mL of anhydrous THF at zero °C, was added 3.1 mL (3.4 g, 19 mmol) of diethylazodicarboxylate, followed after 15 min. by 1.4 mL (1.5 g, 19 mM) of thiolacetic acid. After one hour, the reaction was concentrated and the residue was chromatographed on silica gel using 10%-25% ethyl acetate/hexane to yield 4.4 g of pure thioacetate, m/z = 348 (M+NH<sub>4</sub>) .

Part B: To a solution of 2.0 g (6 mmol) of thioacetate, from Part A, in 40 mL of anhydrous methanol, was added 0.5 g (22 mmol) of sodium metal. After one hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product. This was chromatographed on silica gel using 10%-20% ethyl acetate/hexane to yield 1.3 g of pure 3-[(4-butoxyphenyl)sulfonyl]propane-1-thiol, m/z= 289 (M+H) .

Example 28: Preparation of 3-[(4-butoxyphenyl)-sulfonyl]-4-phenylbutane-1-thiol.



- 161 -

Part A: To a solution of 4.0 g (15 mmol) of 3-[(4-butoxyphenyl)sulfonyl]propan-1-ol from Example 26 and 6 mL of DMPU in 100 mL of anhydrous THF at -70 °C under nitrogen, was added 3.9 mL (1.9 g, 29 mmol) of a 10.0 M solution of n-butyllithium in hexane. After stirring for 30 min. at -70 °C, 1.6 mL (2.3 g, 13 mmole) of benzyl bromide was added. After 15 hours, the reaction mixture was cooled to zero °C and 25 mL of saturated ammonium chloride solution was added. Ethyl acetate and water were added, the layers were separated and the aqueous layer was extracted 2xs with ethyl acetate. The 3 organic layers were combined and washed with brine, dried with magnesium sulfate, filtered and concentrated to afford 8.4 g of crude product. This was chromatographed on silica gel using 25%-35% ethyl acetate/hexane to yield 4.3 g of pure 3-[(4-butoxyphenyl)sulfonyl]-4-phenylbutan-1-ol.

20

Part B: To a solution of 4.3 g (12 mmol) of 3-[(4-butoxyphenyl)sulfonyl]-4-phenylbutan-1-ol from Part A and 4.7 g (18 mmole) of triphenylphosphine in 100 mL of anhydrous THF at zero °C, was added 2.8 mL (3.1 g, 18 mmol) of diethylazodicarboxylate, followed after 15 min. by 1.3 mL (1.4 g, 18 mM) of thiolacetic acid. After one hour, the reaction was concentrated and the residue was chromatographed on silica gel using 10%-15% ethyl acetate/hexane to yield 4.1 g of pure thioacetate.


30  
Part C: To a solution of 2.0 g (5 mmol) of thioacetate, from Part B, in 30 mL of anhydrous methanol, was added 0.4 g (18 mmol) of sodium metal. After one hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and water, the organic layer was separated and washed

-162-

with water and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.9 g of crude product. This was chromatographed on silica gel using 5%-15% ethyl acetate/hexane to yield 1.2 g of  
5 pure 3-[(4-butoxyphenyl)sulfonyl]-4-phenylbutane-1-thiol.

Example 29: Preparation of 3-[(4-propoxyphenyl)-sulfonyl]propanethiol.

10



20

Part A: To a solution of 10.0 g (79 mmol) of 4-hydroxybenzenethiol in 100 mL of anhydrous DMF, was added 7.3 mL (8.2 g, 87 mmol) of 3-chloro-1-propanol. After nitrogen gas was bubbled through the solution for 15 min., 33.0 g (238 mM) of powdered potassium carbonate was added. After 17 hours, the DMF was removed *in vacuo*, ethyl acetate and water were added, the organic layer separated and washed 3xs with brine, dried with magnesium sulfate, filtered and concentrated to afford 16.1 g of pure product, m/z = 183 (M-H).

25

Part B: To a solution of 2.8 g (15 mmol) of compound from Part A in 20 mL of anhydrous DMF, was added 6.3 g (46 mmol) of powdered potassium carbonate, followed by 2.8 g (23 mM) of 1-bromopropane. After 16 hours, ethyl acetate and water were added, the organic layer separated and washed 3xs with brine, dried with magnesium sulfate, filtered and concentrated to afford 3.4 g of product, m/z = 233 (M+Li).

- 163 -


Part C: To a solution of 3.4 g (16 mmol) of compound from Part B in 50 mL of methanol and 10 mL of water, was added 31 g (51 mmol) of potassium peroxyomonosulfate (OXONE®). After 18 hours, the  
5 reaction was filtered, the filter cake was washed with methanol and the filtrate concentrated *in vacuo*, ethyl acetate and water were added, the layers were separated and the aqueous layer was extracted 2xs with ethyl acetate. The 3 organic extracts were  
10 combined and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 3.9 g of 3-[(4-propoxypyhenyl)sulfonyl]propan-1-ol, m/z = 259 (M+H).

15 Part D: To a solution of 3.9 g (15 mmol) of 3-[(4-propoxypyhenyl)sulfonyl]propan-1-ol from Part C and 4.9 g (19 mmole) of triphenylphosphine in 50 mL of anhydrous THF at zero C, was added 2.9 mL (3.2 g, 19 mmol) of diethylazodicarboxylate, followed after  
20 15 min. by 1.4 mL (1.4 g, 19 mM) of thiolacetic acid. After 2 hours, the reaction was concentrated and the residue was chromatographed on silica gel using 15%-25% ethyl acetate/hexane to yield 4.1 g of pure thioacetate, m/z = 334 (M+NH<sub>4</sub>).

25 Part E: To a solution of 2.0 g (6 mmol) of thioacetate from Part D in 40 mL of anhydrous methanol, was added 0.6 g (23 mmol) of sodium metal. After one hour, the reaction was cooled, 1N HCl  
30 solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with water and brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product. This was chromatographed on silica gel  
35 using 10%-20% ethyl acetate/hexane to yield 1.2 g of pure 3-[(4-propoxypyhenyl)sulfonyl]propane-1-thiol, m/z= 275 (M+H).

-164-

Example 30: Preparation of 3-(phenylsulfonyl)propane-1-thiol.



5

Part A: To a solution of 3.0 g (27 mmol) of thiophenol in 50 mL of anhydrous DMF, was added 2.4 mL (2.7 g, 28 mmol) of 3-chloro-1-propanol. After nitrogen gas was bubbled through the solution for 15 min., 11.3 g (81 mM) of powdered potassium carbonate was added. After one hour, the DMF was removed *in vacuo*, ethyl acetate and water were added, the organic layer separated and washed 3xs with brine, dried with magnesium sulfate, filtered and concentrated to afford 4.6 g of product suitable for the next reaction.

Part B: To a solution of 4.6 g (27 mmol) of product from Part A in 80 mL of methanol and 20 mL of water, was added 53 g (87 mmol) of potassium peroxymonosulfate (OXONE®). After 65 hours, the reaction was filtered, the filter cake was washed with methanol and the filtrate concentrated *in vacuo*, ethyl acetate and water were added, the layers were separated and the aqueous layer was extracted 2xs with ethyl acetate. The 3 organic extracts were combined and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 4.7 g of 3-(phenylsulfonyl)propan-1-ol, m/e = 207 (M+H).


Part C: To a solution of 4.7 g (24 mmol) of 3-(phenylsulfonyl)propan-1-ol from Part B and 7.6 g (29 mmole) of triphenylphosphine in 50 mL of

-165-

anhydrous THF at zero C, was added 4.6 mL (5.0 g, 29 mmol) of diethylazodicarboxylate, followed after 15 min. by 2.1 mL (2.2 g, 29 mM) of thiolacetic acid. After 1.5 hours, the reaction was concentrated and 5 the residue was chromatographed on silica gel using 10%-30% ethyl acetate/hexane to yield 4.3 g of pure thioacetate, m/z = 265 (M+Li).

Part D: To a solution of 2.0 g (8 mmol) of 10 thioacetate, from Part C, in 40 mL of anhydrous methanol, was added 0.7 g (29 mmol) of sodium metal. After one hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and water, the organic layer was separated and washed 15 with water and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.6 g of crude product. This was chromatographed on silica gel using 10%-20% ethyl acetate/hexane to yield 0.9 g of pure 3-(phenylsulfonyl)propane-1-thiol, m/z= 217 20 (M+H).

Example 31 : Preparation of



25

Part A: A 100 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 1.0 g 5,6-Dihydro-2H-pyran-2-one, 1.5 g p-methoxy benzenethiol in 35 mL degassed MeOH. To 30 the stirring solution was added 1.5 mL triethylamine. The reaction was stirred 30 minutes then concentrated in vacuo to remove triethylamine. The crude product was dissolved in 35 mL MeCl<sub>2</sub> and treated with 7.6 g MCPBA. The reaction was stirred overnight at room


- 166 -

temperature then quenched with 2 eq sodium sulfite. The reaction mixture was diluted with MeCl<sub>2</sub> and water. The organic phase was washed with 10 % aqueous ammonium hydroxide, brine, and concentrated 5 in vacuo to 2.5 g of an 80:20 ratio of lactone to hydroxy methyl ester, which was used without further purification.

Part B: A 100 mL round bottom flask 10 equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 2.5 g crude from part A, 12.8 mL of 40% aqueous methyl amine (20eq) in 15 mL MeOH. The reaction was stirred one hour then concentrated in vacuo and purified by chromatography (100% ethyl acetate / 10% methanol-ethyl acetate) to yield 1.8 g 15 pure amide.

Part C: To a solution of 1.8 g of hydroxy amide from Part B and 1.65 g of triphenylphosphine in 20 30 mL of anhydrous THF at zero °C , was added 1.0 mL of diethylazodicarboxylate, followed after 5 min. by 0.5 mL of thiolacetic acid. After 1.5 hours, the reaction was concentrated and the residue was chromatographed on silica gel using 75%-100% ethyl 25 acetate/hexane to yield 1.8 g of crude thioacetate contaminated with triphenyl phosphine oxide. 500 mg of this crude material was deprotected with 2 eq sodium methoxide in methanol. After 20 minutes the reaction was quenched with 1N HCl and extracted with 30 ethyl acetate. The organic phase was washed with brine, and concentrated in vacuo to crude product. Purification was accomplished by preparative-scale reverse phase HPLC to afford pure thiol.

35 Example 32: Preparation of N-[1-(mercaptomethyl)-2-[(4-methoxyphenyl)sulfonyl]ethyl]acetamide.



Part A: To a stirred degassed ( $N_2$ ) solution of (20 g, 139 mmol) of N-acetyl-dehydroalanine methyl ester in 400 mL of methanol was added (19.5 g, 139 mmol) of 4-methoxythiophenol followed by 14.0 g, 140 mmol) of triethylamine and the resulting solution stirred for 2 hours. The resulting N-acetyl- $\beta$ -(4-methoxythio-phenyl)-D,L-alanine methyl ester was 10 oxidized *in situ* by the addition of 800 mL of methanol, 160 mL of water followed by (250 g, 417 mmol) of OXONE®. The suspension was stirred for 3 hours and then filtered through a fritted glass buchner funnel. The filtrate was concentrated by 15 rotary evaporation and the concentrated material was partitioned between ethyl acetate and sodium bicarbonate. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated to a white solid which was triturated with cold ethyl acetate and filtered to yield 28.5 g 20 of N-acetyl- $\beta$ -(4-methoxyphenylsulfonyl)-D,L-alanine methyl ester.

Part B: To an ice cooled, stirred solution of (1.6 g, 5 mmol) of N-acetyl- $\beta$ -(4-methoxyphenyl-sulfonyl)-D,L-alanine methyl in 20 mL of anhydrous tetrahydrofuran was added (5 mL, 5mmol) of a 1M lithium aluminum hydride solution in diethyl ether. After 20 minutes the subsequent suspension was 30 quenched by the addition of 2 mL of 2.5 M aqueous sodium hydroxide solution. The resulting suspension

- 168 -

was filtered through CELITE® and the filtrate was concentrated by rotory evaporation to yield 530 mg of N-[1-(hydroxymethyl)-2-[(4-methoxyphenyl)-sulfonyl]ethyl]acetamide.


5

Part C: (471 mg, 1.8 mmol) of triphenylphosphine and (520 mg, 1.8 mmol) of N-[1-(hydroxymethyl)-2-[(4-methoxyphenyl)sulfonyl]ethyl]acetamide were dissolved in 15 mL of tetrahydrofuran and cooled 10 to zero C under nitrogen atmosphere. To this was added (313 mg, 1.8 mmol) of diethyldiazodicarboxylate, followed by (140 mg, 1.8 mmol) of thioacetic acid and the solution stirred for 2 hours. The resulting clear solution was 15 concentrated by rotory evaporation and subjected to silica gel chromatography using 15% methanol in ethyl acetate as the eluant to provide a mixture of triphenylphosphine oxide and the desired N-[1-(thioacetyl methyl)-2-[(4-methoxyphenyl)-sulfonyl]ethyl]acetamide in equal molar ratios. This 20 mixture was dissolved in 10 ml of methanol and to this was added 1 mL of 25% sodium methoxide in methanol and this stirred for 30 minutes. The solution was acidified with 1N hydrochloric acid and 25 extracted with ethyl acetate. The resulting organics were concentrated and purified by reverse phase C<sub>18</sub> chromatography to yield 150 mg of N-[1-(mercaptomethyl)-2-[(4-methoxyphenyl)-sulfonyl]ethyl]acetamide, m/e=310 (M+Li).

30

Example 33: Preparation of 2-R,S-(N-carbobenzyloxy-glycyl)amino-3-(4-methoxybenzenesulfonyl)propanethiol.

-169-



Part A: A solution of (18.13 g, 57 mmol) of N-acetyl- $\beta$ -(4-methoxyphenylsulfonyl)-D,L-alanine methyl ester in 125 mL concentrated hydrochloric acid and 125 mL of glacial acetic acid was refluxed for several hours under nitrogen atmosphere. The contents were concentrated by rotory evaporation to yield a crude solid which was slurried in dry toluene and filtered to yield 14.3 g of  $\beta$ -(4-methoxyphenylsulfonyl)-D,L-alanine hydrochloride as a white crystalline solid.

Part B: To an ice cooled solution of (8.87g, 30 mmol) of  $\beta$ -(4-methoxyphenylsulfonyl)-D,L-alanine hydrochloride in 200 mL of dry methanol was added dropwise over 20 minutes (10.7 g, 90 mmol) of thionyl chloride, and the solution was refluxed overnight under nitrogen atmosphere. The contents were cooled to room temperature and concentrated by rotory evaporation and triturated with ether. The product was collected by filtration to yield 6.2 grams of  $\beta$ -(4-methoxyphenylsulfonyl)-D,L-alanine methyl ester hydrochloride.

Part C: To an ice cooled, stirred solution of (6.2 g, 20 mmol) of  $\beta$ -(4-methoxyphenylsulfonyl)-D,L-alanine methyl ester hydrochloride in tetrahydrofuran under nitrogen was added dropwise, (20 mL, 20 mmol) of lithium aluminum hydride in tetrahydrofuran. After 2 hours the ice cooled solution was carefully quenched by the addition of 5

-170-


mL of 10% sodium hydroxide and the resulting suspension was filtered through CELITE®. The filtrate was dried over magnesium sulfate filtered and concentrated to yield 2.7 grams of  $\beta$ -(4-methoxyphenyl-sulfonyl)-D,L-alaninol.

Part D: (2.4 g, 10 mmol) of  $\beta$ -(4-methoxy-phenylsulfonyl)-D,L-alaninol was added to a solution of dimethylformamide containing (2.0 g, 15 mmol) of 10 hydroxybenzotriazole, (2.0 g, 10 mmol) of EDC and (2.0 g, 10 mmol) of N-carbobenzyloxyglycine and 1.5 g of triethylamine. The reaction stirred overnight at room temperature. The resulting solution was concentrated to an oil and the residue was 15 partitioned between ethyl acetate and saturated sodium bicarbonate. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated to yield a crude material which was purified by column chromatography using 5% methanol 20 in ethyl acetate as the eluant to yield 850 mg of 2-R,S-(N-carbobenzyloxy-glycyl)amino-3-(4-methoxybenzenesulfonyl)propanol.

Part E: To an ice cooled, stirred solution 25 of (650 mg, 1.97 mmol) of 2-R,S-(N-carbobenzyloxy-glycyl)amino-3-(4-methoxybenzenesulfonyl)propanol in 50 mL of anhydrous tetrahydrofuran was added (525 mg, 2.0 mmol) of triphenylphosphine followed by (348 mg, 2.0 mmol) of diethyldiazodicarboxylate, and then 30 (150 mg, 2.0 mol) of thioacetic acid and the clear solution was stirred for several hours. The crude mixture was concentrated on a rotory evaporator and subjected to silica gel chromatography using 100 % ethyl acetate as the eluant yielded 600 mg of 2-R,S-(N-carbobenzyloxy-glycyl)amino-3-(4-methoxybenzenesulfonyl) propanethiol as a white 35 solid. m/e=459 (M+Li)

-171-

Example 34: Preparation of 1-[(4-methoxyphenyl)-sulfonyl]ethane-2-thiol



Part A: To a solution of 5.0 mL (6.0 g, 74.9 mmol) of 2-chloroethanol in 100 mL of anhydrous DMF, was added 8.7 mL (10.0 g, 71.3 mmol) of 10 4-methoxybenzene thiol. After purging with nitrogen for 5 minutes, 31.0 g (224 mmol) of powdered potassium carbonate was added. The temperature of the reaction began to rise, so the reaction was cooled in an ice bath, which was then removed 15 minutes later. After stirring at room temperature for 30 minutes, ethyl acetate and water were added, the organic layer separated and washed with water and brine, dried with magnesium sulfate, filtered and stripped to afford 11.85 g of the desired product, 20 (4-methoxyphenyl)(2-hydroxyethyl) sulfide, m/e = 184 (M+H).

Part B: To a solution of 11.85 g (64 mmol) of the crude product from Part A in 240 mL of 25 methanol and 24 mL of water, was added 118.6 g (193 mmol) of OXONE®, whereupon the temperature began to rise and the reaction was warmed to reflux for 15 minutes. After cooling to room temperature, the solids were filtered off and washed with methanol, 30 the filtrate stripped and redissolved in ethyl acetate. After washing with aqueous sodium bicarbonate and brine, and drying with magnesium sulfate, the solvent was removed to afford 12.8 g of

-172-


the desired 1-[(4-methoxyphenyl)-sulfonyl]ethan-2-ol, m/e=323 (M+Li).

Part C: To a solution of 2.0 g (9.2 mmol) of product from Part B and 2.67 g (10.2 mmol) of triphenylphosphine in 45 mL of anhydrous THF at zero °C, was added 2.0 mL (10.2 mmol) of diisopropylazodicarboxylate, followed by 0.73 mL (10.2 mmol) of thiolacetic acid. After stirring at room temperature for 15 hours, the reaction was concentrated and the residue chromatographed on 150 g of silica gel using 20-50% ethyl acetate/hexane to afford 2.5 g of the desired product, which was recrystallized from ethyl acetate/hexane to afford 0.55 g of desired pure product, m/e = 381 (M+Li).

Part D: To a suspension of 0.54 g (1.95 mmol) of product from Part C above in 5 mL of anhydrous methanol, was added 1.6 mL (7.0 mmol) of 25 weight percent sodium methoxide in methanol. After 30 minutes, the solution was cooled in ice and 2 % hydrochloric acid added. Ethyl acetate was added and the organic layer separated and washed with saturated sodium bicarbonate, brine, dried over anhydrous magnesium sulfate, filtered and stripped to afford 0.30 g the desired 1-[(4-methoxyphenyl)sulfonyl]ethane-2-thiol, m/e=239 (M+Li).

30

Example 35: Preparation of 3-[(4-phenylthio)phenylsulfonyl]propane-1-thiol.



-173-

Part A: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 10 g p-fluorothiophenol and 8.1 g 3-chloro-1-propanol in 80 mL DMF. To this was added 5 32.4 g K<sub>2</sub>CO<sub>3</sub> and the reaction was stirred 45 minutes at room temperature. The reaction was concentrated *in vacuo* and the residue was partitioned between ethyl acetate-H<sub>2</sub>O, dried, and concentrated *in vacuo* to yield 14.5 g pure product.

10

Part B: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 6.0 g product from part A, 4.2 mL (1.5 eq.) thiophenol and 11.4 g (3 eq.) K<sub>2</sub>CO<sub>3</sub> in 70 mL 15 DMF. The reaction was heated to 70 °C for 4 hours, then partitioned between ethyl acetate-H<sub>2</sub>O. The organic phase was washed with 1N HCl, brine, dried, and concentrated *in vacuo*. Chromatography on silica gel (50 % ethyl acetate-hexanes) yielded 6.5 g white 20 solid.

Part C: A 100 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 0.31 g 3-[(4-phenylthio)phenylsulfonyl] 25 propanol, 0.1 mL MsCl (1.25 eq.), 0.2 mL NEt<sub>3</sub> in 6 mL MeCl<sub>2</sub>. The reaction was stirred 20 minutes then concentrated *in vacuo* and partitioned between ethyl acetate-H<sub>2</sub>O. The organic phase was concentrated *in vacuo* and dissolved in 5 mL dry DMF and reacted with 30 114 mg (1 eq.) potassium thioacetate. The reaction mixture was stirred 24 hours then partitioned between ethyl acetate-H<sub>2</sub>O. The organic phase was washed with 1N KHSO<sub>4</sub>, brine, dried, and concentrated *in vacuo*.


- 174 -

Chromatography on silica gel (50 % ethyl acetate-hexanes) yielded 195 mg orange oil.

Part D: A 50 mL round bottom flask  
5 equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 190 mg product from part C, 0.2 mL (3 eq.) 25 % NaOMe in MeOH, and 5 mL MeOH. The reaction was stirred 30 minutes then quenched with 1 N HCl and concentrated *in vacuo*. The residue was partitioned  
10 between ethyl acetate-H<sub>2</sub>O, dried, and concentrated *in vacuo*. HPLC showed a 1:1 ratio of product to disulfide. Chromatography on silica gel (50 % ethyl acetate-hexanes) yielded 40 mg of pure 3-[(4-phenylthio)phenylsulfonyl]propane-1-thiol.

15

Example 36: Preparation of 3-[(4-phenoxy)phenylsulfonyl]propane-1-thiol.



20

Part A: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 10 g *p*-fluorothiophenol and 8.1 g 3-chloro-1-propanol in 80 mL DMF. To this was added  
25 32.4 g K<sub>2</sub>CO<sub>3</sub> and the reaction was stirred 45 minutes at room temperature. The reaction was concentrated *in vacuo* and the residue was partitioned between ethyl acetate-H<sub>2</sub>O, dried, and concentrated *in vacuo* to yield 14.5 g pure product.

30

Part B: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 7.9 g product from part A, 5.1 g phenol,

-175-

15.1 g  $K_2CO_3$  in 75 mL dry DMF. The reaction was heated to 80°C for 24 hours then concentrated *in vacuo* and the residue was partitioned between ethyl acetate- $H_2O$ , dried, and concentrated *in vacuo* to yield 12.3 g red liquid. Chromatography on silica gel (30 % to 60% ethyl acetate-hexanes) yielded 6.8 g 64% off white solid.

Part C: A 250 mL round bottom flask equipped with magnetic stir bar and  $N_2$  inlet was charged with 1.63 g product from part B, in 35 mL dry THF. The reaction was cooled to zero C and charged with 1.83 g triphenylphosphine, 1.2 g DEAD and stirred 5 minutes then charged with 0.5 g thioacetic acid. The reaction was stirred 20 minutes then concentrated *in vacuo*. Chromatography on silica gel (30 % to 60% ethyl acetate-hexanes) yielded 1.45 g product. Crystallization from diethyl ether afforded 900 mg white solid.


20

Part D: A 250 mL round bottom flask equipped with magnetic stir bar and  $N_2$  inlet was charged with 870 mg product from part C, 1.6 mL (3 eq.) 25 % NaOMe in MeOH, and 25 mL MeOH. The reaction was stirred 30 minutes then quenched with dry ice and concentrated *in vacuo*. The residue was partitioned between ethyl acetate- $H_2O$ , dried, and concentrated *in vacuo* to yield 670 mg of white 3-[(4-phenoxyphenyl)sulfonyl]propane-1-thiol.

30

Example 37: Preparation of 3-[(4-phenyl)-phenylsulfonyl]propane-1-thiol.

-176-



Part A: To a stirred solution of 2.80 g (10 mmol) of 3-(4-bromobenzene)sulfonyl propanol in  
5 75 mL of ethylene glycol dimethyl ether was added 1.35 g (11.15 mmol) of phenylboronic acid followed by 25 mL of 2 M aqueous cesium carbonate and then 1.0 g (1 mmol) of tetrakis-triphenylphosphine palladium and the reaction stirred for 48 hours. The resulting  
10 biphasic solution was diluted with ethyl acetate and washed with water 2x 200 mL. The organic layer was dried over magnesium sulfate, filtered and concentrated to a black oil, which was purified by silica gel column chromatography using 2:1 ethyl acetate:hexane as the eluant to yield 1.6 grams, 60%  
15 yield of 3-[(4-phenyl)phenylsulfonyl]-propanol as a clear oil.


Part B: To an ice-cooled solution of 1.6 g (5.8 mmol) of 3-(4-phenylbenzene)sulfonylpropanol and 1.65 g (6.3 mmol) of triphenylphosphine in 25 mL of dry tetrahydrofuran was added by syringe 1.0 g (6.3 mmol) of diethylazodicarboxylate, followed by 500 mg (6.3 mmol) of thioacetic acid. The reaction was  
25 stirred to room temperature over two hours and the resulting solution was concentrated by rotary evaporation and purified by silica gel chromatography to yield 1.93 grams of the desired compound.

30 Part C: To a suspension of 1.33 g (3.99 mmol) of the product from Part B in 10 mL of methanol was added 3 mL of 25 weight percent sodium methoxide in methanol and the solids dissolved in 5 minutes.

-177-

After 30 minutes at room temperature the reaction was quenched by the addition of 50 mL of 1N aqueous hydrochloric acid. The suspension was extracted with ethyl acetate and dried over magnesium sulfate, 5 filtered and concentrated to yield 930 mg of a white solid, identified as 3-[(4-phenyl)phenylsulfonyl]propane-1-thiol, m/e = 293 (M+H).

10 Example 38: Preparation of (R,S) trans-3-[(phenylthio)phenylsulfonyl] cyclohexanethiol



15 Part A: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 5 g p-fluorothiophenol and 3.75 g cyclohexenone in 50 mL degassed MeOH. To this was added 5.5 mL triethylamine. The reaction mixture was 20 stirred one hour at room temperature, then concentrated *in vacuo*. The residue was dissolved in 60 mL MeOH and treated with 1.6 g (1.2 eq.) NaBH<sub>4</sub>. The reaction mixture was stirred 90 minutes at zero °C. The reaction was quenched with concentrated HCl, 25 concentrated *in vacuo* to remove MeOH and partitioned between ethyl acetate-H<sub>2</sub>O. The organic phase was washed with brine and concentrated *in vacuo* to crude sulfide alcohol which was suspended in 160 mL MeOH/10 mL H<sub>2</sub>O and reacted with 72 g (3 eq) OXONE®. The 30 suspension was heated to 65°C to ensure homogeneity. The reaction was stirred 8 hours then filtered and concentrated *in vacuo*. The residue was partitioned

- 178 -

between ethyl acetate-H<sub>2</sub>O, dried, and concentrated in vacuo to 9.5 g of a thick oil. HPLC shows a 78:18 ratio of diastereomers.


5           Part B: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 2.0 g product from part A, 0.87 mL (1.1 eq.) thiophenol and 3.2 g (3 eq.) K<sub>2</sub>CO<sub>3</sub> in 70 mL DMF. The reaction was heated to 70°C for 4 hours then  
10 partitioned between ethyl acetate-H<sub>2</sub>O. The organic phase was washed with 1N HCl, brine, dried, and concentrated in vacuo. Chromatography on silica gel (30 % ethyl acetate-hexanes) yielded 1.7 g pure (R,S) trans-3-[((4-phenylthio)phenyl)sulfonyl]  
15 cyclohexanol.

Part C: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 1.7 g (R,S) trans-3-[((4-phenylthio)phenyl)sulfonyl] cyclohexanol, 0.4 mL MsCl (1.25 eq.), 1.0 mL NEt<sub>3</sub> in MeCl<sub>2</sub>. The reaction was stirred 20 minutes then concentrated in vacuo and partitioned between ethyl acetate-H<sub>2</sub>O. The organic phase was concentrated in vacuo and dissolved in 10 mL dry DMF and reacted with 6.5 g (10 eq.) potassium thioacetate. The reaction mixture was heated to 70°C for 4 hours then partitioned between ethyl acetate-H<sub>2</sub>O. The organic phase was washed with 1N KHSO<sub>4</sub>, brine, dried, and concentrated in vacuo.  
25 Chromatography on silica gel (30 % ethyl acetate-hexanes) yielded 1.1 g orange oil.

Part D: A 250 mL round bottom flask equipped with magnetic stir bar and N<sub>2</sub> inlet was charged with 1.0 g product from part C, 1.7 mL (3

- 179 -

- eq.) 25 % NaOMe in MeOH, and 25 mL MeOH. The reaction was stirred 30 minutes then quenched with dry ice and concentrated in vacuo. The residue was partitioned between ethyl acetate-H<sub>2</sub>O, dried, and 5 concentrated in vacuo to crude thiol. Chromatography on silica gel (30 % ethyl acetate-hexanes) yielded 0.9 g pure (R,S) trans-3-[(4-phenylthio)phenylsulfonyl]-cyclohexanethiol.
- 10 Example 39: Preparation of N1-3-[(4-phenoxyphenyl)sulfonyl]-1sulfanylpropyl-3-morpholinopropanamide:



15 Part A: A solution of 10 g (78 mmol) of 4-fluorothiophenol and 8 g (86 mM) of 3-chloro-1-propanol in 80 mL of anhydrous DMF was purged with nitrogen for 20 min., then treated with 32 g (234 mM) of potassium carbonate. After one hour, the reaction 20 mixture was concentrated in vacuo, and the residue was partitioned between ethyl acetate and water. The layers were separated and the organic layer was washed with brine (3X), dried ( $MgSO_4$ ), and concentrated to afford 16 g of crude product. The 25 crude product was chromatographed on silica gel using 30-45% ethyl acetate/hexane to yield 12 g of pure 3-[(4-fluorophenyl)thio]propan-1-ol, m/z = 203 (M +  $NH_4$ ) .

30 Part B: A solution of 16 g (78 mmol) of 3-[(4-fluorophenyl)thio]propan-1-ol from Part A in 300 mL of methanol and 60 mL of water was treated with 168 g (273 mM) of potassium peroxymonosulfate

-180-

(OXONE®). After 72 hours, the reaction was filtered, the filter cake was washed with methanol and the filtrate concentrated *in vacuo*, ethyl acetate and water were added, the layers were separated and the aqueous layer was extracted with ethyl acetate (2X). The 3 organic extracts were combined and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 13 g of pure 3-[(fluorophenyl)sulfonyl]propan-1-ol, m/z = 225 (M+Li).

Part C: A solution of 13 g (58 mmol) of 3-[(4-fluorophenyl)sulfonyl]propan-1-ol from part B and 16 g (175 mM) of phenol in 100 mL of anhydrous DMF was purged with nitrogen for one-half hour then treated with 24 g (175 mM) of potassium carbonate. The reaction mixture was then placed in a 100°C oil bath. After 24 hours, the reaction mixture was concentrated *in vacuo*, and the residue was partitioned between ethyl acetate and water. The layers were separated and the organic layer was washed with 1N HCl solution, saturated sodium bicarbonate solution and brine, dried ( $MgSO_4$ ), and concentrated to afford 29 g of crude product. This was chromatographed on silica gel using 30-45% ethyl acetate/hexane to yield 12 g of pure 3-[(4-phenoxyphenyl)sulfonyl]propan-1-ol, m/z = 299 (M+Li).

Part D: A cooled solution of 13 g (44 mmol) of 3-[(4-phenoxyphenyl)sulfonyl]propan-1-ol from Part C in 60 mL of anhydrous  $CH_2Cl_2$ , was treated with 25 mL (18 g, 178 mM) of triethylamine. The reaction mixture was then treated with a slurry of 28 g (178 mM) of pyridine-SO<sub>2</sub> complex in 60 mL of methyl sulfoxide added over one-half hour. After stirring for one hour, the reaction mixture was poured over

- 181 -

500 mL of ice and ethyl acetate was added. The layers were separated and the organic layer was washed with 5% KHSO<sub>4</sub> solution, water and brine, dried (MgSO<sub>4</sub>), and concentrated to afford 13 g of 3-[(4-phenoxyphenyl)sulfonyl]propan-1-al, suitable for the next reaction.

Part E: A cooled solution of 13 g (44 mmol) of 3-[(4-phenoxyphenyl)sulfonyl]propan-1-al from Part D in 150 mL of CH<sub>2</sub>Cl<sub>2</sub>, was treated with 8.9 mL (6.6 g, 67 mM) of trimethylsilylcyanide (TMSCN), followed by 15.0 g (67 mM) of zinc bromide. After 18 hours, additional TMSCN and zinc bromide were added to drive the reaction to completion. The reaction was concentrated *in vacuo* and the residue was partitioned between ethyl acetate and 2N HCl solution. The layers were separated and the organic layer was washed with water and brine, dried over MgSO<sub>4</sub>, and concentrated to yield 13.7 g of crude product. This was chromatographed on silica gel using 25-40% ethyl acetate/hexane to yield 9 g of 1-hydroxy-3-[(3-phenoxybenzyl)sulfonyl]propyl cyanide, suitable for the next reaction.

25 Part F: A solution of 9 g (28 mmol) of 1-hydroxy-3-[(3-phenoxybenzyl)sulfonyl]propyl cyanide from Part E in 25 mL of glacial acetic acid was treated with 100 mL of concentrated HCl and placed in a 90°C oil bath for two hours. The reaction was 30 concentrated *in vacuo*, then aliquots of toluene (1X) and acetonitrile (2X) were added to the crude product and stripped. Drying over P<sub>2</sub>O<sub>5</sub> under vacuum afforded 7.1 g of 2-hydroxy-4-[(3-phenoxybenzyl)sulfonyl]butanoic acid suitable for the next reaction.

35

Part G: A solution of 3.4 g (10 mmol) of 2-hydroxy-4-[(3-phenoxybenzyl)sulfonyl]butanoic acid

-182-

from Part F and 2.1 g (15 mM) HOBT in 15 mL of anhydrous DMF was cooled in an ice bath and treated with 2.3 g (12 mM) of EDC. After 2 hours, the reaction was treated with a solution of 1.5 g (12 mM) 5 of 4-(2-aminoethyl)morpholine and 3.3 mL (3.1 g, 30mM) of N-methylmorpholine in 5 mL anhydrous DMF. After stirring for 66 hours, the reaction was concentrated *in vacuo*, and the residue was partitioned between ethyl acetate and water. The 10 layers were separated and the organic layer was washed with saturated sodium bicarbonate solution and brine, dried over MgSO<sub>4</sub>, and concentrated to yield 3.5 g of crude product. The crude product was chromatographed on silica gel using 5% methanol/ethyl 15 acetate followed by 20% ethanol/THF to yield 2.1 g of N1-(2-morpholinoethyl)-2-hydroxy- 4-[(3-phenoxybenzyl)sulfonyl]butanamide suitable for the next reaction.

20                   Part H: A cooled solution of 2.1 g (5 mmol) of N1-(2-morpholinoethyl)-2-hydroxy-4-[(3-phenoxybenzyl)sulfonyl]butanamide from Part G in 55 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub> was treated with 0.5 mL (0.8 g, 7 mM) of methanesulfonyl chloride, followed by 1.0 25 mL (0.7 g, 7 mM) of triethylamine. After 1 hour, the reaction was concentrated *in vacuo*, and the residue was partitioned between ethyl acetate and saturated sodium bicarbonate solution. The layers were separated and the aqueous layer was extracted with 30 ethyl acetate (1X). The organic layers were combined and washed with brine, dried (MgSO<sub>4</sub>) and concentrated to yield 2.5 g of 1-[(2-morpholinoethyl)amino]- carbonyl-3-[(3-phenoxybenzyl)sulfonyl]propyl methanesulfonate suitable for the next reaction.

35

                 Part I: A solution of 2.5 g (5 mmol) of 1-[(2-morpholinoethyl)amino]carbonyl-3-[(3-

- 183 -


phenoxybenzyl)sulfonyl]propyl methanesulfonate from Part H in 20 mL of anhydrous DMF was treated with 0.8 g (7 mM) of potassium thioacetate. After 1 hour, the reaction was partitioned between ethyl acetate and sodium bicarbonate solution. The layers were separated and the organic layer was washed with brine (3X), dried ( $MgSO_4$ ), and concentrated to yield 2.4 g of crude product. This was chromatographed on silica gel using 1-3% methanol/ethyl acetate to yield 1.8 g of 1-[(2-morpholinoethyl)amino]carbonyl-3-[(3-phenoxybenzyl)sulfonyl]propyl ethanethioate suitable for the next reaction.

Part J: A cooled solution of 1.0 g (2 mmol) of 1-[(2-morpholinoethyl)amino]carbonyl-3-[(3-phenoxybenzyl)sulfonyl]propyl ethanethioate from Part I in 8 mL of anhydrous methanol, was treated with a sodium methoxide solution freshly prepared from 0.05 g (2 mmol) of sodium metal and 2 mL anhydrous methanol. After 1 hour, the reaction was quenched with dry ice, then partitioned between ethyl acetate and water. The layers were separated, and the aqueous layer was extracted with ethyl acetate (1X). The organic layers were combined and washed with brine, dried ( $MgSO_4$ ) and concentrated to yield 0.7 g of crude product. Purification was done using reverse-phase HPLC with 20-30% acetonitrile/water. Ion-exchange treatment gave the free base which was converted to the hydrochloride salt using concentrated HCl solution in  $CH_3CN$ . Concentration yielded 0.6 g of pure N1-3-[(4-phenoxyphenyl)sulfonyl]-1-sulfanylpropyl-3-morpholinopropanamide,  $m/z = 465$  ( $M+H$ ).

Example 40 to Example 103 were prepared by the procedures presented above, and are tabulated in the following "Example Tables".

- 184 -


Example Table 1



Example Number	P	N
40	H	o-CH <sub>3</sub>
41	H	m-CH <sub>3</sub>
42		p-CH <sub>3</sub>
43	H	p-CH <sub>3</sub>
44		H
45		H
46		H
47	H	m-CF <sub>3</sub>
48		m-CF <sub>3</sub>

- 185 -


Example Table 2



Example Number	P	N
49	H	m-Cl
50		m-Cl
51		H
52		H
53		H
54		H

- 186 -


Example Table 3



Example Number	P	N
55		H
56		H
57	H	3,4-(OCH <sub>2</sub> O-)
58		3,4-(OCH <sub>2</sub> O-)
59		(para)
60		(para)
61		(para)

- 187 -

Example Table 4


Example  
Number

P



N

62

H




63





64



H





65



66




67



- 188 -


Example Table 5



Example Number	P	N
68		(para)
69		(meta)
70	H	(meta)
71	H	(para)

- 189 -


Example Table 6



Example Number	P	N
72		(p)
73	H	(p)
74	H	(p)
75		(p)
76	H	(p)
77		(p)
78	H	(p)

- 190 -

Example Table 7



Example Number	P	N	R <sup>2</sup>
79	H	(p)-OCH <sub>3</sub>	
80		(p)-OCH <sub>3</sub>	
81	H	(p)-OCH <sub>3</sub>	
82	H	(p)-O(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	
83		(p)-O(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	
84	H	(p)-O(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	
85	H	(p)-O(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	


- 191 -

Example Table 8

Example Number	P	N	R <sup>2</sup>
86		(p)-O(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	
87	H	(p)-O(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	
88	H	(p)-O(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	
89		(p)-O(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	
90	H	(p)-O(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	
91	H	(p)-OCH <sub>3</sub>	
92		(p)-S-phenyl group	H

- 192 -

Example Table 9




Example Number	P	N	R <sup>6</sup>
93	$\text{CH}_3\text{C=O}$	(p)-O-	$\text{CH}_3\text{C(=O)OH}$
94	H	(p)-O-	$\text{CH}_3\text{C(=O)OH}$
95	$\text{CH}_3\text{C=O}$	(p)-O-	$\text{CH}_3\text{C(=O)OC(CH}_3)_3$
96	$\text{CH}_3\text{C=O}$	(p)-O-	$\text{CH}_3\text{C(=O)NH}_2$
97	H	(p)-O-	$\text{CH}_3\text{C(=O)NH}_2$
98	$\text{CH}_3\text{C=O}$	(p)-O-	$\text{CH}_3\text{C(=O)OCH}_3$
99	H	(p)-O-	$\text{CH}_3\text{C(=O)NH-CH}_2-\text{CH}_2-\text{N}_2\text{C}_2\text{H}_4\text{O}$


Example Table 10

Example  
Number


100




101



102



103

5 Example 104: *In Vitro* Metalloprotease Inhibition

Most of the compounds prepared in the manner described in Examples 1 to 39 were tested for activity by an *in vitro* assay. Following the procedures of Knight et al., *FEBS Lett.* 296(3):263 (1992). Briefly, 4-aminophenylmercuric acetate (APMA) or trypsin activated MMPs were incubated with various concentrations of the inhibitor compound at room temperature for 5 minutes (0.02% 2-mercaptop-ethanol added to buffer for thiol compounds with 5 minutes or overnight incubation).

-194-

More specifically, recombinant human MMP-13 and MMP-1 enzymes were prepared in laboratories of the assignee. MMP-13 was expressed in baculovirus as a proenzyme, and purified first over a heparin 5 agarose column and then over a chelating zinc chloride column. The proenzyme was activated by APMA for use in the assay. MMP-1 expressed in transfected HT-1080 cells was provided by Dr. Howard Welgus of Washington University, St. Louis, MO. The enzyme was 10 also activated using APMA and was then purified over a hydroxamic acid column.

The enzyme substrate is a methoxycoumarin-containing polypeptide having the following sequence:

MCA-ProLeuGlyLeuDpaAlaArgNH<sup>2</sup>, wherein MCA is 15 methoxycoumarin and Dpa is 3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl alanine. This substrate is commercially available from Baychem as product M-1895.

The buffer used for assays contained 100 mM 20 Tris-HCl, 100 mM NaCl, 10 mM CaCl<sub>2</sub> and 0.05 percent polyethyleneglycol (23) lauryl ether at a pH value of 7.5. Assays were carried out at room temperature, and dimethyl sulfoxide (DMSO) at a final concentration of 1 percent was used to dissolve 25 inhibitor compound.

The assayed inhibitor compound in DMSO/buffer solution was compared to an equal amount of DMSO/buffer with no inhibitor as control using Microfluor™ White Plates (Dynatech). The inhibitor 30 or control solution was maintained in the plate for 10 minutes and the substrate was added to provide a final concentration of 4 μM.

In the absence of inhibitor activity, a fluorogenic peptide was cleaved at the gly-leu 35 peptide bond, separating the highly fluorogenic peptide from a 2,4-dinitrophenyl quencher, resulting in an increase of fluorescence intensity (excitation

- 195 -

at 328 nm/emission at 415 nm). Inhibition was measured as a reduction in fluorescent intensity as a function of inhibitor concentration, using a Perkin Elmer L550 plate reader. The IC<sub>50</sub> values were 5 calculated from those values. The results are set forth in the Inhibition Table below, reported in terms of IC<sub>50</sub> to three significant figures.

Inhibition Table

10

	<u>Example</u>	<u>hMMP 13 (nM)</u>	<u>hMMP 1 (nM)</u>
	1	400	4000
	2	33	8000
15	3	475	>10,000
	4	1000	>10,000
	5	400	>10,000
	6	>10,000	>10,000
	7	22	1000
20	8	1300	>10,000
	9	500	>10,000
	10	15	4000
	11	>10,000	>10,000
	13	70	8000
25	14	190	6500
	15	700	>10,000
	16	4	600
	17	210	>10,000
	18	0.6	60
30	19	200	7000
	20	7	1500
	21	1500	>10,000
	22	0.5	1100
	23	45	>10,000
35	24	48	3500
	25	700	>10,000
	27	40	>10,000
	28	1.5	9000
	29	55	10,000
40	30	900	>10,000
	31	35	4750
	32	70	4000
	33	42	900
	34	200	8000
45	35	3	>10,000
	36	0.6	2400
	37	170	>10,000
	38	0.4	>10,000
	39	0.2	370

50

-196-

Example 105: *In Vivo Angiogenesis Assay*

The study of angiogenesis depends on a reliable and reproducible model for the stimulation and inhibition of a neovascular response. The corneal micropocket assay provides such a model of angiogenesis in the cornea of a mouse. See, *A Model of Angiogenesis in the Mouse Cornea*; Kenyon, BM, et al., *Investigative Ophthalmology & Visual Science*, 10 July 1996, Vol. 37, No. 8.

In this assay, uniformly sized Hydron™ pellets containing bFGF and sucralfate were prepared and surgically implanted into the stroma mouse cornea adjacent to the temporal limbus. The pellets were formed by making a suspension of 20 µL sterile saline containing 10 µg recombinant bFGF, 10 mg of sucralfate and 10 µL of 12 percent Hydron™ in ethanol. The slurry was then deposited on a 10 x 10 mm piece of sterile nylon mesh. After drying, the nylon fibers of the mesh was separated to release the pellets.

The corneal pocket was made by anesthetizing a 7 week old C57Bl/6 female mouse, then proptosing the eye with a jeweler's forceps. Using a dissecting microscope, a central, intrastromal linear keratotomy of approximately 0.6 mm in length was performed with a #15 surgical blade, parallel to the insertion of the lateral rectus muscle. Using a modified cataract knife, a lamellar micropocket was dissected toward the temporal limbus. The pocket was extended to within 1.0 mm of the temporal limbus. A single pellet was placed on the corneal surface at the base of the pocket with a jeweler's forceps. The pellet was then advanced to the temporal end of the pocket. Antibiotic ointment was then applied to the eye.

-197-

Mice were dosed on a daily basis for the duration of the assay. Dosing of the animals was based on bioavailability and overall potency of the compound. In the case of the compound of Example 39, 5 dosing was 50 mg/kg bid, po. Neovascularization of the corneal stroma began at about day three and was permitted to continue under the influence of the assayed compound until day five. At day five, the degree of angiogenic inhibition was scored by viewing 10 the neovascular progression with a slit lamp microscope.

The mice were anesthetized and the studied eye was once again proptosed. The maximum vessel length of neovascularization, extending from the 15 limbal vascular plexus toward the pellet was measured. In addition, the contiguous circumferential zone of neovascularization was measured as clock hours, where 30 degrees of arc equals one clock hour. The area of angiogenesis was 20 calculated as follows.

$$\text{area} = \frac{(0.4 \times \text{clock hours} \times 3.14 \times \text{vessel length (in mm)})}{2}$$

The studied mice were thereafter compared to control mice and the difference in the area of neovascularization was recorded. The compound of 25 Example 39, N1-3-[(4-phenoxyphenyl)sulfonyl]-1-sulfanylpropyl-3-morpholinopropanamide, exhibited 51 percent inhibition, whereas the vehicle control exhibited zero percent inhibition.

30 From the foregoing, it will be observed that numerous modifications and variations can be effectuated without departing from the true spirit and scope of the novel concepts of the present invention. It is to be understood that no limitation 35 with respect to the specific example presented is

- 198 -



intended or should be inferred. The disclosure is intended to cover by the appended claims all such modifications as fall within the scope of the claims.

- 199 -

WHAT IS CLAIMED IS:


1. A matrix metalloprotease inhibitor compound corresponding to the formula:

5



or

10



wherein

R<sup>1</sup> is a substituted aryl or heteroaryl radical having a length greater than about that of a pentyl group and a length that is less than that of a stearyl group, and when rotated about an axis drawn through the SO<sub>2</sub>-bonded 1-position and the 4-position of a 6-membered ring or the SO<sub>2</sub>-bonded position and substituent-bonded 3- or 5-position of a 5-membered ring defines a three-dimensional volume whose widest dimension has the width of about one phenyl ring to

-200-

about three phenyl rings in a direction transverse to that axis to rotation;

R<sup>2</sup> and R<sup>3</sup> are radicals independently selected from the group consisting of hydrido, C<sub>1</sub>-C<sub>6</sub> alkyl, single-ringed aralkyl or heteroaralkyl having 1-3 carbons in the alkyl chain, cycloalkylalkyl having 4-8 carbons in the ring and 1-3 carbons in the alkyl chain, and heterocycloalkylalkyl in which 4-8 atoms are in the ring, one or two of which atoms are nitrogen, oxygen or sulfur and in which the alkyl chain contains 1-3 carbons, or wherein R<sup>2</sup> and R<sup>6</sup> together with the atoms to which they are bonded form a 5- or 6-membered ring;

R<sup>6</sup> is a radical selected from the group consisting of an C<sub>1</sub>-C<sub>6</sub> alkyl group; a carboxyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, an amino C<sub>1</sub>-C<sub>6</sub> alkanoyl group, a carboxamide group where the amido nitrogen is (i) unsubstituted or substituted with (ii) a C<sub>1</sub>-C<sub>4</sub> alkyl substituted by amino, mono-substituted amino or di-substituted amino, wherein the substituent on the amino nitrogen is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>5</sub>-C<sub>8</sub> cycloalkyl and C<sub>1</sub>-C<sub>6</sub> alkanoyl groups, or wherein two amino nitrogen substitutents and the nitrogen to which they are bonded together form a 5- to 8-membered heterocyclic or heteroaryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur or (iii) the amido nitrogen is the amine of an amino acid;

W is oxygen (O) or sulfur (S); and

R<sup>10</sup> is aryl or heteroaryl having a single ring or C<sub>1</sub>-C<sub>6</sub> alkoxy.


-201-

2. The inhibitor compound according to  
claim 1 wherein R<sup>1</sup> has a length greater than that of  
a hexyl group and less than that of a lauryl group.

5           3. The inhibitor compound according to  
claim 1 wherein R<sup>1</sup> is a single-ringed aryl or  
heteroaryl group that is 5- or 6-membered, and is  
itself substituted at its own 4-position when a  
6-membered ring and at its own 3-position when a  
10 5-membered ring with a substituent selected from the  
group consisting of one other single-ringed aryl or  
heteroaryl group, a C<sub>2</sub>-C<sub>6</sub> alkyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy  
group, a phenoxy group, a thiophenoxy group, a  
4-thiopyridyl group, a phenylazo group and a  
15 benzamido group.


4. The inhibitor compound according to  
claim 1 wherein said wherein R<sup>1</sup> is PhR<sup>11</sup> in which Ph  
is phenyl substituted with R<sup>11</sup> at the 4-position, and  
20 said R<sup>11</sup> is a phenoxy group that is itself  
substituted at the meta- or para-position or both by  
a single atom or a substituent containing a longest  
chain of up to five atoms, excluding hydrogen.

25           5. A matrix metalloprotease inhibitor  
corresponding to the formula:




(I b)

-202-



or



wherein

5 Ph is phenyl substituted with R<sup>11</sup> at the  
4-position;

R<sup>11</sup> is a substituent selected from the  
group consisting of C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>3</sub>-C<sub>6</sub> alkyl,  
phenoxy, thiophenoxy, benzamido, phenylazo, and  
10 phenyl moieties;

R<sup>2</sup> is selected from the group consisting of  
hydrido, a C<sub>1</sub>-C<sub>6</sub> alkyl group, a C<sub>2</sub>-C<sub>3</sub> alkyl  
cycloamino group having five or six atoms in the ring  
and zero or one additional heteroatom that is oxygen  
15 or nitrogen, a C<sub>1</sub>-C<sub>6</sub> aminocarbonyl group whose amido  
nitrogen is unsubstituted or mono- or disubstituted  
with a C<sub>2</sub>-C<sub>3</sub> alkyl or benzyl radical, and a C<sub>1</sub>-C<sub>4</sub>  
alkylheteroaryl group having a single heteroaryl ring  
wherein said single heteroaryl ring contains one or  
20 two nitrogen atoms, or wherein R<sup>2</sup> and R<sup>6</sup> together  
with the atoms to which they are bonded form a 5- or  
6-membered ring;

R<sup>6</sup> is a radical selected from the group  
consisting of an C<sub>1</sub>-C<sub>6</sub> alkyl group, a carboxyl group,  
25 a C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, an amino C<sub>1</sub>-C<sub>6</sub>  
alkanoyl group, a carboxamide group where the amido

nitrogen is (i) unsubstituted or (ii) substituted with a C<sub>1</sub>-C<sub>4</sub> alkyl substituted by amino, mono-substituted amino or di-substituted amino, wherein the substituent on the amino nitrogen is selected 5 from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>5</sub>-C<sub>8</sub> cycloalkyl and C<sub>1</sub>-C<sub>6</sub> alkanoyl groups, or wherein two amino nitrogen substituents and the nitrogen to which they are bonded together form a 5- to 8-membered heterocyclic or heteroaryl ring containing zero or 10 one additional hetero atoms that are nitrogen, oxygen or sulfur or (iii) the amido nitrogen is the amine of an amino acid; and

R<sup>10</sup> is C<sub>1</sub>-C<sub>6</sub> alkoxy, or a single-ringed aryl or heteroaryl group,

15 with the proviso that only one of R<sup>2</sup> or R<sup>6</sup> is present unless R<sup>2</sup> and R<sup>6</sup> together with the atoms to which they are bonded form a 5- or 6-membered ring.

20 6. The inhibitor compound according to claim 5 wherein R<sup>10</sup> is selected from the group consisting of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, thiophene-2-yl, 3-thiophene-3-yl, methoxy and ethoxy.





25 7. The inhibitor compound according to claim 5 wherein the R<sup>11</sup> substituent group is itself substituted at the meta- or para-position or both with a single atom or a substituent containing a 30 longest chain of up to five atoms, excluding hydrogen.

8. The inhibitor compound according to claim 7 wherein said R<sup>11</sup> substituent is phenoxy and 35 is substituted at its own para-position with a moiety that is selected from the group consisting of a

-204-

halogen, a C<sub>1</sub>-C<sub>4</sub> alkoxy group, a C<sub>1</sub>-C<sub>4</sub> alkyl group, a dimethylamino group, a C<sub>1</sub>-C<sub>3</sub> alkyl carboxyl group, a C<sub>1</sub>-C<sub>3</sub> alkylcarbonyl C<sub>1</sub>-C<sub>4</sub> alkoxy group and a C<sub>1</sub>-C<sub>3</sub> alkyl carboxamido group, or is substituted at the 5 meta and para positions by a methylenedioxy group.

9. A matrix metalloprotease inhibitor corresponding to the formula:



10

wherein

R<sup>1</sup> is an aryl radical having a length  
15 greater than that of a saturated six carbon chain,  
and shorter than that of a saturated eighteen carbon  
chain, and when rotated about an axis drawn through  
the SO<sub>2</sub>-bonded 1-position and the 4-position of a  
6-membered ring or the SO<sub>2</sub>-bonded position and  
20 substituent-bonded 3- or 5-position of a 5-membered  
ring defines a three-dimensional volume whose widest  
dimension has the width of about one phenyl ring to  
about three phenyl rings in a direction transverse to  
that axis to rotation; and

25 R<sup>10</sup> is aryl or heteroaryl having a single  
ring or C<sub>1</sub>-C<sub>6</sub> alkoxy.

- 205 -

10. The inhibitor compound according to  
claim 9 wherein R<sup>1</sup> is a single-ringed aryl or  
heteroaryl group that is 5- or 6-membered, and is  
itself substituted at its own 4-position when a  
5-membered ring and at its own 3-position when a  
5-membered ring with a substituent selected from the  
group consisting of one other single-ringed aryl or  
heteroaryl group, a C<sub>2</sub>-C<sub>6</sub> alkyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy  
group, a phenoxy group, a thiophenoxy group, a  
4-thiopyridyl group, a phenylazo group and a  
benzamido group.





11. The inhibitor compound according to  
claim 10 wherein R<sup>1</sup> is PhR<sup>11</sup> in which Ph is phenyl  
15 substituted with R<sup>11</sup> at the 4-position, and said R<sup>11</sup>  
is a phenoxy group that is itself substituted at the  
meta- or para-position or both by a single atom or a  
substituent containing a longest chain of up to five  
atoms, excluding hydrogen.

20 12. The inhibitor compound according to  
claim 10 where R<sup>11</sup> is a substituent selected from the  
group consisting of C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>3</sub>-C<sub>6</sub> alkyl,  
phenoxy, thiophenoxy, benzamido, phenylazo, and  
25 phenyl moieties.

30 13. The inhibitor compound according to  
claim 12 wherein the R<sup>11</sup> substituent group is itself  
substituted at the meta- or para-position or both  
with a single atom or a substituent containing a  
longest chain of up to five atoms, excluding  
hydrogen.

-206-

14. A matrix metalloprotease inhibitor corresponding to the formula:



5

wherein

R<sup>1</sup> is an aryl radical having a length greater than that of a saturated six carbon chain, and shorter than that of a saturated eighteen carbon chain, and when rotated about an axis drawn through the SO<sub>2</sub>-bonded 1-position and the 4-position of a 6-membered ring or the SO<sub>2</sub>-bonded position and substituent-bonded 3- or 5-position of a 5-membered ring defines a three-dimensional volume whose widest dimension has the width of about one phenyl ring to about three phenyl rings in a direction transverse to that axis to rotation; and

R<sup>10</sup> is aryl or heteroaryl having a single ring or C<sub>1</sub>-C<sub>6</sub> alkoxy.

20

15. The inhibitor compound according to claim 14 wherein R<sup>1</sup> is a single-ringed aryl or heteroaryl group that is 5- or 6-membered, and is itself substituted at its own 4-position when a 6-membered ring and at its own 3-position when a 5-membered ring with a substituent selected from the

group consisting of one other single-ringed aryl or heteroaryl group, a C<sub>2</sub>-C<sub>6</sub> alkyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, a phenoxy group, a thiophenoxy group, a 4-thiopyridyl group, a phenylazo group and a  
5 benzamido group.



16. The inhibitor compound according to  
claim 15 wherein said wherein R<sup>1</sup> is PhR<sup>11</sup> in which Ph  
is phenyl substituted with R<sup>11</sup> at the 4-position, and  
10 said R<sup>11</sup> substituent is a phenoxy group that is  
itself substituted at the meta- or para-position or  
both by a single atom or a substituent containing a  
longest chain of up to five atoms, excluding  
hydrogen.  
15

17. The inhibitor compound according to  
claim 16 wherein said R<sup>11</sup> phenoxy substituent is  
itself substituted with a moiety selected from the  
group consisting of C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>3</sub>-C<sub>6</sub> alkyl,  
20 phenoxy, methylenedioxy, thiophenoxy, benzamido,  
phenylazo, and phenyl.

18. The inhibitor compound according to  
claim 17 wherein R<sup>10</sup> is selected from the group  
25 consisting of phenyl, 2-pyridyl, 3-pyridyl,  
4-pyridyl, thiophene-2-yl, 3-thiophene-3-yl, methoxy  
and ethoxy.


19. A process for treating a host mammal  
30 having a condition associated with pathological  
matrix metalloprotease activity that comprises  
administering a metalloprotease inhibitor in an  
effective amount to a mammalian host having such a  
condition, said metalloprotease inhibitor  
35 corresponding in structure to formulas I, II or III  
below

- 208 -



5

or



wherein

- 10            x and y are independently zero, 1 or 2;  
       W is oxygen or sulfur;  
       a starred R\* group, y\* or x\* is the same or  
       different from an unstarred R, y or x;  
       R<sup>10</sup> is selected from the group consisting of  
 15        alkyl, aryl, alkoxy, cycloalkyl, aryloxy, aralkoxy,  
       aralkyl, aminoalkyl, heteroaryl and N-monosubstituted  
       or N,N-disubstituted aminoalkyl wherein the  
       substituent on the nitrogen is selected from the  
       group consisting of alkyl, aryl, aralkyl, cycloalkyl,  
 20        aralkoxycarbonyl, alkoxycarbonyl, and alkanoyl, or  
       wherein the nitrogen and two substituents attached

thereto form a 5 to 8 member heterocyclo or heteroaryl ring;

R<sup>1</sup> is an aryl or heteroaryl substituent selected from the group consisting of aralkyl, 5 heteroaralkyl, aralkoxy, heteroaralkoxy, aralkoxyalkyl, aryloxyalkyl, aralkanoylalkyl, arylcarbonylalkyl, aralkylaryl, aryloxyalkylaryl, aralkoxyaryl, arylazoaryl, arylhydrazinoaryl, alkylthioaryl, arylthioalkyl, alkylthioaralkyl, 10 aralkylthioalkyl, and aralkylthioaryl, the sulfoxide or sulfone of any of said thio substituents, and a fused ring structure comprising two or more 5- or 6-membered rings selected from the group consisting of aryl, heteroaryl, carbocyclic and heterocyclic, said 15 aryl or heteroaryl substituent of which R<sup>1</sup> is comprised being substituted cyano, perfluoroalkyl, trifluoromethylalkyl, hydroxy, with one or more substituents independently selected from among halo, C<sub>2</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, nitro, thiol, 20 hydroxycarbonyl, aryloxy, arylthio, arylamino, aralkyl, aryl, heteroaryloxy, heteroarylthio, heteroarylarnino, heteroaralkyl, cycloalkyl, heterocyclooxy, heterocyclothio, heterocycloamino, cycloalkyloxy, cycloalkylthio, cycloalkylamino, 25 heteroaralkoxy, heteroaralkylthio, heteroaralkylamino, aralkoxy, aralkylthio, aralkylamino, heterocyclic, heteroaryl, arylazo, hydroxycarbonylalkoxy, alkoxycarbonylalkoxy, alkanoyl, arylcarbonyl, aralkanoyl, alkanoyloxy, 30 aralkanoyloxy, hydroxyalkyl, hydroxyalkoxy, alkylthio, alkoxyalkylthio, alkoxycarbonyl, aryloxyalkoxyaryl, arylthioalkylthioaryl, aryloxyalkylthioaryl, arylthioalkoxyaryl, hydroxycarbonylalkoxy, hydroxycarbonylalkylthio, 35 alkoxycarbonylalkoxy, alkoxycarbonylalkylthio, amino, alkanoylamino, arylcarbonylamino, aralkanoylamino, heteroarylcarbonylamino, heteroaralkanoylamino, and

-210-

- N-monosubstituted or N,N-disubstituted aminoalkyl wherein the substituent on the amino nitrogen are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, aralkoxycarbonyl,  
5 alkoxy carbonyl, and alkanoyl, or wherein the nitrogen and two substituents attached thereto form a 5 to 8 member heterocyclo or heteroaryl ring;

R<sup>2</sup> and R<sup>3</sup> are independently selected from the group consisting of hydrido, an alkyl, aryl,  
10 aralkyl, heteroaryl, heteroaralkyl, alkynylalkyl, alkenylalkyl, thioalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, alkoxyalkyl, aralkoxyalkyl, aminoalkyl, alkoxyalkoxyalkyl, aryloxyalkyl, hydroxyalkyl, hydroxycarbonylalkyl,  
15 hydroxycarbonylaralkyl, or N-monosubstituted or N,N-disubstituted aminoalkyl group wherein the substituent on the amino nitrogen are selected from the group consisting of alkyl, aralkyl, cycloalkyl and alkanoyl, or wherein R<sup>3</sup> is hydrido and R<sup>2</sup> and  
20 another substituent selected from the group consisting of R<sup>4</sup>, R<sup>6</sup> and R<sup>8</sup> together with the atoms to which they are bonded form a 4- to 8-membered ring;

R<sup>4</sup> and R<sup>5</sup> are independently selected from  
25 the group consisting of hydrido, alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, aryloxyalkyl, aralkoxyalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, hydroxycarbonylalkyl, alkoxy carbonylalkyl, aralkoxycarbonylalkyl,  
30 hydroxycarbonyl, alkoxy carbonyl, perfluoroalkyl, trifluoromethylalkyl, thioalkyl, alkylthioalkyl, arylthioalkyl, aralkylthioalkyl, heteroaralkylthioalkyl, or a sulfoxide or sulfone of any of said thio substituents, aminocarbonyl,  
35 aminocarbonylalkyl and N-monosubstituted or N,N-disubstituted aminocarbonyl or aminocarbonylalkyl

-211-

wherein the substituent on the amino nitrogen are independently selected from among alkyl, aralkyl, cycloalkyl and alkanoyl, or R<sup>5</sup> is hydrido and R<sup>4</sup> and another substituent selected from the group consisting of R<sup>2</sup>, R<sup>6</sup> and R<sup>8</sup> together with the atoms to which they are bonded form a 4- to 8-membered ring;

R<sup>6</sup> and R<sup>7</sup> are independently selected from the group consisting of hydrido, an C<sub>1</sub>-C<sub>6</sub> alkyl group, a cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, aryloxyalkyl, aralkoxyalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, hydroxycarbonyl, alkoxycarbonyl, perfluoroalkyl, trifluoromethylalkyl, thioalkyl, alkylthioalkyl, arylthioalkyl, aralkylthioalkyl, heteroaralkylthioalkyl, or a sulfoxide or sulfone of any of said thio substituents, a carboxyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, an amino C<sub>1</sub>-C<sub>6</sub> alkanoyl group, a carboxamide group where the amido nitrogen is (i) unsubstituted or (ii) substituted with a C<sub>1</sub>-C<sub>4</sub> alkyl substituted by amino, mono-substituted amino or di-substituted amino, wherein the substituent on the amino nitrogen is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>5</sub>-C<sub>8</sub> cycloalkyl and C<sub>1</sub>-C<sub>6</sub> alkanoyl groups, or wherein two amino nitrogen substituents and the nitrogen to which they are bonded together form a 5- to 8-membered heterocyclic or heteroaryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur or (iii) the amido nitrogen is the amine of an amino acid, or R<sup>7</sup> is hydrido and R<sup>6</sup> and another substituent selected from the group consisting of R<sup>2</sup>, R<sup>4</sup> and R<sup>8</sup> together

- 212 -

with the atoms to which they are bonded form a 4- to 8-membered ring;

R<sup>8</sup> and R<sup>9</sup> are independently selected from the group consisting of hydrido, alkyl, cycloalkyl, 5 cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, aryloxyalkyl, aralkoxyalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, hydroxycarbonyl, alkoxycarbonyl, perfluoroalkyl, 10 trifluoromethylalkyl, thioalkyl, alkylthioalkyl, arylthioalkyl, aralkylthioalkyl, heteroaralkylthioalkyl, or a sulfoxide or sulfone of any of said thio substituents, aminocarbonyl, aminocarbonylalkyl and N-monosubstituted or 15 N,N-disubstituted aminocarbonyl or aminocarbonylalkyl wherein the substituent on the amino nitrogen are independently selected from among alkyl, aralkyl, cycloalkyl and alkanoyl, or R<sup>9</sup> is hydrido and R<sup>8</sup> and another substituent selected from the group 20 consisting of R<sup>2</sup>, R<sup>4</sup> and R<sup>6</sup> together with the atoms to which they are bonded form a 4- to 8-membered ring;

provided that no carbon atom is geminally substituted with more than one sulphhydryl group.

25  
20. The process according to claim 19 wherein both x is zero and y is 1.

30  
21. The process according to claim 20 wherein:

R<sup>4</sup>, R<sup>5</sup> and R<sup>7</sup> are each hydrido; R<sup>1</sup> is a substituted aryl or heteroaryl radical having a length greater than about that of a pentyl group and a length that is less than that of a 35 stearyl group, and when rotated about an axis drawn through the SO<sub>2</sub>-bonded 1-position and the 4-position

- 213 -

of a 6-membered ring or the SO<sub>2</sub>-bonded position and substituent-bonded 3- or 5-position of a 5-membered ring defines a three-dimensional volume whose widest dimension has the width of about one phenyl ring to  
5 about three phenyl rings in a direction transverse to that axis to rotation;

R<sup>2</sup> and R<sup>3</sup> are radicals independently selected from the group consisting of hydrido, C<sub>1</sub>-C<sub>6</sub> alkyl, single-ringed aralkyl or heteroaralkyl having  
10 1-3 carbons in the alkyl chain, cycloalkylalkyl having 4-8 carbons in the ring and 1-3 carbons in the alkyl chain, and heterocycloalkylalkyl in which 4-8 atoms are in the ring, one or two of which atoms are nitrogen, oxygen or sulfur and in which the alkyl  
15 chain contains 1-3 carbons, or wherein R<sup>2</sup> and R<sup>6</sup> together with the atoms to which they are bonded form a 5- or 6-membered ring;

R<sup>6</sup> is a radical selected from the group consisting of an C<sub>1</sub>-C<sub>6</sub> alkyl group, a carboxyl group,  
20 a C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, an amino C<sub>1</sub>-C<sub>6</sub> alkanoyl group, a carboxamide group where the amido nitrogen is (i) unsubstituted or (ii) substituted with a C<sub>1</sub>-C<sub>4</sub> alkyl substituted by amino, mono-substituted amino or di-substituted amino, wherein  
25 the substituent on the amino nitrogen is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>5</sub>-C<sub>8</sub> cycloalkyl and C<sub>1</sub>-C<sub>6</sub> alkanoyl groups, or wherein two amino nitrogen substitutents and the nitrogen to which they are bonded together form a 5- to  
30 8-membered heterocyclic or heteroaryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur or (iii) the amido nitrogen is the amine of an amino acid;

W is oxygen (O) or sulfur (S); and


-214-

$R^{10}$  is aryl or heteroaryl having a single ring or C<sub>1</sub>-C<sub>6</sub> alkoxy.

22. The process according to claim 21  
 5 wherein  $R^1$  is a single-ringed aryl or heteroaryl group that is 5- or 6-membered, and is itself substituted at its own 4-position when a 6-membered ring and at its own 3-position when a 5-membered ring with a substituent selected from the group consisting  
 10 of one other single-ringed aryl or heteroaryl group, a C<sub>2</sub>-C<sub>6</sub> alkyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, a phenoxy group, a thiophenoxy group, a 4-thiopyridyl group, a phenylazo group and a benzamido group.


15 23. The process according to claim 22  
 wherein said  $R^1$  is PhR<sup>11</sup> in which Ph is phenyl substituted with R<sup>11</sup> at the 4-position, and said R<sup>11</sup> substituent is a phenoxy group that is itself substituted at the meta- or para-position or both by  
 20 a single atom or a substituent containing a longest chain of up to five atoms, excluding hydrogen.

24. A process for treating a host mammal having a condition associated with pathological matrix activity that comprises administering a metalloprotease inhibitor in an effective amount to a mammalian host having such a condition, said metalloprotease inhibitor corresponding in structure to a formula shown below  
 30




(I b)

- 215 -



or



5

wherein

Ph is phenyl substituted with R<sup>11</sup> at the 4-position;

10 R<sup>11</sup> is a substituent selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>3</sub>-C<sub>6</sub> alkyl, phenoxy, thiophenoxy, benzamido, phenylazo, and phenyl moieties;

15 R<sup>2</sup> is selected from the group consisting of hydrido, a C<sub>1</sub>-C<sub>6</sub> alkyl group, a C<sub>2</sub>-C<sub>3</sub> alkyl cycloamino group having five or six atoms in the ring and zero or one additional heteroatom that is oxygen or nitrogen, a C<sub>1</sub>-C<sub>6</sub> aminocarbonyl group whose amido nitrogen is unsubstituted or mono- or disubstituted with a C<sub>2</sub>-C<sub>3</sub> alkyl or benzyl radical, and a C<sub>1</sub>-C<sub>4</sub> alkylheteroaryl group having a single heteroaryl ring wherein said single heteroaryl ring contains one or two nitrogen atoms, or wherein R<sup>2</sup> and R<sup>6</sup> together with the atoms to which they are bonded form a 5- or 6-membered ring;

25 R<sup>6</sup> is a radical selected from the group consisting of an C<sub>1</sub>-C<sub>6</sub> alkyl group, a carboxyl group,

-216-

a C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, an amino C<sub>1</sub>-C<sub>6</sub> alkanoyl group, a carboxamide group where the amido nitrogen is (i) unsubstituted or (ii) substituted with (a C<sub>1</sub>-C<sub>4</sub> alkyl substituted by amino, mono-  
5 substituted amino or di-substituted amino, wherein the substituent on the amino nitrogen is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>5</sub>-C<sub>8</sub> cycloalkyl and C<sub>1</sub>-C<sub>6</sub> alkanoyl groups, or wherein two  
10 amino nitrogen substitutents and the nitrogen to which they are bonded together form a 5- to 8-membered heterocyclic or heteroaryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur or (iii) the amido nitrogen is the amine of an amino acid; and  
15 R<sup>10</sup> is C<sub>1</sub>-C<sub>6</sub> alkoxy, or a single-ringed aryl or heteroaryl group,  
with the proviso that only one of R<sup>2</sup> or R<sup>6</sup> is present unless R<sup>2</sup> and R<sup>6</sup> together with the atoms to which they are bonded form a 5- or 6-membered  
20 ring.

25. The process according to claim 24 wherein the R<sup>11</sup> substituent group is itself substituted at the meta- or para-position or both  
25 with a single atom or a substituent containing a longest chain of up to five atoms, excluding hydrogen.

26. The process according to claim 25  
30 wherein said R<sup>11</sup> substituent is phenoxy and is substituted at its own para-position with a moiety that is selected from the group consisting of a halogen, a C<sub>1</sub>-C<sub>4</sub> alkoxy group, a C<sub>1</sub>-C<sub>4</sub> alkyl group, a dimethylamino group, a C<sub>1</sub>-C<sub>3</sub> alkyl carboxyl group, a  
35 C<sub>1</sub>-C<sub>3</sub> alkylcarbonyl, C<sub>1</sub>-C<sub>4</sub> alkoxy group and a C<sub>1</sub>-C<sub>3</sub>

- 217 -

alkyl carboxamido group, or at the meta and para positions by a methylenedioxy group.

## INTERNATIONAL SEARCH REPORT

International application No. PCT/US97/12874
---

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,595,700 A (DONALD et al.) 17 June 1986, see entire document.	1-26
A	FONG et al. The Chlorosulfonyl Moiety as a Leaving Group: Hydride Reduction of Sulfonyl Chlorides. Can. J. Chem. 1979, Vol. 57, pages 1206-1213, especially page 1208.	1-26
A	FIELD et al. Organic Disulfides and Related Substances. 43. Properties of Mercaptoalkyl Sulfoxide, a Novel Class of Structure. J. Org. Chem. 1981, Vol. 46, pages 2771-2775, especially page 2771.	1-26

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search  10 NOVEMBER 1997	Date of mailing of the international search report  01 DEC 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized office  Peter O'Sullivan Telephone No. (703) 308-1235

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US97/12874

**A. CLASSIFICATION OF SUBJECT MATTER:**  
**IPC (6):**

A61K 31/165, 31/19, 31/215, 31/22, 31/27, 31/40, 31/415, 31/425, 31/44, 31/535; C07C 237/20, 317/24, 317/32, 323/65, 327/26; C07D 213/32, 213/70, 233/84, 277/36, 295/13, 295/26

**A. CLASSIFICATION OF SUBJECT MATTER:**  
**US CL :**

514/237.8, 238.8, 239.2, 277, 347, 369, 398, 471, 486, 513, 543, 618, 630, 824, 825, 861, 863, 864, 886, 903, 921; 544/158, 159; 546/294, 339; 548/186, 323.5; 558/252; 560/11, 13; 562/429; 564/162, 223

**B. FIELDS SEARCHED**

Minimum documentation searched

Classification System: U.S.

514/237.8, 238.8, 239.2, 277, 347, 369, 398, 471, 486, 513, 543, 618, 630, 824, 825, 861, 863, 864, 886, 903, 921; 544/158, 159; 546/294, 339; 548/186, 323.5; 558/252; 560/11, 13; 562/429; 564/162, 223